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Cerebral small vessel disease and imaging
Cerebral small vessel disease (CSVD) is one of the most prevalent acquired vessel disorders in 
the ageing human brain.1 CSVD encompasses degenerative alterations of various aetiologies 
in the vessel wall of the small perforating cerebral arteries, arterioles, venules and capillaries.2 
These vessel wall changes can lead to ischemic and/or haemorrhagic damage to the brain 
tissue supplied, including the white matter, brainstem, deep grey nuclei and the cortex. Main 
risk factors for this vessel wall damage are longstanding arterial hypertension, smoking and 
diabetes.3, 4 Since these small vessels are difficult to image and to investigate in vivo, brain 
parenchymal lesions of presumed CSVD origin are adopted as imaging markers of CSVD.5 
Common signs of CSVD on conventional magnetic resonance imaging (MRI) include: areas of 
incomplete infarction or chronic hypoperfusion (white matter hyperintensities (WMH)), small 
areas of focal necrosis (lacunes), vessel wall rupture, manifesting by perivascular hemosiderin 
deposits (cerebral microbleeds) and brain atrophy (Box 1).2, 5 These signs on MRI are regarded 
as the traditional CSVD markers. International criteria on the terminology and definitions of 
these traditional CSVD markers have recently been published as the standards for reporting 
vascular changes on neuroimaging (STRIVE) criteria.5 
In the last decade, the imaging spectrum of CSVD has been extended to more subtle 
changes of the white matter, since the traditional MRI markers of CSVD mentioned above 
are regarded as the end of a continuous spectrum of white matter pathology. With diffusion 
tensor imaging (DTI) the microstructural integrity of the white matter can be assessed. DTI is 
an MRI technique that provides quantitative measures of the mobility of water molecules in 
vivo (Box 2).6 DTI has shown to be sensitive to detect tissue damage, showing abnormalities 
in both WMH and in apparently normal appearing white matter on conventional MRI.7 This 
imaging technique might capture CSVD-related lesions at earlier stages, presumably even 
before the traditional CSVD markers appear on conventional neuroimaging, since changes 
in normal appearing white matter showed tissue pathology less marked than those found in 
WMH.8 Although DTI has a low specificity in detecting the underlying cause of cerebral white 
matter damage, DTI holds promise for giving further insight into the mechanisms underlying 
clinical symptoms of CSVD.
The traditional CSVD markers are frequently reported on brain imaging of older adults 
and their presence rises markedly with increasing age and cardiovascular risk factors. In 
population-based studies, WMH are found in >90% in individuals aged 60 years and over.9 
Lacunes and microbleeds are less frequently seen; their presence varies considerable across 
studies and is related to the study population and the brain imaging protocol. Lacunes 
were found in 11% in individuals aged 60-69 years10 and reaches to >30% in those aged 80 
years and over in a population-based study.11 A similar pattern for microbleeds is seen; their 
prevalence is around 18% in individuals aged 60-69 years, up to 38% in those aged 80 years 
and over in the general population.12 
In this thesis, the focus is on common sporadic CSVD, which is the most prevalent form of 
CSVD and includes age-related and cardiovascular risk-factor-related CSVD.2 Other forms 
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of CSVD, including hereditary forms (e.g. cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) or the recessive form (CARASIL) 
or Fabry disease), inflammatory and immunologically mediated CSVD (e.g. small vessel 
vasculitis) and venous collagenosis are left beyond the scope of this thesis.  
 
Box 1: Conventional MRI characteristics of lesions related to cerebral small vessel 
disease
Based on Wardlaw et al. Lancet Neurol 2013;12:822-8385
White matter hyperintensities of presumed vascular origin (figure A)
White matter hyperintensities (WMH) are characterized by bilateral, typically symmetrical 
hyperintensities on T2-weighted MRI, including fluid-attenuated inversion recovery (FLAIR) 
scan. On T1-weighted sequences they can appear as isointense or hypointense. Their 
diameter is variable; they can range from small focal lesions to more confluent areas in the 
white matter. 
Lacunes of presumed vascular origin (figure B)
A lacune is defined as a round or ovoid, subcortical and fluid-filled cavity, with the same 
signal intensity as cerebrospinal fluid (CSF). The diameter is between 3-15 mm. They can 
be identified on FLAIR images, and have a central CSF-like hypointensity with usually a 
surrounding hyperintensive rim. 
Cerebral microbleeds (figure C)
Microbleeds are round or ovoid lesions that can be visualized on gradient-echo T2*-
weighted imaging or susceptibility-weighted sequences as hypointense or black lesions 
with associated blooming, indicating hemosiderin deposits. They have generally a diameter 
between 2-5 mm, with a maximum of 10 mm. 
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Brain atrophy (figure D)
Brain atrophy can occur in many disorders and has also been documented in cerebral small 
vessel disease (CSVD). Brain atrophy in CSVD is defined as a lower brain volume, not related 
to macroscopic focal injury, as trauma or infarction. Tissue loss in the presence of substantial 
load of CSVD, including WMH seen on the FLAIR image in Figure D (left image), especially 
occurs by sulcal widening (arrow A) and ventricular enlargement (arrow B). 
Baseline 2006 Follow-up 2011 
A 
B 
Brain atrophy 
D 
i
B li  ll  
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Box 2: diffusion tensor imaging
Based on Alexander et al. Neurotherapeutics 2007;4:316-3296 
Diffusion tensor imaging (DTI) is an MRI technique that measures the directionality and 
magnitude of random movement of water molecules in tissue. It is used to study the 
microstructural integrity of the white matter of the brain.  
Without barriers, water molecules move freely and uniformly in all directions in a spherically 
symmetric manner which is termed isotropic diffusion. In the presence of barriers, such as 
nerve fibres, the diffusion is not equal in all different directions, but is larger in one direction 
than in the other. This is called anisotropic diffusion. 
Fractional anisotropy 
Isotropy Low anisotropy High anisotropy 
A 
A measure for the directionality of water 
is fractional anisotropy (FA) (Figure A). 
FA is zero for isotropic diffusion (i.e. the 
fraction of anisotropic diffusion is zero) 
and approaches the value of one as 
the diffusion becomes more and more 
ellipsoid in shape.
Mean diffusivity:  (l1 + l2 + l3 )/3  
 
Axial diffusivity:   l1 
Radial diffusivity:  (l2 + l3)/2 
 
l2 
l3 
l1 
B 
Diffusion of water at each voxel is characterized 
by its three principal eigenvectors with associated 
eigenvalues (λ1, λ2, λ3) (Figure B). 
The average of the three eigenvalues represents the 
overall magnitude of water diffusion and is referred 
as the mean diffusivity (MD). It is expressed in mm2/s. 
Axial diffusivity (AD) represents the magnitude of 
diffusivity parallel to the white matter tracts (λ1). The 
average of λ2 and λ3 is termed radial diffusivity (RD) 
and reflects the magnitude of diffusion perpendicular 
to these tracts. 
In intact axons the diffusion of water will be mostly in one main direction, reflected by a high 
FA and the overall magnitude of diffusion will be restricted as water molecules have less 
space to move, resulting in a low MD. In general, a lower FA and a higher MD are associated 
with a poorer white matter microstructural integrity.13 
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Motor consequences of cerebral small vessel disease
While CSVD has been regarded as an incidental finding with no clinical and therapeutic 
consequences for a long time, during the last two decades it is increasingly being recognized 
as a serious problem, which causes major health problems in the aging society, including 
cognitive decline and dementia, depression and stroke.14 So far, the motor consequences of 
CSVD are relatively understudied. 
Gait is the resultant of the performance of many organ systems, including the peripheral and 
central nerve system, cardiovascular and pulmonary system and musculoskeletal system.15 
As a result, gait disturbances can have many causes. There is now emerging evidence 
(mainly at the cross-sectional level) that CSVD is one of most important vascular contributors 
to gait disturbances.16, 17 The mechanisms of how CSVD can lead to gait disturbances are 
not entirely understood; it is thought that CSVD result in white matter tract disruption 
and loss of connectivity between brain areas. CSVD has also been associated with mild 
parkinsonian signs18 and especially with higher Unified Parkinson’s Disease Rating Scale 
(UPDRS) scores on gait, posture and postural stability.19 The association between CSVD and 
parkinsonism is however controversial and evidence is mainly coming from post-mortem 
pathology studies. The presence of CSVD in patients with parkinsonism in the absence of 
the typical histopathology findings compatible with parkinsonism, including Lewy bodies 
or tau inclusions, is often referred as vascular parkinsonism.20, 21 It is unclear whether gait 
disturbances and parkinsonism represent a clinical continuum in patients with CSVD, with 
isolated mild gait disturbances at the beginning and more severe gait disturbances and 
parkinsonism as the end-stage disease, or if they represent distinctive diseases with separate 
pathologies. Longitudinal studies investigating the role of CSVD in the development of 
parkinsonism are currently lacking. 
There are several reasons why it is of interest to study the contribution of CSVD to gait 
disturbances and parkinsonism by using conventional MRI and DTI. First of all, it can provide 
insight into the pathophysiological mechanisms underlying these symptoms. Secondly, if 
CSVD is proven to be associated with gait decline and parkinsonism, CSVD imaging markers 
might be used as surrogate markers for these motor symptoms  in clinical trials, since clinical 
symptoms often develop in a late stage of the disease. Furthermore, it may open avenues 
for possible interventions (e.g. therapeutic approaches or lifestyle changes) in an earlier 
disease stage of CSVD, thereby delaying or preventing gait disturbances and parkinsonism 
and minimizing their influence on the quality of life of older adults by reducing the risk of 
their adverse consequences, including falls, cognitive impairment, institutionalization and 
death, which socially and economically burden the society.  
CHAPTER 1
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Mortality in cerebral small vessel disease
As already outlined above, the long-term prognosis of CSVD is highly variable, and also death 
may be a consequence.22, 23 To date, it is not exactly known which patients with CSVD are at 
highest risk for these adverse outcomes, including mortality. Important clinical consequences 
of CSVD, including cognitive24 and gait disturbances25 have been associated with mortality in 
population-based studies. The place of neuroimaging in determining the risk of mortality in 
addition to these clinical parameters has never been investigated. Possibly, the association 
between these clinical parameters and mortality is driven by CSVD. Getting insight into 
determinants associated with mortality in an CSVD population might help to identify 
individuals at highest risk for experiencing these adverse events and provide information on 
factors reflecting the vital health status of individuals with CSVD. 
Aim of this thesis and study design
The aim of this thesis was to investigate the associations between imaging characteristics 
of CSVD and different clinical outcome measures, including cognitive disturbances, gait 
deterioration and the development of parkinsonism over time, in individuals with CSVD by 
using conventional MRI and DTI. In addition, we wanted to investigate which individuals with 
CSVD are at highest risk for an unfavourable outcome in the more distant future by identifying 
determinants, which best predicted 8-year mortality in these individuals.  
The studies presented in this thesis are based on the Radboud University Nijmegen 
Diffusion tensor imaging and Magnetic Resonance imaging Cohort (RUN DMC) study. This 
is a prospective cohort study that investigates the risk factors and clinical consequences 
of structural brain changes assessed by MRI among older adults with CSVD. The RUN DMC 
study compromised all consecutive patients referred to the department of Neurology of 
the Radboud University medical centre between October 2002 and November 2006, aged 
between 50-85 years with CSVD on brain imaging, defined as the presence of WMH and/or 
lacunes of presumed vascular origin. In total, 503 individuals with CSVD were included at the 
start of the study in 2006. Main exclusion criteria were parkinsonism or dementia at baseline, 
life-expectancy less than 6 months, non-CSVD related white matter lesions and MRI contra-
indications. All participants underwent a brain MRI-scan and an extensive cognitive and 
motor assessment battery, including the assessment of gait and the presence of parkinsonian 
signs by using the motor section of the UPDRS (UPDRS-m). In 2011 this assessment, including 
a cerebral MRI was repeated, and all participants were screened for the presence of dementia 
and parkinsonism. The studies presented in this thesis are mainly based on the longitudinal 
data, except for chapter 2. For analysis on vital status, participants were followed until their 
death or until November 24, 2014. 
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Outline of the thesis 
Chapter 2 (part II) describes the cross-sectional association between microstructural 
integrity of the cingulum, an important white matter tract in cognitive performance, and 
verbal memory performance. In part III, we explored the longitudinal association between 
imaging characteristics and motor performance after 5 years of follow-up. Chapter 3 reports 
on the association between baseline CSVD markers and gait decline after 5 years. Chapter 4 
is an extension of the previous chapter and describes the longitudinal association between 
progression of CSVD and loss of white matter integrity on follow-up imaging and gait 
decline after 5 years. In chapter 5 the association between baseline CSVD markers and the 
development of parkinsonism after 5 years is studied. Part IV, chapter 6, provides information 
on the potential clinical and imaging determinants of 8-year mortality in individuals with 
CSVD. In part V of this thesis, the main results from the studies presented in the preceding 
chapters are discussed (chapter 7), including possible implications for clinical practice and 
suggestions for furture research are given in chapter 7. In chapter 8 the main results are 
summarized and chapter 9 contains a summary in Dutch of this thesis. 

Part II
Cerebral small vessel disease and 
cognitive performance

2.
Cingular integrity and verbal memory performance in cerebral 
small vessel disease
Published as:
H.M. van der Holst*, A.M. Tuladhar*, A.G.W. van Norden, K.F. de Laat, I.W.M. van Uden, 
L.J.B. van Oudheusden, M.P. Zwiers, D.G. Norris, R.P.C. Kessels, F-E de Leeuw.
Microstructural integrity of the cingulum is related to verbal memory performance 
in elderly with cerebral small vessel disease: the RUN DMC study. Neuroimage, 2013 
Jan;65:416-23
*Both authors contributed equally. 
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Abstract
Background: Cerebral small vessel disease (CSVD) is related to verbal memory failures. It 
is suggested that early white matter damage, is located, among others, in the (posterior) 
cingulum at an early stage in neurodegeneration. Changes in the microstructural 
integrity of the cingulum assessed with diffusion tensor imaging (DTI), beyond detection 
with conventional magnetic resonance imaging (MRI), may precede macrostructural 
changes and be related to verbal memory failures. 
Objective: To investigate the relation between cingular microstructural integrity and 
verbal memory performance in 503 non-demented older adults with CSVD.
Methods: The RUN DMC study is a prospective cohort study in older adults (50-85 
years) with CSVD. All participants underwent T1 MPRAGE, FLAIR and DTI scanning 
and a cognitive test battery, including the Rey Auditory Verbal Learning Test to assess 
verbal memory performance. Mean diffusivity (MD) and fractional anisotropy (FA) were 
assessed in six different cingular regions of interests (ROI). Linear regression analysis was 
used to assess the association between verbal memory performance and cingular DTI 
parameters, with appropriate adjustments. Furthermore, a Tract-based Spatial Statistics 
(TBSS) analysis of the whole brain was performed to investigate the specificity of our 
findings.  
Results: Both our ROI-based and TBSS analysis showed that FA of the cingulum was 
positively related to immediate memory, delayed recall, delayed recognition and overall 
verbal memory performance, independent of confounders. A similar distribution was 
seen for the inverse association with cingular MD and verbal memory performance 
with TBSS analysis. No significant relations were found between cingular integrity and 
psychomotor speed, visuospatial memory and Mini-Mental State Examination (MMSE). 
When stratified on hippocampal integrity, the MD and FA values of the cingular ROIs 
differed significantly between participants with good and poor hippocampal integrity; we 
found lower cingular microstructural integrity in participants with a poor hippocampal 
integrity. 
Conclusion: Microstructural integrity of the cingulum, assessed by DTI, is specifically 
associated with verbal memory performance in older adults with CSVD. Furthermore, 
we found that when the integrity of the hippocampus is disrupted, the cingular 
microstructural integrity is impaired as well. 
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Introduction
Cerebral small vessel disease (CSVD) includes, among others, white matter hyperintensities 
(WMH) and lacunes, and is a frequent finding on magnetic resonance imaging (MRI) scans 
of elderly people.9 Several patient- and population-based studies, have shown that CSVD is 
related to verbal memory failure and may eventually result in cognitive decline and dementia 
in some.26-28 This is thought to be the result of disruption of white matter tracts. White matter 
damage in Alzheimer dementia has been identified both in post-mortem studies29, 30 as well as 
in vivo MRI studies.30, 31 A more detailed investigation of the white matter using neuroimaging 
can be revealed by diffusion tensor imaging (DTI), a non-invasive MRI technique, which 
provides detailed information on the microstructure and integrity of white matter fibre tracts.32, 
33 Two DTI parameters are of special interest: mean diffusivity (MD), a measure of water diffusion 
averaged in all spatial directions, and fractional anisotropy (FA), which provides information 
about the directionality of water diffusion. Loss of microstructural integrity is typically 
accompanied by a decrease in FA and/or an increase in MD.13 There is increasing evidence that 
DTI parameters are an earlier marker of cognitive decline in comparison to volume measures.34, 
35 The cingulum bundle, a white matter bundle which connects the medial temporal lobe 
structures (e.g. hippocampus) and the posterior cingulate cortex, is an important structure 
for memory function, especially verbal memory performance.36-38 Many DTI studies in mild 
cognitive impairment (MCI) and Alzheimer dementia have shown that white matter damage, is 
located, among others, in the (posterior) cingulum at an early stage in neurodegeneration and 
may be a key marker of early pathology.36, 39-45 To our best knowledge, all studies performed so 
far had relatively small sample sizes (n<249), used mostly only patients with MCI and Alzheimer 
dementia, and did not or only limited adjusted for possible confounders. Furthermore, most 
of these studies used either a region of interest (ROI) approach or a voxel-based morphometry 
analysis, which have both methodological limitations. Tract-Based Spatial Statistics (TBSS) 
analysis is a relatively new method, using only those white matter voxels that are in the skeleton 
(core) of the brains connectional architecture, which enables a robust voxelwise analysis of the 
microstructural integrity of white matter and this can be accurately matched across subjects.46
In this study, we combined a ROI-based and TBSS approach in order to investigate the 
association between cingulum integrity and verbal memory performance in non-demented 
older adults with CSVD. We hypothesized that loss of microstructural integrity of the cingulum 
is related to impaired verbal memory performance. We examined this in six different ROIs from 
the posterior to the anterior cingulum in order to get information about regional distribution 
patterns in respect to verbal memory and performed TBSS analysis of the whole brain as well to 
investigate the specificity of our findings. In addition, we investigated the role of hippocampal 
integrity on cingulum integrity in order to assess whether cingular microstructural integrity is 
associated with hippocampal pathology. This study is part of the Radboud University Nijmegen 
Diffusion tensor and Magnetic resonance imaging Cohort (RUN DMC) study that included 503 
non-demented, independently living older adults with CSVD, aged between 50 and 85 years.
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Methods
Study population
The RUN DMC study prospectively investigates the risk factors and clinical consequences of 
brain changes among 503 non-demented older adults with CSVD. The selection procedure 
of the participants and study protocol were described in detail previously.47 In short, on the 
basis of established research criteria, CSVD was defined as the presence of lacunes and/or 
WMH.48 Accordingly, in 2006, consecutive patients referred to the Department of Neurology 
between October 2002 and November 2006 were selected for participation. Inclusion criteria 
were: (a) age between 50 and 85 years; (b) CSVD on neuroimaging (WMH and/or lacunes). 
The main exclusion criteria were dementia,49 (psychiatric) disease interfering with cognitive 
testing or follow-up, white matter lesions not related to CSVD and MRI contraindications or 
known claustrophobia. 
From 1,004 invited individuals by letter, 727 were eligible after contact by phone of whom 525 
agreed to participate. In 22 individuals exclusion criteria were found during their visit to our 
research center, yielding a response of 71.3% (503/705). For the present study, 63 participants 
were additionally excluded because of territorial infarcts (n=59) and inadequate quality of 
the MRI images (n=4). All participants signed an informed consent form. The Medical Review 
Ethics Committee region Arnhem-Nijmegen approved the study.
Measurement of cognitive function
Cognitive function was assessed by a standardized neuropsychological test battery performed 
by two trained investigators (AvN and KdL) and has been described in detail elsewhere.47 For 
this study, the Mini-Mental State Examination (MMSE) (range 0–30)50 was used as an index 
of overall cognitive performance. The three-trial version of the Rey Auditory Verbal Learning 
Test (RAVLT)51 was administered to examine episodic memory formation. To evaluate speed 
of mental processes we used the Stroop test,52, 53 the Paper-Pencil Memory Scanning Task54 
and the Symbol-Digit Substitution Task.55 The Rey Complex Figure Test (RCFT)56 was included 
as an index of visuospatial memory. 
We defined four memory indices based on RAVLT performance (overall verbal memory 
performance, immediate recall, delayed recall, and delayed recognition), as described 
previously.57, 58 Immediate recall was calculated by the mean of the total number of words 
remembered in the three learning trials of the RAVLT. Delayed recall was the number of 
words recalled 30 min after the learning trials. The delayed recognition score was calculated 
by computing the total of each correctly recognized word (the 15 target words among 15 
new distracter items) 30 min after the learning trials. Performance across tests was made 
comparable by transforming the raw test scores into Z-scores as described elsewhere57 for 
which the assumption of normality of the distribution was examined. For data reduction 
purposes, a compound score for overall verbal memory performance was calculated, as 
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described previously,26 by taking the mean of two Z-scores from the RAVLT; one for the added 
scores on three learning trials of this test and one for the delayed recall of this test.
For psychomotor speed and visuospatial memory we also calculated compound scores. 
Psychomotor speed was calculated as the mean of the Z-scores of the 1-letter subtask of 
the Paper-Pencil Memory Scanning Task, the reading subtask of the Stroop test and the 
Symbol-Digit Substitution Task.59 Visuospatial memory is a compound score of the mean of 
the Z-scores of the immediate recall trial and the delayed recall trial of the RCFT.
Conventional MRI Scanning Protocol
All participants underwent a cerebral MRI scan on the same 1.5-Tesla Magnetom scanner 
(Siemens, Erlangen, Germany). The scanning protocol includes whole brain T1-weighted 
3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence (repetition time (TR)/ 
echo time (TE)/ inversion time (TI) 2250/3.68/850ms; flip angle 15°; voxelsize 1.0x1.0x1.0mm); 
a fluid-attenuated inversion recovery (FLAIR) pulse sequences (TR/TE/TI 9000/84/2200ms; 
voxelsize 1.0x1.2x5.0mm with an interslice gap of 1mm); and a DTI sequence (TR/TE 
10100/93ms; voxelsize 2.5x2.5x2.5mm; 4 unweighted scans, 30 diffusion weighted scans, with 
non co-linear orientation of the diffusion-weighting gradient, and b-value 900 s/mm2). For 
more details of our MRI protocol we refer to our study rationale and protocol published in 
BioMed Central Neurology in 2011.47
Conventional MRI Analysis 
One experienced investigator, blinded to clinical data (IvU), manually segmented the left 
and right hippocampus on the MPRAGE image using the interactive software program 
“ITK-SNAP”.60 Anatomical boundaries were determined in coronal sections with the aid of 
neuroanatomical atlases,61, 62 and actual segmentation was performed using a previously 
published protocol63 in which segmentation was performed from posterior to anterior. The 
details on hippocampus segmentation were described previously in detail.57 Volumes were 
calculated for the left and right hippocampus separately by summing all voxel volumes of 
the segmented areas. Inter-rater studies on a random sample of 10% showed an intra-class 
correlation coefficient for the left hippocampus of 0.73 and for the right hippocampus of 0.79. 
Intra-rater studies on this sample showed an intra-class correlation coefficient for the left and 
right hippocampus of 0.97 and 0.96, respectively. 
We created a mask for the cingulum by applying the white matter atlas (Juelich Histological 
Atlas white matter labels, provided FMRIB's software library (FSL)) and warped this to the 
individual T1 volumes (inverse normalization). We counted the number of voxels and 
multiplied this to voxel volume in order to get the volume of the cingulum. 
We computed grey and white matter tissue and cerebrospinal fluid (CSF) probability maps 
using statistical parametric mapping 5 (SPM5) unified segmentation routines on the T1 
MPRAGE images (SPM5; Wellcome Department of Cognitive Neurology, University College 
London, United Kingdom).64 Total grey and white matter, and CSF volumes were calculated 
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by summing all voxel volumes that had a p>0.5 for belonging to that tissue class. Total brain 
volume (TBV) was taken as the sum of total grey and white matter. Intracranial volume (ICV) 
was the summation of all tissue classes (total grey and white matter and CSF volume). To 
normalize for head size, TBV, hippocampal volume and cingulum volume were expressed as 
a percentage of total ICV. 
WMH were manually segmented on FLAIR images and the number of lacunes was rated 
according to a standardized protocol.47 In a random sample of 10%, inter-rater variability for 
total WMH volume yielded an intra-class correlation coefficient of 0.99, intra- and inter-rater 
reliability for the lacunes yielded a weighted kappa of 0.80 and 0.88. 
DTI Analysis
Diffusion data were first pre-processed to detect and correct head and cardiac motion 
artefacts, using an in-house developed iteratively re-weighted-least-squares algorithm 
named ‘PATCH’ (www.ru.nl/neuroimaging/diffusion).65 Corrections of Eddy current and 
motion artefacts from affine misalignment were performed simultaneously by minimization 
of the residual diffusion tensor errors.66 Next, FA and MD images were calculated using a DTIFit 
within the Functional MR of the Brain diffusion toolbox, which were then fed into the TBSS 
pipeline.46 The thinning procedure was conducted on the mean FA image to create a common 
skeleton, which represents the core-structure of the white matter tract. Subsequently this 
skeleton was thresholded at FA-value 0.3 to include the major white matter tracts and to 
account for the inter-subject variability. All normalized FA data were then projected onto this 
skeleton. These skeleton projection factors were then applied to the mean images. These 
data were then fed into the voxel-wise cross-subject statistics. 
In addition, MD and FA values of the cingulum were measured in six bilateral ROIs (A-F) in the 
cingulum bundle as illustrated in figure 1. An experienced neurologist (FEdL) blinded to subject 
information used FSLView67 to overlay an histological atlas (Juelich Histological Atlas)68 over the 
MNI152 standard brain, in order to manually mark out the centre coordinates of the ROIs in the 
different locations of the cingulum and the parahippocampal region (based on neuroanatomy 
data from the literature).69 We marked out 5 ROIs on a sagittal slice of the cingulum. The cingulum 
was divided in 4 parts: anterior, middle, posterior and parahippocampal section.39 The centre 
of ROI C was placed at the centre of the middle curve of the cingulum fibres, just above the 
body of the corpus callosum: this is the middle cingulate region. We placed the centre of the 
2 anterior ROIs (ROI A and B) before the middle curve of the cingulum (around the rostrum 
and genu of the corpus callosum) and the 2 posterior ROIs (ROI D and E) nearby the dorsal 
curve of the cingulum fibres (around the splenium of the corpus callosum). The centre of the 
sixth ROI (ROI F) was placed in the parahippocampal cingulum on the medial temporal portion 
of the cingular fibres. The centre coordinates of each ROI were mirrored with respect to the 
mid-sagittal plane to obtain these same regions in both cerebral hemispheres. The ROI centre 
coordinates were mapped back to the individual DTI space of each subject using the inverse of 
the SPM5 unified T1 normalization parameters.64 ROIs were defined as 6 mm diameter spheres 
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(volume of 0.056 mL) around the DTI-space centre coordinates. We used a modest ROI size to 
ensure that all ROIs included only white matter (which was visually checked). FA and MD values 
within each ROI were averaged. Furthermore, the mean MD was calculated in both hippocampi. 
All images were visually checked for motion artefacts and co-registration errors, especially for 
not including perihippocampal CSF.
Other measurements
The following characteristics were considered possible confounders: age, sex, educational 
level70 and depressive symptoms. Depressive symptoms were assessed using the Centre of 
Epidemiologic Studies on Depression Scale (CES-D).71
Structural integrity of the hippocampus 
In order to investigate the role of hippocampal integrity on the cingular microstructural 
integrity, we composed a score for structural hippocampal integrity. As it has been 
demonstrated that a combination of high diffusivity of the hippocampus and low 
hippocampal volume is related to conversion to Alzheimer dementia in patients with MCI,34 
we compiled a score for hippocampal integrity using both parameters. Both diffusivity and 
volume were given a score, ranging from 1 (poor: lowest tertile of the volume/highest tertile of 
MD distribution) to 3 (good; highest tertile of the volume/lowest tertile of the MD distribution) 
leading to a maximum score between 2 (lowest tertile of the volume and highest tertile of the 
MD distribution (1+1): worst hippocampal integrity) and 6 (highest tertile of the volume and 
lowest tertile of the MD distribution (3+3):best hippocampal integrity). A good hippocampal 
integrity was defined as a score of ≥ 4, while a poor integrity was defined as a score of 2 or 3.
Figure 1. Location of the six (A-F) regions of interest in the left cingulum in a sagittal plane.
A
BDE
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Statistical analysis
Statistical analyses were performed with SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA). 
Baseline characteristics were summarized as mean (standard deviation (SD)) or proportions; 
for skewed variability parameters the median and the interquartile range were calculated. 
For the TBSS analysis, we assessed voxel-wise correlations between the skeletal DTI 
parameters (FA and MD) and cognitive performance, including the four different indices of the 
RAVLT performance, psychomotor speed, visuospatial memory and MMSE. Adjustments were 
made for potential confounders including age, sex, educational level, depressive symptoms 
and normalized total brain. We applied a permutation-based statistical interference tool for 
non-parametric approach as a part of the Functional MRI of the Brain Software Library, with 
number of permutation tests set to 5000.46, 72 Significant clusters were identified using the 
threshold-free cluster enhancement with a p<0.05, corrected for multiple comparisons.73 In 
addition, we performed the same analysis with a threshold at p<0.01. 
For the ROI analyses, we computed regression coefficients of the mean FA and MD of the six 
ROIs in the cingulum with the same cognitive test as mentioned above. Adjustments were 
made for the same confounders as mentioned above. Regression coefficients are presented 
as standardized β-values. To assess whether the structural integrity of the hippocampus 
modified the relation between cingulum microstructural integrity and performance in verbal 
memory, psychomotor speed, visuospatial memory and MMSE, we performed the previously 
described linear regression analyses stratified in two groups of hippocampal integrity (good 
and poor). Adjustments were made for the same confounders as mentioned above. To 
assess whether the groups differed significantly, the correlation coefficients were converted 
to Z-scores using the Fisher r-to-z transformation. The obtained z-scores were used to 
calculate the p-values. In addition, we  performed independent two-sample t-test to assess 
the differences in MD and FA values of the cingulum when stratified on hippocampal integrity 
in order to assess whether cingular microstructural integrity is associated with hippocampal 
pathology. Bonferroni corrections were applied to correct for multiple comparisons 
(p<0.00385 were considered significant). 
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Results 
The baseline characteristics of the 440 participants are shown in Table 1. The mean age of the 
population was 65.2 years (SD 8.9) and 54.3% were male. The mean MMSE score was 28.2 (SD 
1.6). In Table 2 the test scores of the cognitive test battery are shown. 
Table 1. Baseline characteristics of the 440 participants
Baseline characteristics n = 440
Age, mean (SD), years 65.2 (8.9)
Male sex, No. (%) 239 (54.3)
Participants with only primary education, No. (%) 41 (9.3)
MMSE score, mean (SD) 28.2 (1.6)
CES-D score, mean (SD)a 11.1 (9.4)
Participants with depressive symptomsb, No. (%) 151 (34.3)
Imaging characteristics
Total brain volume, mean (SD), mL 1098.6 (119.0)
Intracranial volume, mean (SD), mL 1674.7 (157.4)
Normalized hippocampal volumec, mean (SD) 0.41 (0.06)
Normalized cingular volumec, mean (SD) 0.29 (0.02)
White matter volume, mean (SD), mL 466.8 (66.9)
WMH volume, median (IQR), mL 6.5 (3.2-17.9)
Lacunes presence, No. (%) 135 (30.7)
Abbreviations: CES-D: Centre of Epidemiological Studies on Depression Scale; IQR: interquartile range; MMSE: 
Minimal Mental State Examination; SD: standard deviation; WMH: White Matter Hyperintensity. 
a Two participants had missing values on CES-D score. 
 b Defined as CES-D scores ≥16 and/or the current use of anti-depressive medication.
c Volumes are represented as percentage of total intracranial volume (SD). 
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Table 2. Cognitive test scores
RAVLT: number of words recalled n = 439
Immediate recall trial 1 5.2 (1.8)
Immediate recall trial 2 7.4 (2.3)
Immediate recall trial 3 8.7 (2.6)
Total of immediate recall trial 1-3 21.3 (6.1)
Delayed recall 6.0 (3.1)
Delayed recognition 27.1 (3.2) a
Stroop test (time in seconds) n = 427
Trial 1 (words) 25.5 (6.1)
Trial 2 (colors) 32.9 (7.5)
Trial 3 (concept-shifting) 62.8 (20.9)
Paper and pencil memory scanning task (time in seconds) n = 428
1 character 44.3 (13.5)
2 characters 61.2 (18.7)
3 characters 76.0 (26.2)
Symbol digit substitution task (No. in 60s) n = 437
Total score 27.7 (9.7)
Rey complex figure test (range 0-36) n = 435
Copy trial 33.5 (3.4)
Immediate recall trial 18.1 (6.8) b
Delayed recall trial 18.1 (6.7) c
Abbreviations: RAVLT: Rey Auditory Verbal Learning Test. 
Numbers represent mean (standard deviation). 
a 3 participants had missing values on delayed recognition.
b 5 participants had missing values on immediate recall trial.
c 19 participants had missing values on delayed recall trial.
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Figure 2 shows the association between the voxel-wise analysis of the FA and verbal memory 
performance (p<0.05, corrected for multiple comparisons). For this analysis (and the ROI 
analysis) we had to exclude 2 participants because of missing data on the CES-D. FA in the 
cingulum and corpus callosum were positively associated with immediate memory, delayed 
recall, delayed recognition and overall verbal memory performance, especially in the left 
hemisphere and independent of confounders. By contrast, we found no significant relations 
with psychomotor speed and neither with visuospatial memory and MMSE (data not shown). 
We found a similar distribution for the inverse association with MD and verbal memory 
performance, although these associations were less significant (data are not shown). 
Figure 2. Voxel-wise analyses of the fractional anisotropy values and verbal memory performance 
and psychomotor speed. 
Voxel-wise analyses of fractional anisotropy (FA) values were positively associated with the four memory indices of 
the Rey Auditory Verbal Learning Test (RAVLT), including immediate memory, delayed recall, delayed recognition 
and overall verbal memory performance. No significant associations were found for FA values and psychomotor 
speed. Adjustments were made for age, sex, educational level, depressive symptoms, normalized total brain 
volume, normalized hippocampal volume, white matter hyperintensity volume and the number of lacunes. 
Our ROI analyses show similar results. In Table 3 the associations between the FA of the 
six ROIs in left and right cingulum and the different cognitive tests are shown. Significant 
associations were found between the FA values in the left mid cingulum (ROI C) and 
immediate memory (β=0.09, p=0.041) and delayed recognition (β=0.11, p=0.027); in the 
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left ROI D and overall verbal memory performance (β=0.10, p=0.027), immediate memory 
(β=0.14, p=0.003) and delayed recognition (β=0.10, p=0.043); in the right ROI D and overall 
verbal memory performance (β=0.10, p=0.025) and immediate memory (β=0.10, p=0.018); in 
the right ROI E and overall verbal memory performance (β=0.09, p=0.037) and immediate 
memory (β=0.11, p=0.009), independent of confounders. No significant associations were 
found with psychomotor speed, visuospatial memory and MMSE. Almost no significant 
results were found between MD values and verbal memory performance (data not shown). 
When we stratified the above mentioned relation on a good (n=291) and poor (n=147) 
hippocampal integrity we did not find significant differences in the correlations coefficients 
between both groups, except for the relation with immediate memory and FA in the left ROI 
B (results are not shown). 
Table 4 shows cingulum integrity (expressed as mean MD and FA values of the six ROIs in the 
left and right cingulum) stratified on hippocampal integrity. The MD and FA values of all ROIs 
differed significantly between both groups (good and poor hippocampal integrity), except for 
the FA values in ROI E and F. Our results showed that the cingular microstructural integrity is 
significantly lower in participants with a poor hippocampal integrity than in participants with 
a good hippocampal integrity. 
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Table 4. Mean MD and FA of the six bilateral regions of interest in the cingulum stratified on 
hippocampal integrity
Hippocampal integrity
Good Poor Good Poor
MD MD p-valuea FA FA p-valuea
ROI A: anterior
Left 8.29 (0.74) 8.83 (1.90) <0.01 0.41 (0.10) 0.38 (0.10) <0.05
Right 8.22 (0.60) 8.75 (1.91) <0.01 0.39 (0.08) 0.37 (0.08) <0.01
ROI B: anterior
Left 8.24 (0.93) 8.82 (1.69) <0.001 0.42 (0.10) 0.37 (0.10) <0.001
Right 8.12 (0.67) 8.85 (1.82) <0.001 0.42 (0.09) 0.39 (0.09) <0.001
ROI C: mid cingulum
Left 7.68 (0.55) 8.32 (1.76) <0.001 0.53 (0.09) 0.47 (0.10) <0.001
Right 7.78 (0.55) 8.40 (1.54) <0.001 0.52 (0.09) 0.47 (0.09) <0.001
ROI D: superior-posterior
Left 7.80 (0.42) 8.28 (1.84) <0.01 0.54 (0.07) 0.51 (0.09) <0.001
Right 7.76 (0.48) 8.21 (1.63) <0.01 0.51 (0.07) 0.49 (0.07) <0.01
ROI E: inferior-posterior
Left 7.82 (0.47) 8.10 (1.80) <0.05 0.45 (0.07) 0.46 (0.07) NS
Right 7.98 (0.55) 8.41 1.71) <0.001 0.39 (0.07) 0.38 (0.07) NS
ROI F: parahippocampal
Left 8.57 (0.74) 9.01 (0.81) <0.001 0.25 (0.06) 0.25 (0.07) NS
Right 8.74 (0.71) 9.27 (1.00) <0.001 0.25 (0.08) 0.25 (0.07) NS
Abbreviations: FA: Fractional Anisotropy; MD: Mean Diffusivity, expressed as x10-4 mm2/s; NS: Not Significant; ROI: 
region of interest
Numbers represent mean (standard deviation)
a p-value for difference between both groups (good and poor hippocampal quality) calculaed with a two sample 
t-test
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Discussion
In this study we investigated the association between cingulum microstructural integrity 
and verbal memory performance by as well an ROI based approach and a TBSS analysis 
of the cingulum in 503 non-demented older adults with CSVD. We demonstrated that the 
microstructural integrity of the cingulum is specifically associated with verbal memory 
performance, independent of confounders, including hippocampal volume and coexisting 
CSVD. Furthermore, we found that when the integrity of the hippocampus is disrupted, the 
microstructural integrity of the cingulum is impaired as well. 
To the best of our knowledge, this is the first study investigating the association between the 
microstructural integrity of the cingulum and verbal memory function in a large group of non-
demented, independently living elderly with CSVD. Our data show that the microstructural 
integrity of the cingulum beyond the detection limit of conventional MRI is associated with 
episodic memory formation. On conventional MRI only less than 6% of the ROIs in the 
cingulum of our study population showed the presence of visible WMH, strengthening our 
assumption that we indeed investigated the earliest structural changes in the cingulum 
bundle integrity. 
Our finding is in line with the results of previous studies in patients with MCI or Alzheimer 
dementia showing that loss of structural integrity of the cingulum is associated with impaired 
verbal memory performance.36, 38, 74-76 
Furthermore, we found that participants with a poor hippocampal integrity (low volume and 
high MD) had a significantly lower microstructural integrity of the cingulum (high MD as well 
as low FA) than participants with a good hippocampal integrity (high volume and low MD). 
In addition, we found that the association between cingulum integrity and verbal memory 
performance did not differ significantly between both groups (good and poor hippocampal 
integrity). These results might suggest that hippocampal integrity is not an intermediate 
in this association. There is still much debate whether, in general, white matter pathology 
is related to, or independent of, grey matter pathology. There are three main hypotheses, 
one suggesting that microstructural white matter changes occur as a result of Wallerian 
degeneration,77 meaning that white matter pathology is preceded by grey matter pathology. 
In contrast, the retrogenesis theory proposes that loss of white matter integrity is the result of 
myelin breakdown that occurs in the reverse order to myelogenesis.78, 79 Furthermore, there is 
evidence that CSVD can cause white matter damage occurring as a result of oligodendrocyte 
death and reactive gliosis.80 Our results are not able to distinguish between these theories, 
also because of the cross-sectional design of our study. 
With our TBSS analysis we found that the microstructural integrity of the mid-anterior part 
of the cingulum is associated with impaired verbal memory, while our less precise ROI 
analysis found the mid-posterior part to be involved. As mentioned before, most studies in 
MCI and Alzheimer dementia found mainly involvement of the posterior cingulum. However, 
most of them included only a few ROIs in the cingulum, did not perform a TBSS analysis 
on the cingulum and investigate the cingulum integrity in patients with already MCI and/or 
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Alzheimer dementia. Probably, our results suggest that loss of structural integrity starts in the 
middle-anterior parts of the cingulum and maybe further spreading to the posterior parts, 
near medial temporal lobe structures, with progression of verbal memory impairment and 
ultimately dementia. Future studies are needed to describe the possible spread over time 
of the pathological process throughout the cingulum. A follow-up of the RUN DMC study is 
already being executed to further investigate this. 
Our findings show that cingulum integrity is specifically associated with verbal episodic 
memory. We did not find relations between cingulum integrity and psychomotor speed, 
visuospatial memory and MMSE. Although a recent study found associations between 
(posterior) cingulum integrity and attention/executive functioning and visuospatial memory,75 
this discrepancy might be due to the limited additional adjustments performed in the latter 
study. Furthermore, their study population differed from ours. Of their 220 participants, 149 
had MCI, while our study population had a mean MMSE of 28.1 and only a small percentage 
(10%) sufficed the diagnosis MCI according to the definition of van der Elst.51 As a result, it is 
likely that more damage to the structural integrity of the cingulum and medial temporal lobe 
structures like the hippocampus has occurred in the study population of Kantarci.75  
The reason for not finding a relation between DTI parameters and visuospatial memory 
in our study may be due to the fact that memory performance based on the RCFT may in 
part rely on motor learning. Therefore, the RCFT cannot be regarded as a pure measure of 
spatial memory, as part of episodic memory, which as a result may be less dependent of the 
hippocampal memory circuit. 
In our study also the corpus callosum is involved in verbal memory performance, as shown 
by our TBSS analysis. DTI abnormalities in MCI and Alzheimer dementia have been found in 
the corpus callosum.81, 82 A study of Christman and Propper83 showed that episodic memory is 
at least in part dependent on interhemispheric interaction. Furthermore, it has been reported 
that older adults show reduced hemispheric asymmetry in episodic memory functioning.84 
Disruption of the corpus callosum can lead to impaired interhemispheric interaction, 
resulting in impaired (verbal) memory performance. 
With respect to lateralization effects, our study showed that the strongest association with 
verbal memory in the left hemisphere. As would be expected from a verbal task, the dominant 
(left) hemisphere, containing the language centres (Broca and Wernicke), is more strongly 
involved in performing the RALVT, as most of our participants were right-handed. 
Still, a few methodological considerations need to be addressed. Although our data are 
derived from the largest DTI study on the cingulum thus far, our study design is cross-sectional, 
which prevents us from drawing conclusions with respect to causality. Data of our follow-up 
study,47 which is currently underway, might help to further investigate the structural integrity 
of the cingulum in relation to structural changes in the medial temporal lobe structures and 
in the development of cognitive decline and dementia. Furthermore, we used an atlas to 
identify the cingulum bundle, and manually placed the ROIs in order to avoid grey matter 
and white matter of other tracts to blur our DTI measures. Although the placement of the 
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atlas was visually checked and the placement of the ROIs was performed by an experienced 
neurologist, blinded to clinical data, this method can be somewhat subjective and can make 
interpretation between studies difficult.  
A major strength of our study is the fact that it is a large, single-centre study with a response 
rate of over 70%. All MRI data were acquired on a single scanner in a similar way, and the 
hippocampus and WMH were assessed volumetrically in a reliable, sensitive and objective 
way by two trained experts, who were blinded to all clinical data. Furthermore, extensive 
adjustments were made for possible confounders. Moreover, cognitive function was assessed 
by only two investigators using a standardized cognitive battery. 
In conclusion, this study demonstrates that microstructural integrity of the cingulum, assessed 
by TBSS analysis and a ROI-based approach, is specifically associated with episodic memory 
function, notably verbal memory, in non-demented older adults with CSVD.  Furthermore, we 
showed that the microstructural integrity of the cingulum is significantly lower in participants 
with a poor hippocampal integrity than in those with a good hippocampal integrity. 
Consequently, our findings show that DTI, by using a ROI-based and TBSS approach, is a 
sensitive diagnostic tool to detect early microstructural changes in the cingulum, which are 
related to impaired verbal memory, before structural changes of cingulum can be detected 
on conventional MRI. Future studies should prospectively investigate the predictive value of 
DTI parameters of the cingulum in relation to cognitive consequences of CSVD and incident 
dementia. If the predictive value is proven, DTI of the cingulum could possibly be a surrogate 
marker for development of cognitive decline and dementia and could be a starting point for 
therapeutic trials aiming to prevent disease progression. 

Part III
Cerebral small vessel disease and 
motor performance

3.
Baseline cerebral small vessel disease and gait decline
Published  as:
H.M. van der Holst, I.W.M. van Uden, K.F. de Laat, E.M.C. van Leijsen, A.G.W. van Norden, 
D.G. Norris, E.J. van Dijk, A.M. Tuladhar, F-E de Leeuw. 
Baseline cerebral small vessel disease is not associated with gait decline after 5 years. 
Movement Disorders Clinical Practice, 2016 Nov. DOI:10.1002/mdc3.12435 
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Abstract
Background: Cerebral small vessel disease (CSVD) is cross-sectionally associated with 
gait disturbances; however, the relation between baseline CSVD and gait decline over 
time is uncertain. Furthermore, diffusion tensor imaging (DTI) studies on gait decline are 
currently lacking. 
Objective: To investigate the association between baseline imaging CSVD markers and 
gait decline. 
Methods: In 2006, 310 participants from the RUN DMC cohort, a prospective cohort with 
older adults aged 50-85 years with CSVD, were included. Gait variables were assessed 
using a computerized walkway (GAITRite) during baseline and follow-up. Linear and 
logistic regression analyses were used to investigate the relation between imaging 
measures and gait decline and incident gait impairment (speed ≤ 1.0m/s). Tract-based 
spatial statistics (TBSS) analysis was used to identify possible differences in DTI measures 
of white matter tracts between participants with and without incident gait impairment.
Results: Mean age was 63.3 years (SD 8.4) and mean follow-up duration 5.4 years (SD 
0.2). No significant associations between imaging measures and gait decline were found. 
TBSS analysis revealed no significant differences in DTI measures between participants 
with and without incident gait impairment after additional adjustment for SVD. In sub-
analyses, a high total white matter hyperintensity (WMH) volume (OR 2.8 for highest 
quartile, 95% CI: 1.1-7.1) and high infratentorial WMH volume (OR 1.8 per SD increase, 
95% CI: 1.1-2.9) were associated with an increased 5-year risk of gait impairment, 
although this was not significant after correction for multiple testing. 
Conclusion: Baseline imaging CSVD markers were not associated with gait decline or 
incident gait impairment after 5 years. Future studies should investigate whether CSVD 
progression is related to gait deterioration. 
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Introduction
Gait impairment has a major impact on the quality of life of older adults and is associated with 
adverse outcomes including decline in activities of daily living, falls, cognitive impairment, 
hospitalization and death.25, 85, 86 Cerebral small vessel disease (CSVD) has been identified 
as a possible risk factor of gait impairment, albeit mainly in cross-sectional studies.16, 17 Few 
studies have investigated the relation between CSVD and gait decline over time, often only by 
taking white matter hyperintensities (WMH) into account, whereas the spectrum of traditional 
CSVD markers also includes lacunes, microbleeds and brain atrophy. These previous studies 
showed conflicting results, reporting no,87 or weak positive associations,88-90 of which some 
found a dose-dependent effect,89, 90 while others postulated a threshold effect of WMH88 after 
which gait decline became apparent. 
Possibly, the underlying microstructural integrity of the white matter (WM), which can be 
assessed by diffusion tensor imaging (DTI), plays a role in gait decline. It has been suggested 
that changes in WM integrity precede the development of WMH.91 Gait impairment has been 
cross-sectionally associated with WM integrity,92 however, studies on gait decline using DTI 
are currently lacking.
There is limited evidence about a clinical relevant change in gait speed.85 However, a gait 
speed <1.0m/s has been consistently associated with major adverse health-related outcomes 
in well-functioning older adults,86 which might therefore be a clinical useful cut point for the 
development of  gait impairment in clinical practice. To our knowledge, no previous studies 
have investigated the relation between CSVD and the development of gait impairment 
(speed <1.0m/s).
The aim of this study was to investigate whether baseline CSVD, including conventional MRI 
and DTI markers of CSVD, is associated with gait decline and incident gait impairment after 5 
years of follow-up. This study may provide insight into the role of CSVD and gait deterioration 
and could possibly help to identify adults with CSVD at highest risk for gait decline and 
incident gait impairment. 
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Methods
Study population
This study is part of the Radboud University Nijmegen Diffusion tensor and Magnetic resonance 
Cohort study (RUN DMC study), which studies the risk factors and clinical consequences of 
brain changes as assessed by MRI in 503 participants with CSVD. The recruitment, study 
rationale and protocol of the RUN DMC study have been described in detail elsewhere.47 A 
CSVD diagnosis was made based on the results of brain imaging and included the presence 
of WMH and/or lacunes of presumed vascular origin.48 In 2006, baseline data collection was 
performed. Inclusion criteria were age 50-85 years and CSVD on brain imaging. Main exclusion 
criteria were: parkinsonism, dementia, life expectancy <6 months, non-CSVD related WM 
lesions (e.g. multiple sclerosis), and MRI contra-indications.47 
Follow-up assessment was performed in 2011-2012. Of the 503 baseline participants, 398 
participated in the follow-up examination.  For the present study, we excluded 88 participants, 
yielding a final sample of 310 (see flowchart Figure 1). All participants signed an informed 
consent form. The Medical Review Ethics Committee region Arnhem-Nijmegen approved the 
study. 
Gait measurement and gait impairment
Quantitative gait analysis was performed by using a 5.6 meter electronic portable walkway 
(GAITRite, MAP/CIR Inc., Havertown, PA), which has an excellent test-retest reliability and 
validity.93, 94 Each participant was instructed to walk twice over the walkway at a self selected 
usual gait speed. In order to measure steady-state walking, participants started two meters 
before the walkway and stopped two meters behind it. The following gait parameters were 
averaged over two walks: gait speed (m/s) and its components stride length (m) (the distance 
between the heel points of two consecutive footprints of the same foot) and cadence 
(number of steps per minute). Changes over time in these  gait parameters were calculated 
as the difference between follow-up and baseline assessment. We considered a gait speed 
decline of ≥ 0.1m/s as a significant decline.25, 95 Gait impairment was defined as a gait speed 
<1.0m/s.86
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Baseline study population 
n = 503 
Lost to follow-up n = 2 
 
Deceased n = 49 
 
Unable to visit research centre n = 54 
• Illness that prevented visit (19) 
• Moved (5) 
• Lack of time (30) 
 Follow-up study population 
n = 398 
Exclusion criteria n = 88 
 
• Imaging artefacts at baseline (1) 
•Territorial infarcts at baseline (40) 
•Parkinsonism at follow-up (12) 
•Conditions associated with gait impairment other 
than CSVD at baseline and follow-up  (25) 
•Missing gait data at follow-up  (10) 
 
 Participants for analysis 
n = 310 
Figure 1. Flowchart of the study population
Abbreviations: CSVD: cerebral small vessel disease
Of the 503 baseline participants, 2 participants were lost to follow-up, 49 had died and 54 refused an in-person 
follow-up examination, but their clinical endpoints were available; 398 participated in the follow-up assessment. 
For the present study, we included 310 participants, 88 participants were additionally excluded because of (i) 
baseline T1-T2 artefacts (n=1), (ii) territorial infarcts at baseline imaging (n=40), because these infarcts were 
considered as a potential confounder, (iii) parkinsonism during follow-up examination (n=12), because apart 
from CSVD other pathologies as amyloid pathology, Lewy body pathology and nigrastriatal dopaminergic loss 
could play a role in gait deterioration in these patients, (iv) other conditions than CSVD associated with gait 
impairment which prevent participants from walking unaided at baseline and follow-up (n=25) (e.g. joint fusion, 
severe arthritis, severe polyneuropathy, leg amputation, severe vision problems, severe cardiac or respiratory 
diseases, severe peripheral arterial disease and psychogenic gait disturbance) and (v) missing data on follow-up 
GAITRite (n=10) (because they were wheelchair bound, because of home visit or technical problems), yielding a 
final sample of 310 participants.
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MRI protocol 
All participants underwent a cerebral MRI on a 1.5-Tesla Magnetom Sonata scanner (Siemens 
Medical Solutions, Erlangen, Germany) at baseline. The protocol included the following 
scans: a T1-weighted 3D magnetization-prepared rapid gradient-echo (MPRAGE) imaging 
(repetition time (TR)=2250ms, echo time (TE)=3.68ms, inversion time (TI)=850ms, flip 
angle=15°, voxelsize 1.0x1.0x1.0mm); a Fluid-attenuated inversion recovery (FLAIR) sequence 
(TR=9000ms, TE=84ms, TI=2200ms, voxelsize 1.0x1.2x5.0mm, with an interslice gap of 
1mm); a transversal T2*weighted gradient echo sequence (TR=800ms, TE=26ms, voxelsize 
1.3x1.0x5.0mm with an interslice gap of 1mm) and a DTI sequence (TR=10100ms, TE=93ms, 
voxelsize 2.5x2.5x2.5mm; 4 unweighted scans, 30 diffusion weighted scans with b-value=900 
s/mm²).  
MRI analysis
WMH were manually segmented on the FLAIR images and total WMH volume was calculated by 
summing all segmented areas multiplied by slice thickness, with a good inter-rater variability 
(intraclass correlation coefficient: 0.99). WMH were also determined in predefined regions 
taken from an inversely normalized Talairach-based atlas,96 and included frontal, parietal, 
occipital, temporal lobes and sublobar (basal ganglia, thalamus, internal and external 
capsule, insula), limbic (cingulate gyrus) and infratentorial (brainstem and cerebellum) 
areas. The ratings of lacunes and microbleeds were rated according to the recently published 
Standards for Reporting Vascular changes on neuroimaging (STRIVE)5 by trained raters 
blinded to clinical information (intra-rater and inter-rater reliabilities: for lacunes: weighted 
kappa values 0.87 and 0.95, respectively, and for microbleeds: 0.85 and 0.86, respectively).97 
To obtain grey matter (GM) and WM and cerebrospinal fluid (CSF) volume automated 
segmentation on T1 images was done using Statistical Parametric Mapping 12 unified 
segmentation routines (SPM12; Wellcome Department of Cognitive Neurology,  University 
College London, United Kingdom;  http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). The 
volumes were calculated by summing all the voxel volumes belonging to that tissue class. 
All images were visually checked for co-registration errors and motion and/or segmentation 
artefacts. All volumes were normalized to the total intracranial volume (sum of GM, WM and 
CSF)98 to adjust for head size. GM volume was composed of the volume of the neocortex, 
basal ganglia and thalamus. 
DTI analysis
Diffusion data were pre-processed and analyzed according to a previous described 
procedure.47 The diffusion-weighted images of each participant were realigned on the mean 
of the unweighted image using mutual information based co-registration routines from 
SPM5. The diffusion tensor32 and its eigenvalues were estimated using linear regression using 
an SPM5 add-on (http://sourceforge.net/projects/spmtools). Spurious negative eigenvalues 
were set to zero, after which the tensor derivates fractional anisotropy (FA) and mean 
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diffusivity (MD) were calculated.99 The mean unweighted image was used to compute the co-
registration parameters to the anatomic T1 reference image, which were then applied to all 
diffusion-weighted images and results. All images were visually checked for motion artefacts 
and co-registration errors. The mean FA and MD were then calculated in the total WM. 
For the tract-based spatial statistics (TBSS) analysis, DTIFit within the FSL toolbox was used 
to generate FA and MD images, which were imported into the TBSS pipeline.46 To create a FA 
skeleton, the mean FA image was thinned and subsequently this skeleton was thresholded 
at 0.3 to include major WM tracts. 
Cognition and other measurements
Global cognitive function was evaluated by the Mini Mental State Examination (MMSE)50 and 
the Cognitive Index, a constructed compound score. The cognitive index was calculated as 
the mean of the z-scores of the Speed Accuracy Tradeoff (SAT) score of the 1-letter subtask 
of the Paper-Pencil Memory Scanning Task, the mean of the SAT score of the reading task of 
the Stroop test, the mean of the Symbol-Digit Substitution task and the mean of the added 
score on the three learning trials of the Rey Auditory Verbal learning test and the mean of the 
delayed recall of this test.100 To adjust for the number of faults in the Paper-Pencil Memory 
Scanning Task and the Stroop test, we used SAT scores (accuracy (%)/reaction time). 
Barthel index (range 0-20) was used to assess functional independence.101
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics 20 for Windows. 
To compare the baseline characteristics between participants who were included in this 
study and those who dropped out, age and sex-adjusted ANCOVA or logistic regression were 
used. Gait parameters assessed during baseline and follow-up were compared by using 
paired t-tests. The associations between baseline imaging measures and changes in gait 
parameters were assessed using multiple linear regression analysis. Adjustments were made 
for follow-up duration and baseline age, sex, height, gait parameters, cognitive index and GM 
volume (when investigating traditional CSVD markers and DTI measures) and/or traditional 
CSVD markers (when investigating GM volume and DTI measures). WMH volume was log 
transformed, because of the skewed distribution. To ensure that multicollinearity was not 
present, variance inflation factor (VIF) was calculated for all regression models presented. 
The VIF scores were low (<3) for all models (VIF-scores >5 are considered to reflect high 
multicollinearity). Data were presented as standardized betas. 
Logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence 
intervals (CI) to quantify the relation between baseline imaging measures and incident gait 
impairment (<1.0m/s), adjusted for the same confounders as described above. 
Results with a p<0.05 were considered significant. Bonferroni corrections were used to 
correct for multiple testing. 
CHAPTER 3
50
To compare voxel-wise analyses of DTI measures (FA and MD) between participants with 
incident gait impairment (n=48) and those without gait impairment (n=240) a two-sample 
t-test was performed, using a permutation-based statistical interference as part of FSL 
toolbox (‘randomize’), with a standard number of permutation tests set a 5000. Adjustments 
were made for follow-up duration, baseline age, sex, height, gait speed, cognitive index and 
total brain volume and additionally for traditional CSVD markers. Four participants were 
excluded because of missing values of microbleeds and DTI artefacts.
Table 1. Baseline characteristics of the study sample
 
Characteristics 
Participants 
included 
Participants not 
included 
p-value for 
difference
Demographics n = 310 n = 193
Age, mean (SD), years 63.3 (8.4) 69.5 (8.1) <0.001a
Male sex, No. (%) 173 (55.8) 111 (57.5) 0.80b
MMSE  score, mean (SD) 28.4 (1.5) 27.7 (1.8) 0.005a
Cognitive index, mean (SD) 0.24 (0.74) -0.42 (0.67)c <0.001a
Barthel index, mean (SD) 19.8 (0.5) 19.5 (1.2) 0.002a
Gait characteristics n = 310 n = 189d
Gait speed, mean (SD), m/s 1.37 (0.22) 1.13 (0.29) <0.001a
Gait impairment (gait speed <1.0m/s), No. (%) 18 (5.8) 52 (27.5) <0.001b
Imaging measures e n = 310 n = 192f
WMH volume, median (IQR), mL 5.1 (2.9-12.0) 13.3 (5.9-25.5) <0.001a
Lacunes, presence, No. (%) 56 (18.1) 78 (40.6) <0.001b
Microbleeds, presenceg, No. (%) 43 (14.0) 38 (19.9) 0.82b
WM volume, mean (SD), mL 472.9 (37.9) 450.6 (50.3) 0.02a
GM volume, mean (SD), mL 628.4 (46.9) 596.0 (50.4) <0.001a
WM global FAh, mean (SD) 0.33 (0.02) 0.32 (0.02) 0.007a
WM global MDh, mean (SD), x10-3mm2/s 0.88 (0.04) 0.91 (0.04) 0.008a
Abbreviations: FA: fractional anisotropy; GM: grey matter; IQR: interquartile range; MD: mean diffusivity; MMSE: 
Mini Mental State Examination; SD: standard deviation; WM: white matter; WMH: WM hyperintensity
a age and sex adjusted using ANCOVA.
b age and sex adjusted using logistic regression.
c 1 participant was excluded because of missing cognitive data.
d 4 participants were excluded because of missing values on baseline gait speed.
e Brain volumes are represented normalized to the total intracranial volume.
f 1 participant was excluded because of imaging artefacts
g  Respectively 3 (in group included in analysis) and 1 participant(s)(in group not included in analysis) were 
excluded because of missing values of baseline microbleeds.
h Respectively 2 (in group included in analysis) and 1 participant(s) (in group not included in analysis) were 
excluded because of baseline DTI artefacts. 
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Results
Characteristics of the study population are shown in Table 1. Mean age of the study population 
at baseline was 63.3 years (SD8.4) and mean follow-up duration was 5.4 years (SD0.2). Those 
who were excluded were older, had a slower gait, had smaller GM and WM volumes, higher 
WMH volume, higher presence of lacunes and lower FA and higher MD parameters at baseline 
in comparison to those who participated (Table 1). 
Out of 310 participants, 48 (15.5%) developed gait impairment during follow-up, 18 had 
already an impaired gait at baseline and 244 participants maintained a gait speed above 
1.0 m/s at follow-up. In total, 11.6% showed no gait decline and 71.9% had gait decline of 
≥0.1m/s.  After 5 years of follow-up, there was a significant reduction in gait speed, stride 
length and cadence in the total study population (Table 2). 
There were no significant associations between the baseline traditional CSVD markers (WMH 
volume, WM and GM volume and the number of lacunes and microbleeds) and DTI measures 
of the WM and changes in gait parameters (including gait speed, stride length and cadence) 
(Table 3) and incident gait impairment (Table 4). 
The TBSS analysis revealed higher MD values in multiple WM tracts in participants with 
incident gait impairment compared to those without (Figure 2). However, these differences 
were not significant after additional adjustment for conventional CSVD markers. For FA values 
no significant differences were found between both groups (data not shown).
In sub-analyses, a possible threshold effect was seen for WMH volume; participants with the 
highest quartile of WMH volume (>11.6mL) had an increased 5-year risk for the development 
of gait impairment (OR 2.8, 95%CI: 1.1-7.1, p=0.03 in comparison to participants with the 
1st-3rd quartiles of WMH volume, range 0.6-11.6mL), although this remained not significant 
after correction for multiple testing (data not shown). No threshold effects were found for the 
other imaging measures. 
The region-specific sub-analyses of WMH, showed that baseline WMH volume in the 
infratentorial region (brainstem and cerebellum) was associated with gait decline (gait 
speed decline β=-0.22, p=0.008; stride length decline β=-0.18, p=0.03; cadence decline β=-
0.24, p=0.01) (Table 5) and incident gait impairment after 5 years of follow-up (OR 1.8 per SD 
increase, 95%CI: 1.1-2.9, p=0.02) (Table 6), although this was not significant after correction 
for multiple testing. 
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Table 3. Association between baseline imaging measures and changes in gait 
Change in gait parameters
Baseline imaging characteristics 
(n=310)
Δ Gait 
speed (m/s)
Δ Stride 
length (m)
Δ Cadence 
(steps/min)
WMH volumea, per SDb -0.04 -0.09 0.03 
Lacunes, per numberb 0.01 0.01 -0.02
Microbleedsc, per numberb 0.04 0.03 0.06 
WM volume, per SDb 0.10 0.09 0.07 
GM volume, per SDd 0.07 0.09 -0.02 
WM global FAe, per SDb,d -0.02 -0.05 0.04
WM global MDe, per SDb,d 0.05 0.04 0.01
Abbreviations: FA: fractional anisotropy; GM: grey matter; MD: mean diffusivity (x10-4 mm2/s); SD: standard 
deviation; WM: white matter; WMH: WM hyperintensity
Data are standardized beta-values. 
All covariates are adjusted for time between baseline and follow-up assessment and the following baseline 
covariates: age, sex, height, gait parameters and cognitive index. 
a log transformed.
b adjusted in addition for grey matter volume.
c 3 participants were excluded because of missing values of microbleeds at baseline.
d adjusted in addition for traditional CSVD markers (WMH volume, number of lacunes and microbleeds and WM 
volume). 
e 2 participants were excluded for DTI analyses because of baseline DTI artefacts.
*p<0.05.
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Table 4. Association between baseline imaging measures and the risk of incident gait impairment 
at follow-up 
Baseline imaging characteristics 
(n=292)a
Odds ratio (95% CI) for 
incident gait impairmentb  
(n=48)
p-value
WMH volume, per SD  1.35 (0.93-1.96)c 0.12
Lacunes, presence 0.90 (0.33-2.48)c 0.84
Microbleeds, presenced 1.55 (0.57-4.24)c 0.39
WM volume, per SD 0.98 (0.63-1.51)c 0.92
GM volume, per SD 0.89 (0.52-1.53)e 0.68
WM global FA, per SDf 0.98 (0.58-1.23)c,e 0.95
WM global MD, per SDf  0.98 (0.51-1.88)c,e 0.94
Abbreviations: CI: confidence interval; FA: fractional anisotropy; GM: grey matter; MD: mean diffusivity (x10-
4mm2/s); per SD: odds ratios per standard deviation difference from the mean; WM: white matter; WMH: WM 
hyperintensity. 
All covariates are adjusted for time between baseline and follow-up assessment and the following baseline 
covariates: age, sex, height, gait speed and cognitive index.
a 18 participants with baseline gait speed impairment were excluded from this analysis.
b defined as a gait speed <1.0 m/s at follow-up. 
c adjusted in addition for grey matter volume.
d 3 participants were excluded because of missing values of microbleeds at baseline.
e adjusted in addition for traditional CSVD markers (WMH volume, number of lacunes and microbleeds and WM 
volume).
f 2 participants were excluded for DTI analyses because of baseline DTI artefacts.
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Discussion
In this cohort study with older adults with CSVD we found no significant associations 
between baseline imaging markers of CSVD and gait decline or incident gait impairment 
after 5 years, even though our population showed a mean gait decline of 0.2m/s in 5 years 
and a considerable amount of participants developed gait impairment (15.5%). In our TBSS 
analysis, we found higher baseline MD values in multiple WM tracts in participants with 
incident gait impairment compared to those without. However, this remained not significant 
after additional adjustment for traditional CSVD markers. In sub-analyses, we found that 
participants with the highest quartile of baseline WMH volume had an increased 5-year 
risk of incident gait impairment. Furthermore, region-specific analyses revealed that WMH 
in the infratentorial region were associated with gait decline and incident gait impairment 
after 5 years. Although, results of these sub-analyses were not significant after correction for 
multiple testing. 
Major strengths of our study include the single-centre design, the quantitative measurement 
of gait, the inclusion of multiple imaging markers of CSVD, including DTI measures, and 
the follow-up duration of 5 years. Furthermore, all imaging data were analyzed by raters 
blinded to clinical information and adjustments for several confounders, including cognitive 
performance, were made. No adjustments were made for cardiovascular risk factors, as we 
considered them part of the causal chain of CSVD. 
A methodological consideration includes the occurrence of attrition bias, because a 
considerable number of participants could not be included in the present study. As these 
participants were older, more disabled and had a higher load of CSVD, it is possible that the 
strength of the associations may have been underestimated. 
Previous performed studies on baseline CSVD and gait decline over time are limited and 
their results are conflicting.87-90 These studies are mostly performed in ageing populations 
(mean age>72years), with often already a low gait speed (<1.0m/s) at baseline,89, 90 which 
make comparison to our study difficult. Furthermore, no corrections were made for multiple 
testing in these previous studies.  Extending our previous findings in which we showed 
that baseline CSVD is associated with incident parkinsonism, with lower body symptoms, 
including gait difficulties, being the dominant feature of these patients,97 we hypothesized 
that baseline CSVD might also be associated with gait decline over time. Surprisingly, we 
found no associations between baseline CSVD markers and gait decline after 5 years of follow-
up, despite the observation of a considerable deterioration of gait in our participants. Several 
possible explanations could be proposed for finding. First, CSVD is just one of multiple risk 
factors of gait impairment, as gait is the result of a complex interaction between many (organ) 
systems, including the peripheral and central nerve system, cardiovascular and pulmonary 
system and musculoskeletal system.15 This is in accordance with the results of a recent 
study, showing that a high disease burden across multiple organ systems at baseline was 
associated with gait decline in a community-based population aged  ≥65 years.102 No specific 
system was found to be primarily responsible for the observed gait decline over 6 years.102 
CHAPTER 3
56
Table 5. Association between baseline WMH volume per location and changes in gait
Change in gait parameters
Baseline WMH volume per location 
(n=310)
Δ Gait 
speed (m/s)
Δ Stride 
length (m)
Δ Cadence  
(steps/min)
Frontal lobe WMH volumea -0.06 -0.09 0.15
Parietal lobe WMH volumea 0.01 0.05 -0.02
Temporal lobe WMH volumea -0.04 -0.03 -0.10
Occipital lobe WMH volumea -0.05 -0.05 -0.06
Sublobar WMH volumea 0.22 0.18 0.17
Limbic WMH volumea -0.01 0.03 -0.03
Infratentorial WMH volumea -0.22b -0.18b -0.24b
Abbreviations: WMH: white matter hyperintensity
Data are standardized beta-values. 
All covariates are adjusted for time between baseline and follow-up assessment and the following baseline 
covariates: age, sex, height, gait parameters, cognitive index, grey matter volume and total WMH volume.
a log transformed.
bp<0.05. Bold values indicate significance after Bonferroni correction (p<0.007).
Table 6. Association between baseline WMH volume per location and the risk of incident gait 
impairment at follow-up 
Baseline WMH volume per location 
(n=292)a
Odds ratio (95% CI) for 
incident gait impairmentb 
(n=48)
p-value
Frontal lobe WMH volume, per SD  0.34 (0.09-1.22) 0.34
Parietal lobe WMH volume, per SD  0.75 (0.34-1.64) 0.47
Temporal lobe WMH volume, per SD  1.49 (0.73-3.03) 0.27
Occipital lobe WMH volume, per SD  1.20 (0.74-1.96) 0.46
Sublobar lobe WMH volume, per SD  0.63 (0.28-1.45) 0.63
Limbic lobe WMH volume, per SD  1.13 (0.42-3.07) 0.81
Infratentorial WMH volume, per SD 1.77 (1.10-2.85) 0.02
Abbreviations: CI: confidence interval; per SD: odds ratios per standard deviation difference from the mean; 
WMH: white matter hyperintensity. 
All covariates are adjusted for time between baseline and follow-up assessment and the following baseline 
covariates: age, sex, height, gait speed, cognitive index, grey matter volume and total WMH volume.
a 18 participants with baseline gait speed impairment were excluded from this analysis.
b defined as a gait speed <1.0 m/s at follow-up. 
Bold values indicate significance after Bonferroni correction (p<0.007).
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Figure 2. Differences in baseline mean diffusivity values between participants with and without 
incident gait impairment after 5 years
Voxel-wise analysis of the differences in baseline mean diffusivity (MD) values between participants with 
incident gait impairment (n=48) and without gait impairment (n=240; 4 participants were additionally excluded 
because of missing values of microbleeds and DTI artefacts). Adjusted for follow-up duration, baseline age, sex, 
height, gait speed, cognitive index and normalized total brain volume (model 1) and additionally for traditional 
CSVD markers (WMH volume, number of lacunes and microbleeds) (model 2), performed with a two sample 
t-test, thresholded at p<0.05 and corrected for multiple comparisons. These images are superimposed onto the 
spatially normalized Montreal Neurological Institute (MNI) stereotactic space FA map. R indicates right side. The 
x, y and z coordinates represent the MNI coordinates of each slide. 
odel 1
Model 2
z = 19   x = -13
<0.01
p<0.05
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This indicates that accumulation of pathology in multiple organ systems, which in part may 
share the same common pathway by cardiovascular risk factors, might be a better predictor 
of gait decline. This might possibly also explain our result that only participants with the 
highest quartile of WMH at baseline seemed to have an increased risk for the development of 
gait impairment, as a high WMH volume might be a reflection of increased  (vascular) damage 
to cerebral networks and possibly also to other organ systems. However, a note of caution 
is needed here, due to wide confidence intervals and multiple testing. Second, by initially 
analyzing total burden of the different CSVD markers, we could have missed region-specific 
associations.  We therefore performed region-specific sub-analysis revealing associations 
between WMH in the infratentorial region and gait decline, although these associations 
were not significant after correction for multiple testing. Our results are in line with a cross-
sectional study, which also showed that participants with WMH in the brainstem walked 
slower.103 An explanation for this finding might be that these WMH could damage motor fibres 
in the corticospinal and spinocerebellar tracts, as well as numerous cerebellovestibular 
connections, which are centered in a relatively small area in comparison to supratentorial 
regions.103 Third, it may be that progression of CSVD is associated with gait decline, rather 
than baseline burden of CSVD. Most of our participants had only mild to moderate severe 
CSVD at baseline, which may have prevented us for finding significant associations. A recent 
study showed that WM atrophy and WMH progression were associated with gait decline after 
2.5 years of follow-up.104 A future study of the RUN DMC is underway to further investigate this. 
Our study is unique in using baseline DTI measures in relation to gait decline. Nevertheless, 
our TBSS analysis revealed no significant differences in baseline WM microstructural 
integrity between participants with and without incident gait impairment independent of 
conventional MRI markers of CSVD. DTI might however be of interest for future research as 
a recent study showed that change in DTI  measures could serve as a sensitive marker for 
CSVD progression, especially MD.105 Therefore, future studies should  focus on changes in DTI 
measures in relation to gait decline, in addition to changes in conventional MRI markers of 
CSVD. We hypothesize that changes in diffusion measures might be a better marker of gait 
deterioration than traditional CSVD markers, as loss of WM microstructural integrity might 
possibly underlie and precede the earlier observed relation between WM atrophy and WMH 
progression and gait decline.104
In conclusion, in older adults with CSVD traditional CSVD markers and WM microstructural 
integrity at baseline are not associated with gait decline or incident gait impairment after 5 
years. This result might, however, in part be driven by the attrition bias in our study, despite 
the fact that a high percentage of our participants experienced a significant gait decline. 
Future studies should be directed at changes in these cerebral imaging markers in relation 
to gait decline, as this could provide more insight into the role of (progression of) CSVD to 
gait deterioration, which more and more burdens the health care system of aging societies. 
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White matter changes and gait decline
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Leijsen,  M. Ghafoorian, B. Platel, M.I. Bergkamp, A.G.W. van Norden, D.G. Norris, E.J. van 
Dijk, A.J. Kiliaan, F-E de Leeuw.
White matter changes are associated with gait decline in cerebral small vessel disease 
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Abstract
Objective: To investigate the longitudinal associations between (micro)structural brain 
changes and gait decline in cerebral small vessel disease using diffusion tensor imaging. 
Methods: From the Radboud University Nijmegen Diffusion tensor and Magnetic 
resonance imaging Cohort (RUN DMC), a prospective cohort of participants with 
cerebral small vessel disease aged 50-85 years, 275 participants were included. Gait 
(using GAITRite) and magnetic resonance imaging measures were assessed during 
baseline (2006-2007) and follow-up (2011-2012). Linear regression analysis was used 
to investigate the association between changes in conventional magnetic resonance 
and diffusion tensor imaging measures and gait decline. Tract-based spatial statistics 
analysis  was used to investigate region-specific associations between changes in white 
matter integrity and gait decline. 
Results: Of the 275 participants, 56.2% were male, mean age was 62.9 years (SD8.2), 
mean follow-up duration was 5.4 years (SD0.2) and mean gait speed decline was 0.2m/s 
(SD0.2). Stride length decline was associated with white matter atrophy (β=0.16,FDR-
adjusted p=0.04) and increase in mean white matter radial diffusivity (β=-0.14, FDR-
adjusted p=0.04), independent of age, sex, height, follow-up duration and baseline 
stride length. Tract-based spatial statistics analysis showed significant associations 
between stride length decline and fractional anisotropy decrease and mean diffusivity 
increase (primarily explained by radial diffusivity increase) in multiple white matter 
tracts, with the strongest associations found in the corpus callosum and corona radiata, 
independent of traditional cerebral small vessel disease markers.
Conclusion: white matter atrophy and loss of white matter integrity are associated with 
gait decline in older adults with cerebral small vessel disease after 5 years of follow-up.
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Introduction
Gait disturbances are prevalent in older adults aged ≥65 years and have important 
consequences as they can lead to falls, functional dependence and institutionalization.85, 
86 Cerebral small vessel disease (CSVD) ranks highest among vascular causes of gait 
decline, with evidence mainly coming from cross-sectional studies.17, 106 A few studies have 
investigated whether baseline CSVD can predict gait decline over time. However, their 
results are inconclusive.87-89 In a previous study, we found no associations between baseline 
CSVD and gait decline after 5 years in our CSVD population.107 One possible hypothesis is 
that progression of CSVD, rather than baseline CSVD load, is associated with gait decline 
over time. The results of recent longitudinal population-based studies investigating the 
association between progression of CSVD and gait decline are however conflicting.90, 104, 
108 Moreover, these studies did not include the whole CSVD spectrum, nor was the white 
matter (WM) integrity, which can be assessed using diffusion tensor imaging (DTI), taken into 
account. Since a recent study showed that scalar measures of DTI were sensitive markers of 
CSVD progression,105 we hypothesized that changes in DTI measures are stronger associated 
with gait decline than progression of the traditional CSVD markers. 
Here, we investigated the longitudinal associations between changes in the traditional 
CSVD markers (WMH, lacunes, microbleeds and brain atrophy) and changes in WM integrity 
(assessed by DTI), and gait decline in a population of adults with CSVD, aged 50-85 years, over 
a period of 5 years. 
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Methods
Study population
The Radboud University Nijmegen Diffusion tensor and Magnetic resonance Cohort study 
(RUN DMC study) prospectively investigates the risk factors and clinical consequences of 
brain changes as assessed by MRI. This cohort study consists of 503 participants with CSVD, 
aged 50-85 years at baseline (2006). The recruitment, study rationale and protocol of the 
RUN DMC study have been described elsewhere.47 Inclusion criteria were age 50-85 years and 
CSVD on neuroimaging (defined as the presence of WMH or lacunes of presumed vascular 
origin).48 All consecutive patients referred to our outpatient clinic who underwent diagnostic 
brain imaging for several reasons (e.g. stroke, TIA, cognitive complaints) were eligible for 
participation. Main exclusion criteria were: parkinsonism, dementia, life expectancy < 6 
months, non-CSVD related WM lesions and MRI contra-indications.47 
Follow-up assessment was completed in 2012. Of the 503 baseline participants, 398 
participated in the follow-up assessment. For the present study, 123 participants were 
additionally excluded, yielding a final sample of 275. Exclusion reasons at baseline and follow-
up were: missing data on MRI and gait data, territorial infarcts, parkinsonism and conditions 
associated with gait impairment other than CSVD and parkinsonism (see flowchart Figure 1). 
Standard protocol approvals, registration, and patient consents
All participants signed an informed consent form. The Medical Review Ethics Committee 
region Arnhem-Nijmegen approved the study. 
Gait measurement and gait impairment
The assessment of gait was performed by using a 5.6 meter electronic portable walkway 
(GAITRite, MAP/CIR Inc., Havertown, PA), which has an excellent test-retest reliability and 
validity.93, 94 Participants were instructed to walk over the walkway at their comfortable 
walking speed. In order to measure steady-state walking, they started two meters before the 
walkway and stopped two meters behind it. The following gait parameters were averaged 
over two walks: gait speed (m/s) and its components stride length (m) (the distance between 
the heel points of two consecutive footprints of the same foot) and cadence (number of steps 
per minute). Changes in these gait parameters were calculated as the difference between 
follow-up and baseline assessment. 
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Figure 1. Flowchart of the study sample 
Abbreviations: DTI: diffusion tensor imaging; MRI: magnetic resonance imaging; CSVD: cerebral small vessel 
disease. 
Of the 503 baseline participants, 2 participants were lost to follow-up, 49 had died and 54 refused an in-
person follow-up examination, but their clinical endpoints were available; 398 participated in the follow-up 
assessment. For the present study, we included 275 participants, 123 participants were additionally excluded 
because of because of (i) MRI contra-indications, MRI artefacts or missing values at follow-up (n=46), (ii) missing 
data on follow-up GAITRite (n=12) (because they were wheelchair bound, because of home visit or because of 
technical problems), (iii) territorial infarcts at baseline and follow-up imaging (n=43), because these infarcts were 
considered as a potential confounder, (iv) conditions associated with gait impairment other than CSVD which 
prevented participants from walking unaided at baseline and follow-up (n=13) (joint fusion, severe arthritis, 
severe polyneuropathy, leg amputation, severe vision problems, severe cardiopulmonary diseases, severe 
peripheral arterial disease and psychogenic gait disturbance), (v) parkinsonism during follow-up examination 
(n=6), because apart from CSVD other pathologies as amyloid pathology, Lewy body pathology and nigrastriatal 
dopaminergic loss could play a role in gait deterioration in these patients, and (vi) DTI artefacts (n=3).
Baseline study population 
n = 503 
Lost to follow-up n = 2 
 
Deceased n = 49 
 
Unable to visit research centre n = 54 
• illness that prevented visit (19) 
• moved (5) 
• lack of time (30) 
 Follow-up study population 
n = 398 
Exclusion criteria n = 123 
 
• MRI contra-indications/artefacts/missing (46) 
• Missing gait data at follow-up (12)  
• Territorial infarcts baseline and follow-up (43) 
• Conditions associated with gait impairment       
other than CSVD at baseline and follow-up (13) 
• Parkinsonism at follow-up (6) 
• DTI artefacts (3)  
 
 Participants for analysis 
n = 275 
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MRI protocol 
A cerebral MRI was acquired on a 1.5-Tesla scanner at baseline and follow-up (baseline: 
Magnetom Sonata; follow-up: Magnetom Avanto Tim (76x32); Siemens Medical Solutions, 
Erlangen, Germany). The same 8-channel head coil was used at baseline and follow-
up. The protocol included: a T1-weighted 3D magnetization-prepared rapid gradient-
echo (MPRAGE) imaging (baseline: repetition time (TR)/ echo time (TE)/ inversion time 
(TI) 2250ms/3.68ms/850ms, flip angle=15°, voxelsize 1.0x1.0x1.0mm; follow-up: TR/TE/
TI 2250ms/2.95ms/850ms, flip angle=15°, voxelsize 1.0x1.0x1.0mm); a Fluid-attenuated 
inversion recovery (FLAIR) sequence (baseline: TR/TE/TI 9000ms/84ms/2200ms, voxelsize 
1.2x1.0x5.0mm (interslice gap 1mm); follow-up: TR/TE/TI 14240ms/89ms/2200ms, voxelsize 
1.2x1.0x2.5mm (interslice gap 0.5mm); a transversal T2*weighted gradient echo sequence 
(baseline and follow-up: TR/TE 800ms/26ms, voxelsize 1.3x1.0x5.0mm (interslice gap 1mm)) 
and a DTI sequence (baseline: TR/TE 10100ms/93ms, voxelsize 2.5x2.5x2.5mm; 4 unweighted 
scans, 30 diffusion weighted scans with b-value=900 s/mm²; follow-up: TR/TE 10200ms/95ms, 
voxelsize 2.5x2.5x2.5mm; 7 unweighted scans, 61 diffusion weighted scans with b-value=900 
s/mm²).  
Traditional CSVD markers and brain volumetry
Traditional CSVD makers (WMH, lacunes and microbleeds) were rated according to the 
STRIVE criteria.5 Lacunes were manually rated on FLAIR/T1-weighted scans and microbleeds 
on T2*-weighted MRI scans by raters blinded to clinical data. The follow-up FLAIR images 
were resliced to match the slice thickness of baseline FLAIR images, limiting the differences 
in partial volume effects between baseline and follow-up scans. Intrarater and interrater 
reliabilities were good (for lacunes: weighted kappa values 0.87 and 0.95, respectively, and 
for microbleeds: 0.85 and 0.86, respectively). WMH were segmented by using an in-house 
developed semi-automatic detection method on baseline and follow-up FLAIR sequences.109 
All scans were visually checked by 1 rater and corrections were made when segmentation 
failures had occurred. Total WMH volume was calculated by summing all segmented areas 
multiplied by slice thickness.
Automated segmentation on T1 images of baseline and follow-up was performed using 
Statistical Parametric Mapping 12 unified segmentation routines (SPM12; Wellcome 
Department of Cognitive Neurology, University College London, United Kingdom, http://
www.fil.ion.ucl.ac.uk/spm/software/spm12/), in order to obtain grey matter (GM), WM and 
cerebrospinal fluid (CSF) probability maps. To avoid the erroneous segmentation of WM 
regions with WMH as GM, the T1 images were first corrected using the binary maps of WMH 
by replacing the voxel intensities of WMH with the average intensity of the normal-appearing 
WM on the T1 images. The volumes were calculated by summing all the voxel volumes 
belonging to the tissue class. All images were visually checked for co-registration errors and 
motion and/or segmentation artifacts. Total brain volume was taken as the sum of total GM 
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and WM volume. GM volume was composed of the volume of the neocortex, basal ganglia 
and thalamus. 
To account for inter-scan-effects, we corrected the normalized follow-up brain volumes 
for the difference in intracranial volume (ICV; sum of GM, WM and CSF) between baseline 
and follow-up by multiplying all volumes by the factor ‘ICV baseline/ICV follow-up’. Next, all 
volumes were normalized to the baseline ICV to adjust for head size.98 We calculated brain 
volume change and changes in the number of lacunes and microbleeds as the difference 
between follow-up and baseline. 
DTI analysis
Diffusion data were preprocessed and analyzed according to a previous described 
procedure47 for baseline and follow-up DTI scans. In short, after eddy current and motion 
artifacts corrections on the raw diffusion data, we created fractional anisotropy (FA), mean 
diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD) images using DTIFit within 
FSL, which were then fed into the tract-based spatial statistics (TBSS) pipeline.46 An FA 
skeleton was created by thinning the mean FA image based on the FA values. This skeleton 
was then thresholded at 0.3 to include major WM tracts. The images of MD, AD and RD were 
subsequently projected on this mean FA skeleton, by applying the projection vectors from 
each participant’s FA-to-skeleton transformation. Changes in the diffusion parameters were 
derived by calculating the difference between DTI measures of the skeleton at follow-up and 
baseline. 
Statistical analysis 
Statistical analyses were performed using IBM (Armonk, NY) SPSS Statistics 20. To compare 
the baseline characteristics of participants who were included and those not, we used age 
and sex-adjusted ANCOVA or logistic regression analysis. For those included, gait and imaging 
characteristics at baseline and follow-up were compared by using a paired t-test, Wilcoxon 
signed rank test or McNemar test when appropriate. Multiple linear regression analysis was 
used to investigate the association between change in each gait variable and change in the 
different MRI and DTI measures. Adjustments were made for age, sex, follow-up duration 
(time between baseline and follow-up assessment), height and baseline gait variable. WMH 
volume was log transformed, because of the skewed distribution. The variance inflation factor 
(VIF) was calculated for all regression models to test for the presence of multicollinearity. The 
VIF scores were low for all models (scores were below 3, where VIF-scores >5 are considered 
to reflect high multicollinearity). Regression coefficients were presented as standardized 
beta-values. False discovery rate (FDR)-correction was used at a q-value<0.05 to correct for 
multiple comparisons.110 
Voxel-wise statistical analyses for changes in TBSS data and individual gait variables were 
performed by using permutation-based statistical interference tool for non-parametric 
approach as part of the FSL toolbox (randomize). The number of permutation tests was 
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set at 5000. Significant associations were determined by using a threshold-free cluster 
enhancement with a p-value<0.05, corrected for multiple comparisons. Adjustments were 
made for follow-up duration, age, sex, height and baseline gait variable (model A) and 
additionally for changes in MRI measures (including WMH volume, number of lacunes and 
microbleeds, WM and GM volume) (model B). 
Table 1. Baseline characteristics of the study population
Baseline characteristics Participants  
included
Participants not  
included
p-value for  
difference
Demographics n=275 n=228
Age, mean (SD), years 62.9 (8.2) 69.0 (8.3) <0.001a
Male sex, No. (%) 155 (56.4) 129 (56.6) 0.96b
MMSE score, mean (SD) 28.5 (1.5) 27.7 (1.8) 0.004a
Gait characteristics n=275 n=224c
Gait speed, mean (SD), m/s 1.4 (0.2) 1.2 (0.3) <0.001a
Gait impairment (<1.0m/s), No. (%) 12 (4.4) 58 (25.9) <0.001b
Imaging measuresd n=275 n=227e
WMH volume, median (IQR), mL 2.2 (0.8-6.3) 7.2 (2.6-15.9) 0.001a
WM volume, mean (SD), mL 467.2 (37.8) 439.6 (50.2) <0.001a
GM volume, mean (SD), mL 622.3 (49.0) 586.8 (50.2) <0.001a
Lacunes presence, No. (%) 44 (16.0) 88 (38.6) <0.001b
Microbleeds presence f, No. (%) 39 (14.3) 44 (19.5) 0.81b
WM global FA, mean (SD) 0.33 (0.02) 0.32 (0.02)g 0.01a
WM global MD, mean (SD), x10-3 mm2/s 0.88 (0.04) 0.91 (0.05)g <0.001a
Abbreviations: FA: fractional anisotropy; GM: grey matter; IQR: interquartile range; MD: mean diffusivity; MMSE: 
Mini Mental State Examination; SD: standard deviation; WM: white matter; WMH: white matter hyperintensity 
a age and sex adjusted using ANCOVA. 
b age and sex adjusted using logistic regression. 
c 4 participants were excluded because of missing values on baseline gait. 
d Brain volumes are represented normalized to the total intracranial volume. 
e 1 participant was excluded because of imaging artefacts. 
f 2 participants in both groups were excluded because of missing values of baseline microbleeds. 
g 3 participants were excluded because of baseline DTI artefacts. 
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Results
The total study population consisted of 275 participants with a mean (SD) follow-up duration 
of 5.4 (0.2) years and a mean age at baseline of 62.9 (8.2) years; 56.4% was male. Characteristics 
of the participants included in this study and those not included are shown in Table 1. Those 
not included were older, had a poorer cognitive performance, slower gait speed, higher WMH 
volume, more lacunes, lower WM and GM volume and lower FA and higher MD values of the 
WM. 
Table 2. Comparison of gait and imaging measures at baseline and follow-up (n=275)
Baseline Follow-up p-value
Gait characteristics
Gait speed, mean (SD), m/s 1.38 (0.21) 1.19 (0.21) <0.001a
Stride length, mean (SD), m 1.46 (0.18) 1.26 (0.18) <0.001a
Cadence, mean (SD), steps/min 113.9 (9.4) 113.0 (9.3) 0.06a
Imaging measures
WMH volume, median (IQR), mL 2.2 (0.8-6.3) 2.8 (1.2-8.0) <0.001b
WM volume, mean (SD), mL 467.6 (37.9) 457.0 (42.8) <0.001a
GM volume, mean (SD), mL 622.8 (49.1) 612.0 (50.2) <0.001a
Lacunes presence, No. (%) 44 (16.0) 61 (22.2) <0.001c
Microbleeds presence d, No. (%) 39 (14.3) 56 (20.4) <0.001c
FA of skeleton, mean (SD) 0.49 (0.03) 0.47 (0.03) <0.001a
MD of skeleton, mean (SD), x10-3 mm2/s 0.80 (0.04) 0.82 (0.05) <0.001a
Abbreviations: AD: axial diffusivity; FA: fractional anisotropy; GM: grey matter; IQR: interquartile range; MD: mean 
diffusivity; RD: radial diffusivity; SD: standard deviation; WM: white matter; WMH: white matter hyperintensity
a paired T-test
b Wilcoxon signed rank test
c McNemar test
d respectively 2 and 1 participant(s) had missing values of microbleeds at baseline and follow-up  
Table 2 shows the gait and imaging characteristics of our study population at baseline and 
follow-up. Mean gait speed decline was 0.2m/s (SD0.2) over 5 years (p<0.001, one sample 
t-test), mainly due to reduction in stride length (mean decline of 0.2m (SD0.1), p<0.001). We 
found a non-significant decrease of cadence (mean decline 0.9 steps/min (SD7.5), p=0.06).  
There was a significant increase of WMH volume, presence of lacunes and microbleeds and 
MD, RD and AD values of WM tracts between baseline and follow-up. A significant decrease 
was seen for WM and GM volume and FA value of the WM tracts during follow-up (Table 2).
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Progression of traditional CSVD markers and gait decline
A decline in WM volume was associated with a decline in stride length (β=0.16, FDR-adjusted 
p=0.041), after adjustment for age, sex, follow-up duration, height, and baseline stride length 
(Table 3). No significant associations were found for changes in stride length and the other CSVD 
markers, or for changes in gait speed or cadence and changes in all traditional CSVD markers. 
Table 3. Association between changes in imaging measures and changes in gait 
Change in gait parameters
Change in imaging measures Δ Gait speed  
(m/s)
Δ Stride length  
(m)
Δ Cadence 
(steps/min)
ΔWMH volume a, mL -.03 -.05 .02
Δ WM volume, mL .10 .16 .04
Δ GM volume, mL .08 .10 .06
Δ Lacunes, No. .04 .01 .06
Δ Microbleeds, No. -.09 -.10  -.07
Δ FA of skeleton .06 .10  .01
Δ MD of skeleton, x10-4 mm2/s -.06 -.12 .05
Δ RD of skeleton,  x10-4 mm2/s -.07 -.14 .02
Δ AD of skeleton,  x10-4 mm2/s .01 -.03 .07
Abbreviations: AD: axial diffusivity; FA: fractional anisotropy; GM: grey matter; MD: mean diffusivity; RD: radial 
diffusivity; WM: white matter; WMH: white matter hyperintensity. 
Data are standardized beta-values.
Adjustments were made for age, sex, follow-up duration, height and baseline gait parameter (baseline gait 
speed, stride length or cadence respectively).
Bold values indicate significance at p<0.05, false discovery rate-corrected.
Δ indicates difference between follow-up and baseline assessment. 
a log transformed. 
Changes in DTI parameters and gait decline
Only significant associations were found for changes in DTI measures and changes in stride 
length, and not for changes in gait speed or cadence .An increase of RD value of WM tracts 
was associated with a decline in stride length (β= -0.14, FDR-adjusted p=0.041). Marginally 
significant associations were found between an increase of MD and stride length decline (β=-
0.12, FDR-adjusted p=0.054) (Table 3). 
Our longitudinal TBSS analysis showed significant associations between an increase of MD 
(primarily explained by an increase of RD) and to a lesser extent decrease of FA and decline 
in stride length (Figure 2), independent of traditional CSVD markers. These associations 
were primarily found in the corpus callosum, and superior and posterior corona radiata. 
In contrast, no significant associations were found between change in AD and decline in 
stride length or between changes in DTI measures and decline in gait speed or cadence after 
additionally controlling for the traditional CSVD markers (data not shown). 
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Discussion
In this longitudinal study, we found that WM atrophy and loss of WM integrity (indicated by an 
increase of MD and RD, and to a lesser extent decrease of FA) were associated with gait decline 
by affecting stride length in older adults with CSVD after 5 years of follow-up. Changes in DTI 
measures associated with stride length decline were primarily found in corpus callosum, and 
posterior and superior corona radiata, and were independent of traditional CSVD markers. In 
contrast, progression of the other CSVD markers, including increase of WMH volume, number 
of lacunes and microbleeds and GM atrophy, were not associated with gait decline.
Main strengths of this longitudinal and single-centre study include the quantitative 
assessment of gait parameters on the same GAITRite at baseline and follow-up, the follow-up 
duration of 5.4 years, in which participants showed a significant gait decline and progression 
of CSVD, and the exclusion of participants with conditions associated with gait impairment 
other than CSVD which allowed us to further elucidate the role of CSVD in gait decline. 
Several methodological issues need to be addressed. First, the dropout rate (45% of the study 
population) may have resulted in attrition bias. However, as those who were not included 
had a higher load of CSVD and a slower gait at baseline it may be that the found associations 
have been underestimated. Second, due to the observational design of our study, causal 
inference cannot be reliably made. The possibility of reverse causality, indicating that gait 
deterioration leads to a sedentary lifestyle and thereby to progression of CSVD and reduction 
of microstructural integrity, cannot be excluded. Third, we cannot rule out the possibility 
of residual confounding by unmeasured variables. Fourth, the effect of scanner upgrade 
(baseline: Avanto and follow-up: Avanto MRI scanner, using the same Siemens head coil) 
is unknown. It has previously been found that the volumetric measures remained reliable, 
even after scanner upgrade and that the variance of the volume differences relative to test-
retest reproducibility did not significantly change, however it may introduce a bias in the 
mean volume differences.111 Therefore, our results on macrostructural brain changes have 
to be interpreted with caution. The DTI protocol did not differ between baseline and follow-
up, except from the number of diffusion weighted scans (30 versus 61 diffusion-encoding 
gradient directions). The effect of number of gradient directions is however limited, as we 
have applied the diffusion tensor model (with 6 degree of freedom). With regard to the 
scanner upgrade, a previous study showed that the DTI parameters did not differ between 
the scanners.112 Therefore, we consider the DTI results as robust. 
We found that a decline in gait speed is primarily caused by a decline in stride length and not 
in cadence in our population. This is in line with our previous finding that stride length is a 
more sensitive marker for gait abnormalities in CSVD compared to cadence and gait speed.17
Furthermore, we showed that WM atrophy and changes in DTI measures were associated with 
gait decline in older adults with CSVD. The association between WM atrophy and gait decline 
has been reported earlier by Callisaya et al.104 In contrast to this study, we found no significant 
associations between gait decline and progression of WMH volume, or progression of other 
traditional CSVD markers. This could possibly be explained by the limited contribution of 
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each of these CSVD markers to gait decline, possible regional-specific associations of these 
CSVD markers on gait decline or a threshold-effect rather than a dose-dependent relation, as 
some evidence has been found for WMH.88 Furthermore, it might be that WM microstructural 
integrity is a moderator in the association between progression of traditional CSVD markers 
and gait decline, as one cross-sectional study showed that in participants with a greater WM 
microstructural integrity WMH were less strongly associated with gait in comparison to those 
with a low WM microstructural integrity.113 
Regional analysis of DTI determined several WM tracts involved in gait decline commonly 
affected by CSVD pathology.106 Consistent with, and extending our previous cross-sectional 
study,92 we demonstrated that the strongest associations between changes of DTI measures 
and decline in stride length were found in corpus callosum and corona radiata. The corpus 
callosum is an important WM tract in motor control, as this region contains commissural 
fibres connecting multiple cortical areas involved in gait planning, initiation and execution, 
including frontal, parietal and occipital cortices.114 Fibres from these regions converse into the 
corona radiata that as such contains projection fibres that are involved in motor pathways 
and thus plays a pivotal role in motor function.115 Our results suggest that progression of 
disruption of these WM tracts is associated with gait decline in CSVD. 
We found the strongest association with increase in MD, and especially RD values of the WM 
tracts and gait decline. This is consistent with data from a recent study showing that MD 
is a more sensitive marker for CSVD progression in comparison to FA in a CSVD population 
over a period of 3 years.105 An increase of MD, primarily explained by an increase in RD, is 
thought to represent demyelination in homogeneous parallel WM regions,116 which might 
be related to volume reduction of WM. This result might provide some support for the role of 
(ischemic) demyelination in CSVD related gait decline above axonal degeneration (reflected 
by an increase in AD), which has also been described in neuropathological studies of CSVD.117 
However, as DTI measures are dependent on eigenvalue sorting, it may be difficult to obtain 
reliable measures in complex WM architecture (e.g. areas with crossing fibres) or pathology 
(e.g. CSVD)118 and therefore our results should be interpreted with caution. Our results might 
suggest that changes in MD of the WM, especially of the corpus callosum and corona radiata, 
could serve as an early marker of gait decline in an CSVD population.  
In conclusion, our data suggest that WM atrophy and loss of WM integrity, especially of the 
corpus callosum and corona radiata, are associated with gait decline over a period of 5 years 
in older adults with CSVD. These findings favour a role for WM pathology progression in gait 
decline in patients with CSVD and should therefore be considered as one of the possible 
causes of gait decline. Future studies should investigate the reproducibility of our results and 
the potential of DTI as surrogate and early marker of gait impairment in CSVD, for example in 
clinical trials. Meanwhile, clinical practitioners should focus on prevention strategies directed 
against progression of WM pathology in order to maintain ambulatory function in an aging 
society. 
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Abstract
Objective: To investigate the relation between baseline cerebral small vessel disease 
(CSVD) and the risk of incident parkinsonism using different MRI and diffusion tensor 
imaging (DTI) measures.
Methods: In the Radboud University Nijmegen Diffusion tensor and Magnetic resonance 
Cohort (RUN DMC) study, a prospective cohort study, 503 elderly participants with 
CSVD and without parkinsonism were included in 2006. During follow-up (2011-2012), 
parkinsonism was diagnosed according to UK Brain Bank criteria. Cox regression 
analysis was used to investigate the association between baseline imaging measures 
and incident all-cause parkinsonism and vascular parkinsonism (VP). Tract-Based 
Spatial Statistics analysis was used to identify differences in baseline DTI measures of 
white matter (WM) tracts between participants with VP and without parkinsonism.  
Results: Follow-up was available from 501 participants (mean age 65.6 years; mean 
follow-up duration 5.2 years). Parkinsonism developed in 20 participants; 15 were 
diagnosed with VP. The 5-year risk of (any) parkinsonism was increased for those with a 
high white matter hyperintensity (WMH) volume (Hazard ratio (HR) 1.8 per SD increase, 
95% confidence interval (CI) 1.3-2.4) and a high number of lacunes (HR 1.4 per number 
increase, 95% CI 1.1-1.8) at baseline. For VP, this risk was also increased by the presence 
of microbleeds (HR 5.7, 95% CI 1.9-16.8) and a low grey matter volume (HR 0.4 per SD 
increase, 95% CI 0.2-0.8). Lower fractional anisotropy values in bifrontal WM tracts 
involved in movement control were observed in participants with VP compared to 
participants without parkinsonism. 
Conclusions: CSVD at baseline, especially a high WMH volume and a high number of 
lacunes, is associated with incident parkinsonism. Our findings favour a role of CSVD in 
the aetiology of parkinsonism.
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Introduction 
Cerebral small vessel disease (CSVD) is a frequent finding on brain imaging of the elderly 
population9 and has been identified as a cause of motor impairment119 and gait and balance 
decline over time.120 CSVD has also been related to parkinsonism, with evidence coming 
from cross-sectional autopsy studies that found pathological proof of CSVD in patients with 
parkinsonism, who did not exhibit evidence of histopathologic findings compatible with 
parkinsonism, including Lewy bodies or tau inclusions.20, 21 Whether parkinsonism is a direct 
consequence of CSVD or a coincidental finding is unknown. 
The imaging spectrum of CSVD is rapidly expanding from lesions visible on conventional 
MRI, including white matter hyperintensities (WMH), lacunes, microbleeds, and (sub)cortical 
atrophy,5 to changes in diffusion measures of the white matter (WM) assessed by diffusion 
tensor imaging (DTI),91 which is regarded as an index of WM structural integrity. Recent cross-
sectional DTI studies have shown a relation between diffusion abnormalities in the WM 
and parkinsonism121, 122; however, longitudinal studies investigating the role of these MRI 
and DTI imaging characteristics in the development of parkinsonism are currently lacking. 
We therefore prospectively investigated the relation between CSVD, using baseline MRI 
and DTI measures, including tract-based spatial statistics (TBSS), and the development of 
parkinsonism, in order to gain insight into the role of CSVD in incident parkinsonism. 
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Materials and methods
Study population
This study is embedded in the Radboud University Nijmegen Diffusion tensor and Magnetic 
resonance Cohort (RUN DMC) study, a prospective cohort study that investigates the risk 
factors and clinical consequences of functional and structural brain changes as assessed 
by MRI in 503 independently living elderly participants with CSVD. The primary outcome 
of the longitudinal part of the RUN DMC study is incident parkinsonism and dementia. The 
recruitment, study rationale and protocol of the RUN DMC study have been described in 
detail elsewhere.47 CSVD was defined as the presence of any WMH or lacunes of presumed 
vascular origin on brain imaging,48 because the onset of CSVD is often insidious and clinically 
heterogeneous with acute symptoms (transient ischemic attacks (TIA) or lacunar syndromes), 
or subacute symptoms, including cognitive, motor or mood disturbances.123 All consecutive 
patients referred to our department who underwent diagnostic brain imaging (CT or MRI scan) 
for several reasons (e.g., stroke, TIA, cognitive complaints) were selected for participation. 
Inclusion criteria were age between 50-85 years and CSVD on brain imaging. Main exclusion 
criteria were parkinsonism, dementia, CSVD mimics, and MRI contra-indications. Patients 
eligible because of a lacunar syndrome were included >6 months after the event.
Baseline assessment, including an extensive cognitive and motor evaluation and a cerebral 
MRI, took place in 2006 among 503 participants. In 2011-2012, this assessment was repeated; 
2 participants were lost to follow-up (but not deceased), 49 had died and 54 refused an in-
person follow-up, but their clinical endpoints were available; 398 participated in the follow-
up examination (Figure 1). 
Standard protocol approvals, registrations, and patient consents
All participants signed an informed consent form. The Medical Review Ethics Committee 
region Arnhem-Nijmegen approved the study. 
BASELINE CEREBRAL SMALL VESSEL DISEASE AND INCIDENT PARKINSONISM. 
79
1
2
3
4
5
6
7
8
9
A
Figure 1. Flowchart of RUN DMC study design of baseline and follow-up 
Baseline and follow-up study population are presented in double lined boxes. 
Abbreviations: MRI: Magnetic Resonance Imaging
Baseline study population 
n = 503 
 
Free of dementia and parkinsonism  
completed MRI protocol 
Lost to follow-up 
n = 2 
Follow-up study population 
n = 501 
Deceased  
n = 49 
but clinical endpoints were obtained 
Follow-up cognitive, motor and MRI 
investigation 
n = 398 
Unable to visit our research centre 
n = 54  
but clinical endpoints were assessed 
19 illness that prevented visit 
5 removal from the area 
30 lack of time 
Participants available for renewed 
assessment 
n = 452  
Potential participants invited by letter 
n = 1004 
Eligible after telephone conversation 
n = 727 
Participants 
n = 525 
Exclusion criteria n = 172 
Contra-indication MRI / claustrophobia  
n = 105 
Non responders  
n = 202 
Exclusion n = 22: 
14 MRI contra-indications / claustrophobia 
1 died before MRI 
1 multiple sclerosis 
1 parkinsonism 
4 dementia 
1 language problem 
Screening for parkinsonism
A flowchart of the screening for parkinsonism is shown in figure 2. The presence of 
parkinsonian signs was evaluated during an in-person follow-up assessment (n=398) by 2 
trained residents in neurology by using the motor part of the Unified Parkinson’s Disease 
Rating Scale (UPDRS-m, 27 items, score 0-108).124 Parkinsonism was defined as the presence 
of bradykinesia and at least one of the 3 other following signs: tremor, rigidity, or gait and 
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postural instability, according to the UK Parkinson’s Disease Society Brain Bank criteria.125 We 
screened the presence of these 4 signs on the basis of previously established parkinsonian 
sign scores derived from the UPDRS-m,126 including limb bradykinesia (based on 8 items: 
right and left finger taps, handgrip, hand pronation-supination and leg agility), rigidity 
(based on 5 items: rigidity of neck and the 4 extremities), tremor (based on 7 items: rest 
tremor of lip/chin and 4 extremities and action tremor of  both arms) and parkinsonian gait 
(based on 5 items: arise from chair, posture, gait, postural stability and body bradykinesia). 
We considered bradykinesia as present when ≥1 items on limb bradykinesia had a score of 
≥2,18, 124 to guarantee a high sensitivity of this main symptom of parkinsonism. The other 3 
signs (tremor, rigidity, and gait and postural instability) were considered present when the 
participant had either ≥2 items with a score of ≥1 or 1 item with a score of ≥2 in that specific 
category. 
Participants were considered screen-positive when (1) they were already diagnosed with 
parkinsonism by a neurologist after baseline assessment or (2) they had bradykinesia and one 
or more of the other 3 signs,127 according to abovementioned criteria, or (3) had an UPDRS-m 
score ≥10, but did not meet the criteria mentioned in (1) or (2). We added this last criterion 
because other co-morbidities (e.g., stroke, severe polyneuropathy, or rheumatic disease) 
often influence the UPDRS-m scores, which could hinder the evaluation of the presence of 
parkinsonism. 
Of the 398 participants, 68 were considered screen-positive and 40 of them were 
subsequently examined by a neurologist specialized in movement disorders (R.A.J.E ) for 
the presence of parkinsonism (10 were diagnosed with parkinsonism, 30 were not). The 
remaining 28 participants refused this additional evaluation, and for them a consensus 
diagnosis of parkinsonism was made by a panel, consisting of 2 neurologists, one of whom 
was specialized in movement disorders (R.A.J.E). They reviewed all available information 
on motor performance and imaging, including (1) UPDRS-m scores at baseline and follow-
up assessment; (2) information from follow-up neurological examination, including muscle 
strength, gait, upper motor neuron signs, sensory deficits, (primitive) reflexes; (3) medical 
history; (4) medication; (5) follow-up MRI-scan, or if not available, baseline imaging (n = 
12); and (6) if applicable, information on the presence of parkinsonism from their treating 
neurologist. Of these 28 participants, 8 were diagnosed with parkinsonism. 
For the participants who did not participate in person (49 deceased and 54 were not able to 
visit our research centre), medical records were reviewed and their treating physician was 
contacted for information on the presence of parkinsonism. In 2 participants, the diagnosis 
parkinsonism was reported; after review by the panel, these diagnoses were confirmed, 
yielding a total of 20 participants with incident parkinsonism.  
Parkinsonism was diagnosed based on the UK Parkinson’s Disease Society Brain Bank criteria 
for Idiopathic Parkinson’s disease (IPD),125 Zijlmans et al.21 criteria for vascular parkinsonism 
(VP), and National Institute of Neurological Disorders and Stroke Society for Progressive 
Supranuclear Palsy criteria for progressive supranuclear palsy (PSP).125 VP requires the 
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presence of relevant cerebrovascular disease on neuroimaging, operationalized in our study 
as WMH beginning to become confluent (Fazekas score ≥2),128 or the presence of lacunes in 
basal ganglia or thalamus.21 Participants with drug-induced parkinsonism were excluded (n 
= 1). The age at onset of parkinsonism was defined as the midpoint between the date on 
which parkinsonism was first identified and baseline RUN DMC assessment,129 or if applicable 
the date at which participants were last reviewed by a neurologist without notification of 
hypokinetic-rigid symptoms in-between baseline and follow-up assessment. 
Participants with CSVD and without 
parkinsonism 
(n=503) 
 2  participants lost to follow-up  
Follow-up participants (n=501) 
Participants with parkinsonism mentioned by 
specialist; reviewed in consensus meeting (n=2) 
 
Renewed motor assessment (n=398) No renewed assessment of participants but  
clinical endpoints were obtained (n=103) 
• deceased (49) 
• unable to visit (54) Screened positive for parkinsonism (n=68) 
Analysis at 
Neurology OPD 
(n=40) 
Refused analysis; 
consensus meeting 
(n=28) 
10 
parkinson 
(ism) 
30 no 
parkinson 
(ism) 
8 
parkinson 
(ism)  
20 no 
parkinson 
(ism) 
2 parkinsonism 
7 
VP 
3  
IPD 
7 
VP 
1 
VP 
1  
PSP 
Total participants with incident 
parkinsonism 
n = 20 (4%) 
1     
IPD  
 
Figure 2. Flowchart of parkinsonism case finding during follow-up
Abbreviations: IPD: idiopathic Parkinson’s Disease; OPD: outpatient department; PSP: Progressive Supranuclear 
Palsy; CSVD: cerebral Small Vessel Disease; VP: vascular parkinsonism
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MRI scanning and processing
Baseline MRI was performed on a single 1.5-Tesla Magnetom Sonata scanner (Siemens 
Medical Solutions, Erlangen, Germany), and included a 3D T1 magnetization-prepared rapid 
gradient echo, fluid-attenuated inversion recovery (FLAIR), gradient-echo T2*-weighted 
sequence and a DTI sequence. Details have been described in detail elsewhere.47
WMH were manually segmented on the FLAIR images, with a good inter-rater variability 
(intraclass correlation coefficient 0.99). The ratings of lacunes and microbleeds were 
revised according to the recently published Standards for Reporting Vascular Changes on 
Neuroimaging (STRIVE)5 by trained raters blinded to clinical information. The intra-rater and 
inter-rater variability in a random sample of 10% was good, with weighted kappa of 0.87 and 
0.95, respectively, for presence of lacunes, and 0.85 and 0.86 for presence of microbleeds. 
Automated segmentation on T1 images was performed using Statistical Parametric Mapping 
(SPM5), to obtain grey matter (GM), WM and cerebrospinal fluid probability maps. These 
maps were binarized by applying a 0.5 threshold and summed to supply total volumes. All 
volumes were normalized to the total intracranial volume to adjust for head size.98 The DTI 
analysis has been described in detail elsewhere.47 For TBSS analysis, DTIFit within the FSL 
toolbox was used to generate fractional anisotropy (FA) and mean diffusivity (MD) images, 
which were imported into the TBSS pipeline.46 To create a FA skeleton, the mean FA image 
was thinned and subsequently this skeleton was thresholded at 0.3 to include major WM 
tracts. Of the 501 participants (2 were lost to follow-up), 4 were excluded from TBSS analysis 
because of imaging artefacts, 54 because of territorial infarcts, 2 because of missing values 
of microbleeds, and 5 because of parkinsonism other than VP, yielding a subgroup of 436 
participants (9 with VP and 427 without parkinsonism). 
Other measurements
We used the Mini Mental State Examination (MMSE) score to indicate global cognitive status. 
Statistical analysis
Statistical analyses were performed using IBM (Armonk, NY) SPSS Statistics 20. The person-
years at risk for each participant were defined as the time between baseline assessment and 
onset of parkinsonism, date of follow-up assessment, or death, depending on which event 
occurred first. Cumulative risk of (any) parkinsonism and separate for VP, being the largest 
group in our study, was estimated with a Kaplan-Meier analysis. Differences in baseline 
characteristics between participants with VP or IPD / PSP and without parkinsonism were 
tested by univariate analyses, using an independent samples t test, χ2 test, Fisher exact test, 
or Mann-Whitney U test, when appropriate (Table 1). 
Cox regression analysis was used to calculate hazard ratios (HR) with their corresponding 
95% confidence intervals (CI) of baseline imaging characteristics for (any) parkinsonism 
and VP separately. Adjustments were made for baseline age, sex, UPDRS-m score, territorial 
infarcts, and for GM volume and or 4 CSVD characteristics (WMH volume, WM volume, number 
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of lacunes, and microbleeds). Verification of proportionality of hazards was performed by 
examining Schoenfeld residuals. Bonferroni corrections were used to correct for multiple 
comparisons; p≤0.00714 were considered significant. 
To compare voxel-wise analyses of DTI measures between those with VP and without 
parkinsonism a 2-sample t test was performed, using a permutation-based statistical 
interference as part of FSL toolbox (randomise), with a standard number of permutation tests 
set at 5000. To identify significant associations, a threshold-free cluster enhancement with a 
p<0.025, corrected for multiple comparisons, was used. 
Table 1. Baseline characteristics of the total study population and of participants with VP, IPD/PSP 
and participants without parkinsonism
Total VP IPD/PSP No parkinsonism 
Baseline demographics n = 500 n = 14 n = 5 n = 481
Age, mean (SD), years 65.6 (8.8) 70.7 (6.3) 68.7 (8.1) 65.5 (8.8)
Male sex, No. (%) 284 (56.8) 9 (64.3) 4 (80.0) 271 (56.3)
MMSE score, mean (SD) 28.1 (1.6) 27.4 (1.4) 27.0 (1.9) 28.2 (1.6)
UPDRS-m total score, median (IQR) 0.0 (0.0-1.0)b 2.0 (0.0-6.0) 3.0 (2.0-4.0)b 0.0 (0.0-1.0)
MRI measuresa n = 500 n = 14 n = 5 n = 481
WMH volume, median (IQR), mL 7.2 (3.6-18.4) 30.0 (16.6-56.9) 5.4 (3.7-22.1) 7.0 (3.4-17.7)
Lacunes presence, No. (%) 134 (26.8) 11 (78.6) 2 (40.0) 121 (25.2)
Microbleeds presence, No. (%) 80 (16.0)c 8 (57.1) 0 (0.0) 72 (15.0)c
White matter volume, mean (SD), mL 464.7 (51.9) 422.9 (63.4) 452.9 (33.8) 466.1 (51.2)
Grey matter volume, mean (SD), mL 630.9 (53.9) 580.0 (48.2) 634.5 (76.7) 632.3 (53.2)
Territorial infarcts presence, No. (%) 56 (11.2) 5 (35.7) 1 (20.0) 50 (10.4)
Baseline DTI measures, mean (SD) n = 497d n = 14 n = 5 n = 478d
White matter global FA 0.33 (0.02) 0.31 (0.03) 0.34 (0.02) 0.33 (0.02)
WMH global FA 0.34 (0.03) 0.31 (0.03) 0.35 (0.03) 0.34 (0.03)
NAWM global FA 0.33 (0.02) 0.31 (0.03) 0.34 (0.02) 0.33 (0.02)
White matter global MD 0.89 (0.05) 0.95 (0.05) 0.87 (0.04) 0.89 (0.04)
WMH global MD 1.00 (0.07) 1.09 (0.06) 0.99 (0.07) 1.00 (0.07)
NAWM global MD 0.89 (0.04) 0.94 (0.04) 0.87 (0.03) 0.89 (0.04)
Abbreviations: DTI: diffusion tensor imaging; FA: fractional anisotropy; IPD: idiopathic Parkinson disease; IQR: 
interquartile range; MD: mean diffusivity (x10-3 mm2/s); MMSE: Mini-Mental State Examination; NAWM: normal-
appearing white matter; PSP: progressive supranuclear palsy; SD: standard deviation; UPDRS-m: Unified 
Parkinson’s Disease Rating Scale motor score; VP: vascular parkinsonism; WMH: white matter hyperintensities.
a Brain volumes are represented normalized to the total intracranial volume.
b 1 participant was excluded because of a missing values on UPDRS-m at baseline.
c 4 participants were excluded because of missing values of microbleeds at baseline.
d 3 participants were excluded because of baseline DTI artefacts.
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Results
The total study population consisted of 501 participants; 2 were lost to follow-up. Mean 
follow-up duration was 5.2 years (SD 0.7). Parkinsonism developed in 20 participants (4.0%); 
15 were diagnosed with VP, with all patients having predominantly lower body symptoms and 
a bilateral onset, 4 with IPD, and 1 with PSP. The cumulative 5-year risk of (any) parkinsonism 
was 3.5% (95% CI 1.9-5.2) and of VP 2.9% (95% CI 1.4-4.4). One participant with VP was 
excluded because of baseline T1/T2 artefacts.
Table 1 shows the baseline characteristics of the total study population, and for participants 
with VP, IPD/ PSP, and without parkinsonism separately. The mean baseline age of the total 
population was 65.6 years (SD 8.8); 56.8% were men. Participants with VP, in comparison to 
participants without parkinsonism, were older (p=0.009), had a lower MMSE score (p=0.039), 
and a higher UPDRS-m score (p=0.001) at baseline. Furthermore, all baseline imaging 
characteristics shown in table 1 differed substantially (p<0.05) between those groups.
For further analyses one participant with IPD was additionally excluded because of a missing 
baseline UPDRS-m score.
There was a strong relation between WMH volume and the number of lacunes and the 5-year 
risk of (any) parkinsonism (Table 2). The 5-year risk of VP was increased for those with a high 
WMH volume (HR 2.0 per SD increase (mL); 95% CI 1.4-2.7), a high number of lacunes (HR 1.5 
per number increase; 95% CI 1.2-1.9), presence of microbleeds (HR 5.7; 95% CI 1.9-16.8), and 
a low GM volume (HR 0.4 per SD increase (mL); 95% CI 0.2-0.8) (Table 3). 
A TBSS analysis showed differences in baseline DTI values between participants with VP 
and those without parkinsonism (Figure 3). Lower FA values were seen in WM tracts in the 
bilateral frontal and right parietal lobe – genu of corpus callosum, internal capsule, superior 
longitudinal fasciculus, forceps minor, inferior fronto-occipital fasciculus, cingulum bundle, 
superior and posterior (right) corona radiata and right posterior thalamic radiation – in 
participants with VP, even after adjustment for different CSVD characteristics. In addition, 
higher MD values were seen in VP patients in a similar pattern, although most voxels lost 
signal after adjustment for CSVD, except in the anterior corona radiata (data not shown). 
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Discussion
This is a unique prospective study investigating the relation between CSVD at baseline and 
the risk of incident parkinsonism. We showed that a high WMH volume and a high number of 
lacunes were associated with an increased 5-year risk of (any) parkinsonism. For VP, this risk 
was also increased by the presence of microbleeds and a low GM volume. Furthermore, we 
observed lower FA values especially in bifrontal WM tracts involved in movement control in 
participants with VP compared to participants without parkinsonism, independent of CSVD. 
Major strengths of our study are its longitudinal and single-centre design, which allowed us to 
use identical motor and cognitive assessments during baseline and follow-up. Furthermore, 
the large sample size and high follow-up rate of 99.6% are main advantages. Moreover, all 
imaging data were analyzed by raters blinded to clinical information with a good intra-rater 
and inter-rater variability. Finally, we were able to make appropriate adjustments, reducing 
the risk of confounding. We intentionally did not adjust for vascular risk factors as we 
considered them part of the causal chain between CSVD and parkinsonism. 
Several methodological issues need to be addressed. First, because of the small number 
of patients with parkinsonism in our study, our results should be interpreted with caution. 
Second, we were not able to diagnose parkinsonism in the same way for all patients. For 
participants who were not able to participate in person, we had to rely on information 
from medical files and we could have missed the diagnosis parkinsonism in some, since 
parkinsonism is frequently accepted as part of normal aging. Some participants who 
participated in-person and were considered screen-positive for the presence of parkinsonian 
signs, refused additional evaluation by a neurologist specialized in movement disorders (28 
of 68 participants). However, all 28 participants were examined in the follow-up assessment 
by 2 skilled neurologists in training with extensive experience in diagnosing parkinsonism, 
after which a consensus diagnosis was made by an expert panel. The similarity of the 
diagnostic approaches  is well-illustrated by a virtual identical proportion of the patients with 
parkinsonism identified by the 2 approaches. Third, misclassification could have occurred 
as the accuracy of clinical diagnosis of the different aetiologies underlying parkinsonism, 
compared to neuropathologic diagnosis, is relatively low.130 We therefore initially classified 
any parkinsonism; thereafter, neuroimaging was used to allow for the diagnosis of VP. Fourth, 
as imaging information is needed to classify the different aetiologies of parkinsonism, 
especially concerning VP, circular reasoning might have occurred in our analyses with 
VP, although we used baseline MRI and DTI measures, when all participants were free of 
parkinsonism.  
Even though this is a hospital-based cohort study, our results have a high external validity for 
an elderly population with CSVD who visit a general neurology department, as we included 
all consecutive patients with CSVD on neuroimaging (CT or MRI-scan) performed because of 
major referral reasons (e.g., TIA, stroke, cognitive complaints) and there were no restrictions 
for admission to our hospital. 
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Figure 3. Differences in fractional anisotropy values between participants with vascular 
parkinsonism and without parkinsonism
Voxel-wise analysis of the differences in fractional anisotropy (FA) values between participants with vascular 
parkinsonism (n=9) and without parkinsonism (n=427). Adjusted for age, sex, baseline motor part of the 
Unified Parkinson’s Disease Rate Scale score, and normalized total brain volume (A) and for cerebral small 
vessel characteristics (white matter volume, white matter hyperintensity volume and number of lacunes 
and microbleeds) (B), performed with a 2 sample t test, thresholded at p <0.025 and corrected for multiple 
comparisons. These images are superimposed onto the spatially normalized Montreal Neurological Institute 
(MNI) stereotactic space FA map. 
R indicates right side, L indicates left side. The x, y and z coordinates represent the MNI coordinates of each slide.
               x = -1                          R     y = -17     L                R     z = 19     L 
p<0.025 
p<0.01 
A 
B 
  -     y  -            L
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So far, the exact role of CSVD in parkinsonism is unknown. Some studies have suggested 
that WMH are more common in patients with parkinsonism,131, 132 whereas others failed 
to demonstrate that.133, 134 Furthermore, in autopsy studies, only a small subset (<10%) of 
parkinsonism was attributed to vascular lesions, because of the absence of other pathologic 
findings (Lewy bodies or tau inclusions) compatible with a known parkinsonian syndrome.130 
Our findings favour a role for CSVD in the development of parkinsonism, as we showed that 
participants with a high degree of CSVD had an increased risk of incident parkinsonism. 
Furthermore, we found a relative high incidence of parkinsonism compared to population-
based studies; in the Rotterdam Study, 2% of the 6566 participants (≥55 years) developed 
(any) parkinsonism after a mean follow-up duration of 5.8 years,129 versus 4% in our study, 
which may also indicate that CSVD contributes to the aetiology of parkinsonism.
DTI has gained increased interest in the diagnostic process of parkinsonism in recent years,121 
as it has been suggested that this technique could be of help in differentiating among the 
different subtypes of parkinsonism.135, 136 We therefore performed a TBSS analysis in patients 
with a clinical diagnosis of VP, because this was the largest group of patients in our study and 
a recent study showed that DTI can differentiate between VP and parkinsonian syndromes of 
degenerative origin.136 We found lower FA values in bilateral WM tracts involved in movement 
control in VP compared to participants without parkinsonism, even after adjustment for CSVD 
characteristics. This result is in line with a recent cross-sectional DTI study in patients with VP 
and healthy controls; however, no adjustments were made for CSVD.122 Using DTI measures 
of scans at a point in time when all participants were free of parkinsonism is unique in our 
study. Our results may suggest that diffusion changes can be an early marker of VP. However, 
a note of caution is due here owing to the small number of patients with VP in our study.  
We can hypothesize about the role of CSVD in parkinsonism; it may be that CSVD disrupts the 
structural integrity of WM tracts, including disruption of the thalamocortical fibres, thereby 
reducing the influence of the basal ganglia on motor, premotor and supplementary motor 
cortices.137 Disconnection of the basal ganglia-thalamocortical circuit possibly leads to (sub)
cortical atrophy, ultimately resulting in parkinsonism. Furthermore, CSVD could possibly 
lower the threshold for developing parkinsonism, by lowering the threshold for Lewy 
body pathology to become symptomatic, for example. In addition, marked loss of striatal 
dopaminergic innervations that occurs during aging might contribute as well.138  
Future  studies are needed to further investigate the contribution of CSVD to incident 
parkinsonism, ideally taking into account the changes in these imaging markers over time.

Part IV
Long-term mortality in cerebral small vessel disease

6.
Factors associated with 8-year mortality in cerebral small 
vessel disease
Published as:
H.M. van der Holst, I.W.M. van Uden, A.M. Tuladhar, K.F. de Laat, A.G. van Norden, D.G. 
Norris, E.J. van Dijk, L.C. Rutten-Jacobs, F-E de Leeuw. 
Factors associated with 8-year mortality in older patients with cerebral small vessel 
disease: The Radboud University Nijmegen Diffusion tensor and Magnetic resonance 
Cohort (RUN DMC) study. JAMA Neurology, 2016 Apr; 73(4):402-9.
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Abstract
Importance: Gait and cognition have been related to mortality in population-based 
studies. This is possibly mediated by cerebral small vessel disease (CSVD), which has 
been associated with mortality as well. It is unknown which parameters can predict 
mortality in individuals with CSVD. Identification of high-risk patients may provide 
insight into factors that reflect their vital health status. 
Objective: To assess mortality in patients with CSVD and to identify potential clinical 
and/or imaging predictors of mortality. 
Design, setting, and participants: A prospective, single-centre cohort study was 
conducted. The present investigation is embedded in the Radboud University Nijmegen 
Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) study. Between January 
17, 2006, and February 27, 2007, all participants underwent a cognitive and motor 
assessment and cerebral magnetic resonance imaging (MRI) including a diffusion tensor 
imaging sequence to assess microstructural integrity of the white matter. Participants were 
followed until their death or November 24, 2014. Participants included 503 older adults 
with CSVD noted on brain imaging. Data analysis was performed from November 26, 2014, 
to February 2, 2015.
Main outcomes and measures: Eight-year all-cause mortality. 
Results: Of 503 participants (mean [SD] age, 65.7 [8.8] years; range, 50-85 years; 284 
[56.5%] were male), 80 individuals (15.9%) died during a mean (SD) follow-up of 7.8 (1.5) 
years. In the final analysis, 494 (98.2%) were included, of whom 78 (15.8%) died. Gait speed, 
cognitive index, conventional MRI markers of CSVD (white matter hyperintensity volume, 
brain volume, and lacunes), and diffusion measures of the white matter were associated 
with an 8-year risk of mortality independent of age, sex, and vascular risk factors. The 
prediction of mortality was determined using Cox proportional hazards models with 
backward stepwise selection and including age, sex, vascular risk factors, gait speed, 
cognitive index, MRI, and diffusion measures. Results are reported as hazard ratios (HRs) 
(95%CI). Older age (1.05 per 1-year increase [1.01-1.08]), lower gait speed (1.15 per 0.1-
m/s slower gait [1.06-1.24]), lower grey matter volume (0.72 per 1-SD increase [0.55-0.95]), 
and greater global mean diffusivity of the white matter (1.51 per 1-SD increase [1.19-1.92]) 
were identified as the main factors associated with mortality. Cognitive index and other 
conventional CSVD markers were not retained in the prediction model. 
Conclusions and relevance: Gait, cognition, and imaging markers of CSVD are 
associated with 8-year risk of mortality. In the prediction of mortality, an older age, lower 
gait speed, lower grey matter volume, and greater global mean diffusivity of white matter 
at baseline best predicted mortality in our population. Further research is needed to 
investigate the reproducibility of this prediction model and to elucidate the association 
between the factors identified and mortality.
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Introduction
Cerebral small vessel disease (CSVD)  is prevalent on brain imaging of older adults.9 It consists 
of white matter hyperintensities (WMH) and lacunes of presumed vascular origin, microbleeds 
and subcortical and cortical atrophy on conventional magnetic resonance imaging (MRI).5 
The radiological spectrum of CSVD extends beyond lesions visible on conventional MRI, 
including impaired white matter (WM) microstructural integrity which can be assessed by 
diffusion tensor imaging (DTI).91 The clinical presentation and long-term prognosis of CSVD 
are both highly variable, including cognitive and motor impairment and mood disturbances, 
which could lead to functional decline139 and even death.22, 23 It is unknown which patients 
with CSVD are at the highest risk for these adverse outcomes, including mortality. Several 
population-based studies among community-dwelling older adults have shown that gait 
speed25 and cognition24, 140 are important clinical characteristics associated with mortality; 
nevertheless, to our knowledge, whether this prediction was independent of the presence of 
CSVD has not been investigated. We could hypothesize that this association is driven by CSVD 
since CSVD has been previously associated with mortality, particularly, WMH and lacunes.23, 141 
However, to our knowledge, it has never been investigated whether imaging characteristics 
of CSVD have added value in the prediction of mortality regarding clinical factors such as gait 
and cognition. 
In this observational study, we prospectively investigated the cumulative mortality in 
a  population of older adults with CSVD after 8 years of follow-up. Our main objective was 
to identify baseline risk factors of all-cause mortality, including clinical (gait speed and 
cognition) and imaging (MRI and DTI measures) factors. We were especially interested in 
which of these parameters were most predictive for all-cause mortality. This information may 
provide insight into factors that reflect the vital health status of older adults with CSVD.  
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Methods
Study population
This present study is embedded in the Radboud University Nijmegen Diffusion tensor 
and Magnetic resonance Cohort study (RUN DMC study), a prospective cohort study that 
investigates the risk factors and clinical consequences of functional and structural brain 
changes as assessed by MRI. A total of 503 older adults with CSVD aged 50 to 85 years were 
included. The recruitment, study rationale and protocol of the RUN DMC study have been 
reported.47 Because the onset of CSVD is often insidious and clinically heterogeneous with 
acute symptoms (transient ischemic attacks or lacunar syndromes), or subacute symptoms 
(cognitive, motor and mood disturbances),123 an CSVD diagnosis was made on the basis 
of brain imaging and included the presence of WMH and/or lacunes of presumed vascular 
origin.48 Major referral reasons of the participants to our department included those 
corresponding to symptoms of CSVD (e.g., transient ischemic attacks or minor stroke and 
cognitive disturbances). After inclusion, all participants were subsequently asked about 
acute or subacute symptoms of CSVD. Main exclusion criteria were baseline parkinsonism, 
dementia, life expectancy of less than 6 months, non-CSVD related WM lesions (e.g., multiple 
sclerosis), and MRI contra-indications. Subsequently, the above-mentioned acute or subacute 
clinical symptoms of CSVD were assessed by standardized structured assessments. Patients 
who were eligible because of a lacunar syndrome were included more than 6 months after 
the event to avoid acute effects on the outcomes. 
Baseline assessment included a cognitive and motor examination and a cerebral MRI. The 
present study was conducted from January 17, 2006, to February 27, 2007. Participants were 
followed until their death or until November 24, 2014. 
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study. All 
participants signed an informed consent form; there was no financial compensation. 
Mortality
All-cause mortality was the primary outcome of this study. Information on vital status was first 
retrieved from the Dutch Municipal Personal Records database (https://www.government.nl
/topics/identification-documents/contents/the-municipal-personal-records-database). 
Information on the cause of death was obtained from the general practitioner or treating 
physician and medical records. Subsequently, the cause of death was classified according 
to the International Statistical Classification of Diseases and Related Health Problems, Tenth 
Revision (ICD-10)142 by 1 rater (H.M. v.d. H.) and grouped as ischemic stroke, intracranial 
haemorrhage, cardiac cause, other vascular causes (when the cause of death was presumably 
vascular, but did not meet the criteria for fatal stroke or cardiac cause), malignant neoplasms, 
infections and miscellaneous. 
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MRI scanning and processing
All participants underwent a cerebral MRI, including a 3-dimensional T1 magnetization 
prepared rapid acquisition gradient-echo (MPRAGE), fluid-attenuated inversion recovery 
(FLAIR), gradient-echo T2*-weighted sequence and a DTI sequence on a 1.5-Tesla scanner at 
baseline. Imaging details have been described elsewhere.47
WMH were manually segmented on the FLAIR images and total WMH volume was calculated 
by summing all segmented areas multiplied by section thickness, with a good inter-rater 
variability (intra-class correlation coefficient, 0.99). The ratings of lacunes and microbleeds 
(including subcortical and lobar ones) were revised according to the recently published 
Standards for Reporting Vascular changes on neuroimaging5 by trained raters (including H.M. 
v.d. H. and I.W.M. v. U.) blinded to clinical information (intra-rater and inter-rater reliabilities: 
weighted ĸ values, 0.87 and 0.95, respectively, for presence of lacunes and 0.85 and 0.86, 
respectively, for presence of microbleeds, calculated in a random sample of 10% of the 
scans). 
Automated segmentation on T1 images was performed using Statistical Parametric Mapping, 
version 5 (SPM5; http://www.fil.ion.ucl.ac.uk/spm/software/), to obtain grey matter (GM) and 
WM and cerebrospinal fluid probability maps. The volumes were calculated by summing all 
the voxel volumes belonging to the tissue class. All volumes, including WMH were normalized 
to the total intracranial volume (sum of GM, WM, and cerebrospinal fluid volumes)98 to adjust 
for head size. GM volume was composed of the volume of the neocortex, basal ganglia and 
thalamus.
For DTI analysis, the diffusion-weighted images of each participant were realigned on the 
mean of the unweighted image using mutual information-based coregistration routines from 
SPM5. The diffusion tensor32 and its eigenvalues were estimated using linear regression and 
spurious negative eigenvalues were set to zero, after which the tensor derivates of fractional 
anisotropy and mean diffusivity (MD) were calculated.99 The mean unweighted image was 
used to compute the coregistration variables to the anatomical T1 reference image, which 
were then applied to all diffusion-weighted images and results. All images were visually 
checked for motion artefacts and coregistration errors. The volume-averaged fractional 
anisotropy and MD were calculated in the total WM. 
Cardiovascular risk factors 
Information on the presence of cardiovascular risk factors was investigated with structured 
questionnaires. The use of medication for treatment of any vascular risk factor was verified 
by a medication list from the pharmacy provided by the participant. 
Information on smoking behaviour was dichotomized into ever (current and former) and 
never smoking. Diabetes mellitus was considered to be present if the participant was 
receiving oral glucose-lowering drugs or insulin. Hypertension was defined as the use of 
blood pressure-lowering medication and/or a current systolic blood pressure of 140 mmHg 
or higher or diastolic blood pressure of 90 mmHg or higher, assessed during baseline 
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examination, with the mean determined after 3 measurements with the patient in a supine 
position after 5 minutes of rest.143 
Cardiovascular diseases and malignant neoplasms
To identify cardiovascular disease or malignant neoplasms in the medical history, structured 
questionnaires were used and this information was subsequently retrieved by their treating 
physician or from medical files and was verified thereafter. A history of cardiovascular 
diseases was defined as the presence of an ischemic stroke, intracerebral haemorrhage, 
transient ischemic attack, myocardial infarction, percutaneous coronary intervention, 
coronary bypass surgery, or peripheral arterial disease. A history of cancer was defined as the 
presence of any malignant neoplasm (mentioned in the ICD-10).142
Measurement of gait
Gait speed was assessed by using a 5.6-m electronic portable walkway (GAITRite; MAP/
CIR Inc). This walkway system has an excellent test-retest reliability and validity.93, 94 Each 
participant was instructed to walk over the walkway at his or her usual speed. Participants 
started 2 m before the walkway and stopped 2 m behind it to measure steady-state walking. 
The mean gait speed (meters per second) of two walking episodes of each participant was 
used for analysis. 
Cognitive assessment
Global cognitive function was evaluated by the Mini Mental State Examination.50 A Cognitive 
Index was constructed to obtain a more robust outcome measure for global cognition. The 
cognitive index was calculated as the mean of the z-scores of the Speed Accuracy Tradeoff 
score of the 1-letter subtask of the Paper-Pencil Memory Scanning Task,54 the mean of the 
Speed Accuracy Tradeoff  score of the reading task of the Stroop test,52 the mean of the 
Symbol-Digit Substitution task,55 and the mean of the added score on the 3 learning trials of 
the Rey Auditory Verbal learning test and the mean of the delayed recall of this.51, 100 
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics 20 for Windows (SPSS Inc) 
and R, version 2.15 (http://www.R-project.org) software packages. Cumulative mortality 
was estimated using Kaplan-Meier analysis and stratified for different imaging markers. 
Differences between the lowest and highest quartiles and presence versus absence were 
estimated with the log-rank test. Data analysis was performed from November 26, 2014, to 
February 2, 2015. Differences in baseline characteristics between survivors and those who 
died were tested by using an independent samples t test, χ2 test, or Mann-Whitney test when 
appropriate. 
Cox regression analysis was used to calculate hazard ratios (HR) and 95% confidence 
intervals (CI) of gait speed, cognitive index and different imaging measures for mortality after 
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adjustment for age, sex and vascular risk factors. For the prediction models, we used the 
variables with a significance level of p≤0.10 after adjustment for age, sex and vascular risk 
factors. Because of the high correlation between DTI variables, only MD of the WM was included 
in the model. Three Cox proportional hazards models were constructed to predict all-cause 
mortality. In the first model, age, sex and vascular risk factors were entered simultaneously 
into the Cox model. For the next models these factors were fixed. Subsequently, gait speed 
and cognitive index (model 2) and imaging parameters (MRI and DTI measures, model 3) 
were entered by a backward, stepwise selection procedure until these nonfixed variables 
had a significance level of p≤0.10. A fourth model was constructed by using a backward, 
stepwise selection procedure for all covariates (age, sex, vascular risk factors, cognition, gait 
and MRI and DTI measures); none of these were fixed. Models 1 to 3 were also constructed 
for vascular mortality; using proportional hazard model by means of Fine and Grey,144 causes 
of death other than vascular factors were considered a competing risk. Schoenfeld residuals 
were investigated to verify proportionality of hazards. There were no indications that the 
proportional hazard assumption was violated. 
The C-statistic was used to assess the discriminatory performance of the different prediction 
models. An increase of C-statistic values by 0.025 or more was considered a significant 
improvement of accuracy.25 Furthermore, Akaike information criterion (AIC) was used to 
investigate the goodness of fit of the models.145 The most appropriate model is the one 
with the lowest AIC value.146 We considered a decrease of 10 or more values as significantly 
improved goodness of fit. 
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Table 1. Baseline characteristics by vital status of the study population 
                                                                                               Vital status at follow-up
 
Characteristics
Alive 
(n = 416) 
Dead 
(n = 78)
p-value
Baseline demographics 
Age, mean (SD), years 64.5 (8.4) 72.1 (8.4) <0.001a
Male sex, No. (%) 236 (56.7) 43 (55.1) 0.79b
Vascular risk factors at baseline, No. (%)
Smoking 286 (68.8) 60 (76.9) 0.15b
Diabetes mellitus 44 (10.6) 19 (24.4) 0.001b
Hypertension 299 (71.9) 64 (82.1) 0.06b
Co-morbidity at baseline, No. (%)
Cardiovascular morbidity 195 (46.9) 48 (61.5) 0.02b
Malignant neoplasm 42 (10.1) 10 (12.8) 0.47b
Baseline clinical scores
Gait velocity, mean (SD), m/s 1.32 (0.26) 1.09 (0.28) <0.001a
MMSE score, mean (SD) 28.3 (1.6) 27.5 (1.8) <0.001c
Cognitive index, mean (SD) 0.08 (0.76) -0.52 (0.68) <0.001a
Baseline MRI characteristicsd
WMH volume, median (IQR), mL 6.0 (3.2-15.2) 17.7 (9.8-35.1) <0.001c
WM volume, mean (SD), mL 470.5 (50.7) 433.6 (41.8) <0.001a
GM volume, mean (SD), mL 636.9 (52.9) 597.6 (47.1) <0.001a
Lacunes present, No. (%) 92 (22.1) 41 (52.6) <0.001b
Microbleeds, present, No. (%)e 62 (14.9) 19 (24.4) 0.03b
Territorial infarcts present, No. (%) 42 (10.1) 13 (16.7) 0.09 b
Baseline DTI parameters
WM global FA, mean (SD) 0.33 (0.02) 0.32 (0.02) <0.001a
WM global MD, mean (SD), x 10-4 mm2/s 8.8 (0.4) 9.3 (0.4) <0.001a
Abbreviations: DTI, diffusion tensor imaging; FA, fractional anisotropy; GM, grey matter; IQR, interquartile range; 
MD, mean diffusivity; MMSE, Mini-mental State Examination; MRI, magnetic resonance imaging; SD: standard 
deviation; WM, white matter; WMH, WM hyperintensities. 
a Independent samples t-test.
 b Chi-square test. 
 c Mann-Whitney Test.
 d Brain volumes are represented as normalized to the total intracranial volume. 
e Two participants were excluded because of missing values of microbleeds at baseline (1 in each group)
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Results
The study population consisted of 503 participants; 493 individuals (98.0%) were white, with 
a mean (SD) age at baseline of 65.7 (8.8) years and a mean follow-up duration of 7.8 (1.5) 
years. Eighty participants (15.9%) died during the follow-up period. The 8-year cumulative 
all-cause mortality was 14.5% (95% CI, 11.3-17.6). Nine participants were excluded because of 
imaging artefacts (4) and missing values on gait or cognitive tests (5); 2 of these 9 individuals 
had died. Table 1 reports the baseline characteristics of the study population (494 [98.2% 
of the original population]). The cause of death was vascular related in 26 (33.3%) of the 
participants (Table 2). 
Table 2. Cause of death according to ICD-10 classification
Cause of death Participants, No. (%)
Vascular 26 (33.3)
    Ischemic stroke 5 (6.4)
    Intracerebral haemorrhage 3 (3.8)
    Cardiac cause 12 (15.4)
    Other vasculara 6 (7.7)
Malignancies 20 (25.6)
Infections 12 (15.4)
Miscellaneous 15 (19.2)
Unknown 5 (6.4)
Abbreviation: ICD-10, International Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision
a Deaths that were presumably vascular but did not meet the criteria for fatal stroke or cardiac cause
The Figure shows the cumulative mortality stratified for different imaging characteristics. All-
cause 8-year mortality was highest in participants with lacunes and microbleeds, with the 
highest WMH volume and MD of the WM and the lowest WM and GM volumes. 
Gait speed, cognitive index, conventional MRI markers of CSVD (except for microbleeds) and 
diffusion measures of the WM were identified as potential risk factors of all-cause mortality 
(Table 3). The presence of territorial infarcts was not associated with mortality. 
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Figure. Cumulative mortality stratified by imaging characteristics
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Abbreviations: CI: confidence interval; DTI: diffusion tensor imaging; FA: fractional anisotropy; GM: grey matter; 
HR: hazard ratio; MD: mean diffusivity (*10-4 mm2/s); MMSE: Mini-mental State Examination; MRI: magnetic 
resonance imaging; SD: standard deviation; WM: white matter; WMH: WM Hyperintensity.
a Adjusted for age and sex.
b Cox regression analysis.
c Adjusted additionally for vascular risk factors (smoking, diabetes mellitus and hypertension).
d Brain volumes are represented normalized to the total intracranial volume.
e Log transformed.
f Two participants were excluded because of missing values of microbleeds at baseline. 
Table 3. Association between baseline factors and all-cause mortality 
Characteristic HR (95% CI)a p-valueb HR (95% CI)c p-valueb
Clinical scores
Gait speed, per 0.1m/s slower gait 1.19 (1.10-1.28) <0.001 1.17 (1.08-1.26) <0.001
MMSE 0.89 (0.79-1.01) 0.07 0.91 (0.81-1.03) 0.15
Cognitive index 0.54 (0.38-0.77) 0.001 0.59 (0.41-0.84) 0.004
MRI measuresd
WMH volume, per 1-SD increase, mLe 1.65 (1.28-2.15) <0.001 1.62 (1.24-2.11) <0.001
WM volume, per 1-SD increase, mL 0.71 (0.54-0.92) 0.009 0.74 (0.57-0.97) 0.03
GM volume, per 1-SD increase, mL 0.61 (0.47-0.81) 0.001 0.65 (0.49-0.86), 0.003
No. of lacunes 1.28 (1.09-1.49) 0.002 1.23 (1.05-1.44) 0.01
No. of microbleedsf 1.02 (0.96-1.09) 0.52 1.01 (0.95-1.09) 0.69
Territorial infarcts, presence 1.39 (0.77-2.54) 0.28 1.25 (0.69-2.29), 0.46
DTI parameters 
WM global FA, per 1-SD increase 0.70 (0.57-0.87) 0.001 0.70 (0.56-0.87) 0.002
WM global MD, per 1-SD increase 1.70 (1.35-2.14) <0.001 1.68 (1.32-2.13) <0.001
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In the prediction of all-cause mortality (Table 4), model 2 shows that gait speed and cognitive 
index added substantially to model 1. In model 3, imaging parameters were also included; 
GM volume and global MD of the WM were retained in the model together with gait speed. 
Cognitive index and other imaging markers were not retained in the prediction model. This 
last model predicted the best mortality in our population. When we applied backward 
stepwise selection for all covariates mentioned in model 3, the following covariates were 
retained (reported as HR [95% CI]): age (1.05 per 1-year increase [1.01-1.08]; p=0.01), gait 
speed (1.15 per 0.1-m/s slower gait [1.06-1.24]; p=0.001), GM volume (0.72 per 1-SD increase 
[0.55-0.95]; p=0.02), and global MD of the WM (1.51 per 1-SD increase [1.19-1.92]; p=0.001). 
This model was as accurate as model 3 (C-statistic, 0.79 [95% CI, 0.72-0.85] and AIC, 854.8). 
When cardiovascular morbidity and malignant neoplasms were additionally added as fixed 
covariates, the above-mentioned prediction models were not  substantially altered.  
Hazard ratios of the same magnitude were found for vascular mortality compared with all-
cause mortality (model 3 with age, sex and vascular risk factors as fixed factors; reported as 
HR [95% CI])): gait speed (1.11 per 0.1-m/s slower gait [0.97-1.28]; p=0.13), GM volume (0.72 
per 1-SD increase  [0.45-1.13]; p=0.15), and the MD of the WM (1.85 per 1-SD increase [1.29-
2.65]; p<0.001), with other causes of death considered a competing risk. However, because of 
the small number of patients (n=26), significance was lost for gait speed and GM volume and 
only the MD of the WM was retained in the model (Table 5).
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Discussion 
This study shows that older age, lower gait speed, lower GM volumes and greater global MD 
of the WM at baseline significantly increased the 8-year risk of mortality in individuals 50 
years and over with CSVD and together had the best predictive ability for all-cause mortality 
in our population. Cognitive performance and conventional MRI markers of CSVD (including 
WMH volume, WM volume and lacunes) did not significantly contribute to the prediction of 
mortality, although these factors were associated with 8-year mortality after adjustment for 
age, sex, and vascular risk factors. 
This is a unique longitudinal study that assesses potential clinical and imaging risk factors 
of mortality in patients with CSVD. The strengths of this study include the large sample size, 
the complete follow-up for mortality, and its longitudinal and single-centre design, which 
allowed us to consistently collect gait, cognitive, and imaging measures. Furthermore, all 
imaging data were analyzed with the reviewers blinded to clinical information with good 
intra and inter-rater variability.47 
Some limitations need to be addressed. First, the observational design of the study prevents us 
from elucidating the exact association between the baseline factors identified and mortality. 
However, it is conceivable that these factors reflect the vital health status of our participants 
rather than their having a direct causal association with mortality. Second, because age 
is the strongest predictor of mortality,147 the additional predictive value of gait speed, GM 
volume, and global MD of the WM was relatively low. Nonetheless, risk factors or diseases 
underlying slower gait, lower GM volume, or lower WM microstructural integrity might be 
modifiable. Future research is needed to investigate whether treatment of these underlying 
risk factors results in improved survival. Third, our results on vascular mortality should be 
interpreted with caution owing to limited statistical power. Fourth, we could not exclude 
the possibility that residual confounding by unmeasured variables (e.g., socioeconomic 
status and genetics) or years of uncontrolled vascular risk factors could, at least in part, have 
explained our results. Finally, although this was a hospital-based cohort study, we believe 
that our results can be generalized to patients with CSVD referred to a general neurologic 
clinic because we included all consecutive patients with CSVD and there were no restrictions 
for admission to our department.
Of the clinical parameters included in our prediction model, gait speed was retained in 
all models and cognitive performance was not retained after including imaging markers. 
A possible explanation for this finding might be that gait relies not only on intact cerebral 
networks but also on the functioning of several organ systems, including respiratory, 
circulatory, musculoskeletal, and peripheral nerve systems.25 As a result, slower gait might 
not be primarily caused by dysfunction of one system (e.g., the brain) but is probably due 
to accumulation of pathology among several organ systems, which is in accordance with 
the results of one recent study.102 Because cognition is less affected by damage to other 
organ systems compared with the brain, it could be that the association between cognitive 
performance and mortality is mediated by CSVD. Cognitive performance has been related 
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to conventional markers of CSVD and DTI measures.148, 149 In our prediction model, cognitive 
index was not retained in the model when these imaging markers were added. 
Another interesting finding was that the microstructural integrity of the WM seems to be 
more important in the prediction of mortality in our population than the conventional MRI 
markers of CSVD because none of these markers were retained in the prediction model. An 
explanation for this finding might be that diffusion abnormalities in the WM probably better 
reflect the overall WM damage of our population since most of our participants had mild 
to moderate severe CSVD at baseline. Conventional MRI markers of CSVD probably reflect a 
small amount of WM abnormalities because it has been suggested that changes in diffusion 
parameters precede the development of WMH.91 Furthermore, other (neurodegenerative) 
abnormalities may have influenced the microstructural integrity of the WM of our participants 
and the association with mortality.  
GM volume has been associated with mortality in population-based studies.150 We showed 
that this factor had a significant contribution in the prediction of mortality in a CSVD 
population. As 17 (21.8%) of the patients who died had developed dementia during the 
follow-up of our study, this may be an explanation for the observed association between 
lower GM volume at baseline and mortality. However, the causes of increased mortality in 
patients with dementia have not been fully elucidated.151
Conclusions
This study showed that, in the prediction of mortality in older adults with CSVD, older age, 
lower gait speed, lower GM volume, and a greater global MD of the WM were the factors 
primarily associated with 8-year all-cause mortality. These factors probably reflect the vital 
health status of this group. Future studies are needed to investigate the reproducibility of 
our prediction model on mortality. Furthermore, research is needed to elucidate the exact 
association between these risk factors and mortality and should investigate whether, for 
example, intervention in these risk factors (e.g., by treatment of CSVD and/or treatment of 
the underlying causes of gait impairment) could improve life expectancy in older adults with 
CSVD. 
FACTORS ASSOCIATED WITH 8-YEAR MORTALITY IN CEREBRAL SMALL VESSEL DISEASE. 
109
1
2
3
4
5
6
7
8
9
A

Part V
Summary and discussion

7.
General discussion and future perspectives
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The overall objective of this thesis was to gain a better understanding of the brain changes 
underlying motor performance, including gait decline and incident parkinsonism, in cerebral 
small vessel disease (CSVD) using conventional magnetic resonance imaging (MRI) and 
diffusion tensor imaging (DTI). Identification of determinants of adverse outcomes (i.e. 
mortality) in CSVD was another aim of this thesis. The studies described in this thesis are 
conducted as part of the RUN DMC study, a prospective cohort study, which investigates the 
risk factors and clinical consequences, including motor, cognitive and mood disturbances, of 
brain changes as assessed by MRI and DTI. This cohort study consists of 503 participants with 
CSVD, aged between 50 and 85 years, who were initially free of parkinsonism and dementia. 
Baseline assessment (2006) included a cerebral MRI and extensive cognitive and motor 
evaluation, with, among others, quantitative measurement of gait and parkinsonian signs. 
This assessment was repeated in 2011-2012 and in 2015 (9 years follow-up). 
In this chapter, I will discuss several important methodological considerations. Next, an 
overall view of the main findings of the studies in this thesis is provided. Finally, the clinical 
relevance of our findings and suggestions for future research are discussed.  
Methodological considerations
Internal validity
The internal validity of a study refers to the reliability of the observed findings of the data 
collected. Internal validity depends on the extent to which potential sources of bias have 
been avoided.152 There are several forms of bias with selection bias, information bias and 
confounding being the most important. 
Selection bias may occur when selection of participants is reliant on the outcome and 
has not been a random selection.152 In our study, selection bias may have occurred at both 
baseline and follow-up. At baseline, the initial response rate was 71.3%; non-participants 
were older and had more severe white matter hyperintensities (WMH) measured by the Age-
Related White Matter Changes (ARWMC) scale on a cerebral scan prior to inclusion.153 Higher 
age and higher load of WMH of this group may have resulted in more motor and cognitive 
disabilities, which could have prevented them from participation. As a result, it is likely that 
we have missed patients with a higher degree of both motor impairment and CSVD. This bias 
might have led – if any - to an underestimation of the found associations between CSVD and 
the clinical outcomes, as well as to an underestimation of the incidence of parkinsonism and 
mortality in our study population. A part of our study population (20.9%) did not participate 
in the follow-up assessment, because they deceased, were lost to follow-up or were not 
able to participate, leading to selective drop-outs (attrition bias). Since we were able to 
identify primary outcomes of almost all baseline participants, including on the presence 
of parkinsonism and mortality, this bias had not influenced our results on these outcome 
measures. However, this bias might have influenced our analyses on gait decline, as from a 
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substantial part (26.6%) of our initial participants gait assessment was not available at follow-
up (chapter 3 and 4). In order to get insight in the potential magnitude of this attrition bias 
we compared the baseline characteristics between the participants and non-participants in 
our gait studies. We found that the non-participants were older, had a significant lower gait 
speed and higher load of CSVD at baseline; this may have resulted in an underestimation of 
the strength of the found associations.   
Information bias might arise as a result of measurement errors in either the determinant (i.e. 
CSVD markers) or outcome (i.e. motor performance), which might lead to misclassification.152 
The risk of measurement errors is higher when the determinant or outcome is not properly 
defined. A distinction can be made between differential misclassification, when the degree 
of misclassification is different between groups that are compared, and non-differential 
misclassification, indicating that the frequency of errors is approximately the same in 
groups being compared. In general, differential misclassification can lead to an under- or 
overestimation, whereas non-differential misclassification often leads to underestimation of 
the true association. The risk of information bias in the RUN DMC study was reduced by the 
single-centre design, which allowed us to systematically and uniformly collect information at 
baseline and follow-up. Furthermore, the assessment of the determinants (imaging markers) 
was performed independently and blinded to clinical information, minimizing differential 
misclassification. 
Information bias might however have occurred when determining imaging measures and 
motor performance, which will be discussed in the following section. 
Measurement errors in MRI parameters: By using a 1.5-Tesla MRI with 5mm thick slices, 
instead of a 3.0-Tesla or even 7.0-Tesla MRI with small slices, underestimation might especially 
have occurred in the assessment of CSVD. Stronger magnetic field strengths with lower slice 
thickness, as well as susceptibility-weighted imaging have improved the detection of WMH, 
(micro)infarcts and microbleeds in recent years. It is however, unclear whether this improved 
detection is linearly present in the whole range of the CSVD spectrum or predominantly plays 
a role in those with a moderate to severe load of CSVD on 1.5-Tesla MRI. 
For brain volumetry we initially used Statistical Parametric Mapping 5 (SPM5) (chapter 2, 5 
and 6) and later switched to a major update of the SPM software (SPM12)  for the studies 
on gait decline (chapter 3 and 4). This recent updated version of SPM12 included, among 
others, a ‘New Segment’ segmentation procedure, which included additional tissue maps 
for non-brain soft-tissue (i.e. dura, venous sinus), bone and air/background. This might help 
to reduce the amount of non-brain tissue misclassified as grey matter or cerebrospinal 
fluid (CSF). Determining brain volumes with SPM5 might therefore have possibly led to 
an overestimation of grey matter volume and/or CSF in comparison to brain volumes 
determined with SPM12. In general, determining brain volumes with SPM in participants at 
the extremes of a spectrum (high brain volumes with slit like ventricles versus severe brain 
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atrophy) is much more under the influence of measurement error than in participants with 
a relatively standard brain volume, with better registration to the probability distribution 
maps of SPM. This might have led to differential misclassification, because participants with 
primary and secondary outcomes are expected to have a higher age and possibly more brain 
atrophy. To avoid the erroneous segmentation of WMH as grey matter, we corrected the T1 
images for these segmentation errors using WMH mask. However, this procedure was not 
performed in SPM5, which may have led to an overestimation of grey matter, especially in 
participants with a high WMH volume (differential misclassification). Since we found lower 
grey matter volume to be associated with incident vascular parkinsonism (chapter 5) and 
8-year mortality (chapter 6), which were also associated with higher WMH volumes, this 
possible differential misclassification might not be of significance in our study. We tried to 
reduce this bias by visual inspection of all scans by 1 rater. Corrections were made if co-
registration errors, motion artefacts or segmentation failures had occurred.  
The microstructural integrity of the white matter was investigated with DTI by using a diffusion 
tensor model, which describes a Gaussian diffusion process.154 In complex brain tissue, i.e. 
areas with crossing fibres and pathology, the water diffusion is non-Gaussian, which possibly 
have led to a misclassification of the water molecules diffusion in those areas.118  
The DTI post processing technique we mainly used in this thesis was a Tract-Based Spatial 
Statistics (TBSS) analysis, whereby local fractional anisotropy maxima are projected onto a 
skeleton of the core of major white matter tracts. This technique is easy to use, fast and is 
an automatic procedure, which reduces registration inaccuracies and smoothing procedure 
errors. Disadvantages of this technique may be that these maxima do not represent the true 
anatomical centre of a white matter tract in a diseased brain, particularly in the presence 
of territorial infarcts, CSVD related lesions and/or atrophy, which could result in differential 
misclassification. We tried to overcome this, by excluding participants with territorial infarcts 
from the TBSS analyses. Since the white matter not included in the white matter tracts is 
not evaluated in TBSS, we included global DTI measures of the whole white matter in our 
analyses as well. 
Measurement errors in motor decline: The diagnosing of parkinsonism at follow-up in our 
population was vulnerable to misclassification, as different case finding methods were 
used and not all diagnoses could be confirmed by neurological examination in our centre. 
For participants who were not able to visit our research centre, we had to rely on medical 
files and information from general practitioners. As parkinsonism is often accepted as 
part of normal ageing and may not be recognized by general practitioners, it is likely that 
we have missed at least some incident cases and incorrectly classified them as having no 
parkinsonism, which probably resulted in an underestimation of our found associations 
(differential misclassification). Furthermore, the clinical distinction between different 
subtypes of parkinsonism, is prone to errors, since the diagnostic accuracy is low in 
comparison to neuropathologic diagnosis.130 For the diagnosis of vascular parkinsonism (VP) 
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the presence of cerebrovascular lesions on neuroimaging is required.21 This might have led 
to an overestimation of VP in our study, as all of our participants had at least some amount 
of CSVD and may have caused circular reasoning as well. In order to reduce the effects of 
possible misclassification of the different types of parkinsonism, we first performed the 
analyses with all types of parkinsonism, after which we performed separate analysis for a 
clinical diagnosis of VP, which showed similar results.  Unfortunately, we were not able to 
take the course of disease into account or observe any treatment effect with Levodopa, 
which may have hampered the accuracy of diagnosis the subtypes of parkinsonism. 
Confounding occurs in every observational study and may result in spurious associations. 
Confounding exists when an association between the determinant and outcome is 
explained by a third variable, which is not part of the causal pathway.152 There are several 
ways of controlling for confounding, including the use of multivariate analyses. We adjusted 
our analyses for major known confounders in the association between CSVD and motor 
decline, including age, gender and follow-up duration. We intentionally did not adjust for 
cardiovascular risk factors, as they are part of the causal chain of CSVD. We adjusted all our 
DTI analyses for traditional CSVD characteristics, which with no exception weakened the 
found associations. As structural integrity is now considered part of the CSVD spectrum, it 
can be questioned whether traditional CSVD markers are a true confounder and whether 
they are independent of these markers. We therefore presented DTI analyses in 2 models: 
without and with additional adjustment for CSVD. For our gait analyses, we excluded 
participants with other severe conditions than CSVD that affected gait, including severe 
arthritis, polyneuropathy, vision problems and cardiopulmonary diseases, because these 
diseases are not directly part of the causal pathway of CSVD. In addition, we chose other 
potential confounders (e.g. height, baseline gait parameters, and cognition) on information 
from previous studies and on our findings of univariate analyses. However, we could not rule 
out that residual confounding by unmeasured or unknown variables have influenced our 
associations.
Precision
The precision of a study is high in the absence of random error, indicating fluctuations 
around the true value.152  Random error is inversely related to study size and is also related 
to the manner outcome measures are determined.152 To favour precision, we firstly included 
a large sample of older adults with CSVD at baseline and made a great effort to include as 
many of the baseline participants for follow-up examination. Second, we tried to minimize 
random errors in the assessment of determinants and outcomes by using the same research 
protocol at baseline and follow-up. We quantitatively assessed gait using  GAITRite, which 
has a high test-retest reliability and validity93, 94 and averaged the gait parameters over two 
walks. Cognitive and other motor assessments, including unified Parkinson’s disease rating 
scale motor section (UPDRS-m) for the screening of parkinsonism, were performed by mostly 
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the same and trained neurologist in training, promoting precision. Information on vital status 
was retrieved from the Dutch Municipal Personal Records database and the exact cause 
of death was obtained from the general practitioner, treating physician and medical files. 
All imaging measures were also quantitatively assessed. For the traditional CSVD markers 
(manual rating of WMH, lacunes and microbleeds) an intra- and inter-rater agreement was 
obtained in a sample of 10% of the scans with good intra- and inter-rater reliabilities. The 
change of MRI-scanner between baseline and follow-up, leading to a distorting of the T1 
images, has possibly affected precision (chapter 4). The effect of this scanner-upgrade is 
unknown, but previous studies have showed that brain volumes remained reliable; however, 
it may have introduced a bias in the main volume differences, which are probably random 
errors.111 We considered our longitudinal DTI measures as more robust, as the protocol did 
not differ between these two time-points, except from the number of diffusion directions (30 
versus 61 at baseline and follow-up), which has probably not influenced our results since 
we applied a diffusion tensor model with 6 degree of freedom. A previous study showed no 
differences in DTI parameters between scanners.112 The detection of WMH with an in-house 
developed semi-automatic detection method used in chapter 4,155 yielded significant lower 
WMH volumes than with manual segmentation. This is possibly be explained by the fact that 
automatic procedures might minimize the false-positive classifications, because the signal 
intensity in WMH typically overlaps with that of normal tissue and the borders of abnormal-
normal tissue are difficult to notice with the human eye, promoting precision. Another 
advantage of an automatic segmentation is that it is completely reproducible; manual 
segmentation usually suffers from intra- and inter-observer variability, although the inter-
rater variability for manual segmentation was good in our study.  
Causal inference
The RUN DMC study has a longitudinal design, which allowed us to investigate changes over 
time, regarding changes in imaging measures and clinical parameters, including gait decline 
and the development of parkinsonism. This relative long follow-up period enabled us to 
study clinical significant changes in both CSVD imaging markers and clinical parameters. 
A temporal relationship strengthens the evidence for a link between these parameters in 
comparison to cross-sectional studies. However, due to the observational nature of our 
study we were not able to study the directionality of the associations found in our studies. 
We assumed that CSVD leads to gait decline and parkinsonism. However, there is a possibility 
of reverse causality, indicating that gait decline or parkinsonism may lead to (progression of) 
CSVD and loss of white matter microstructural integrity, e.g. by leading to motor inactivity 
and a sedentary lifestyle and thereby promoting cardiovascular risk factors. 
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External validity
The extent to which the results of a study can be generalized to a population beyond the 
sample  studied is defined as external validity.152 The RUN DMC study includes a large group 
of older adults with a broad age range (50-85 years), with no dementia and parkinsonism 
at baseline, and with diverse neuroimaging characteristics of sporadic CSVD. The frequent 
coexistence of lacunes and microbleeds in our population, as well as the high prevalence 
of vascular risk factors at baseline suggests a vascular aetiology in most of our participants. 
Although our participants were seen in a university hospital, we feel that our results can be 
extended to a CSVD population aged ≥50 years referred to a general neurologic clinic, since 
we included all consecutive patients referred to our out-patient department with CSVD on 
neuroimaging. There were no restrictions for admission and participants were usually seen as 
a first opinion at our clinic. Furthermore, in community-dwelling populations the prevalence 
of vascular risk factors and CSVD-related lesions, with a prevalence of WMH of >90% in adults 
over 60 year of age9, is comparable to our study population. To get more insight into the 
generalization of our results we compared our cohort with other CSVD cohorts. One of the 
largest CSVD cohorts is the Leukoariosis and Disability in the elderly (LADIS) study (n=639), 
which is a multicentre and multinational (European) collected hospital-based cohort of CSVD 
patients.156 Participants were referred to the hospitals for similar reasons and the inclusion 
criteria greatly overlap with our study, except for age at inclusion; 65-84 year in the LADIS 
study (mean age (SD) 74.1 (5.0) years) versus 50-85 year in ours (65.7 (8.8) years). As a result, 
the LADIS study had a higher proportion of participants with Fazekas 3 score at baseline (25% 
versus 13% in our study). Furthermore, there was a female predominance in contrast to ours, 
which could also be the result of the higher age at baseline, as the female sex has a higher life 
expectancy. There was a similar distribution of vascular risk factors between the LADIS and 
the RUN DMC study. Therefore, we regard the RUN DMC cohort as a good representation of 
older patients (aged ≥ 50 years) with sporadic CSVD visiting a neurological clinic. 
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General discussion of the main findings
Motor decline in cerebral small vessel disease
Gait decline
White matter atrophy and loss of white matter integrity were associated with gait decline in 
our CSVD population after 5 years of follow-up, by affecting stride length instead of cadence 
(chapter 4). As previous studies have thoroughly established cross-sectional associations 
between CSVD and gait performance,17, 157 it was interesting to note that baseline CSVD was 
not associated with gait decline in our population (chapter 3), although we observed a 
considerable decline of gait (≥0.1m/s) after 5 years in more than 70% of our participants. 
The selective drop-out, which is often inherent to a prospective cohort study, resulted in 
a relatively good study population with a lower baseline burden of CSVD and higher gait 
speed, which might have partially contributed to this result. Furthermore, our participants 
might be better able to compensate for CSVD pathology than the non-participants, as they 
had higher white and grey matter volumes and had an overall better cognitive function at 
baseline as well. This hypothesis is captured in the reserve hypothesis, indicating that a 
reserve in brain or cognitive functioning can sustain more pathological damage, which might 
explain the lack of association between brain pathology and its clinical manifestation in 
specific populations.158, 159 Recently, this concept has also been applied to motor function, 
by showing that older adults with a higher cognitive reserve (reflected by higher education) 
were less susceptible to the effect of WMH on gait speed, than persons with a low cognitive 
reserve.160 However, we did not investigate the existence of a possible brain or cognitive 
reserve in our study population. Next, the multifactorial nature of gait decline could have 
prevented us from finding significant associations with CSVD at baseline. A recent study 
showed that accumulation of pathology in multiple organ systems was associated with gait 
decline; no specific organ system was found to be primarily or independently responsible for 
gait decline.102 At last, by using a self-selected gait speed, instead of a maximum gait speed, 
the interindividual variations in gait speed between baseline and follow-up could have been 
smaller than with a challenging maximum gait speed161 in which compensation mechanisms 
will possibly fail earlier. This may have led to underestimation of our associations.  
Only a few studies have investigated changes in both variables (imaging and gait measures) 
and their results are conflicting; one found that progression of WMH and white matter 
atrophy was associated with a greater decline in gait,104 which is in line with our results, while 
others have found no associations.108 The associations between changes in DTI measures 
gait decline has not been studied before, but the results of the former study could imply that 
loss of white matter integrity might underlie the found association between white matter 
atrophy and gait decline. We observed that loss of white matter microstructural integrity is 
associated with gait decline. We found the strongest associations between DTI measures and 
decline in stride length in the corpus callosum and corona radiata, which are important white 
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matter tracts in motor control. The corpus callosum is not specific for motor functioning, but 
is also important in cognitive performance.114 Both CSVD162 and slowing of gait163 have been 
shown to be associated with cognitive decline in older adults. Since we did not adjust our 
analyses on gait decline for cognitive decline, we could not rule out the possibility that the 
observed association between corpus callosum integrity, as well as white matter atrophy, 
and gait decline is partially explained by cognitive decline. It has recently been suggested 
that the association between white matter damage and gait impairment is, at least in part, 
mediated by cognitive performance.164 Future studies should further unravel the underlying 
mechanisms of gait decline in CSVD, and investigate the interaction between gait and 
cognitive decline in CSVD as well. 
Parkinsonism 
Until now, only retrospective and cross-sectional studies have investigated the relationship 
between CSVD and parkinsonism and yielded mostly contradictory results. We showed that 
CSVD at baseline, especially WHM volume and lacunes, is associated with the development 
of parkinsonism after 5 years (chapter 5). The development of VP was, in addition, associated 
with the presence of microbleeds and a lower grey matter volume at baseline, as well as 
with lower baseline structural integrity in multiple bifrontal white matter tracts. This latter 
finding is in accordance with the results of previous cross-sectional studies, which showed 
that DTI measures, especially of the frontal white matter can be of help in distinguishing 
healthy controls from patients with VP122 and also in differentiating among different other 
subtypes of parkinsonism.136 Our findings advocate a role of CSVD in the aetiology of 
parkinsonism and indicate that severity of CSVD, but possibly also the location of CSVD, 
in view of the lower bifrontal white matter integrity in our participants with VP, might be 
important in the development of parkinsonism. We did not investigate the role of location 
of the traditional CSVD markers in the development of parkinsonism. CSVD, especially WMH, 
in the frontal regions and lacunes in the basal ganglia and thalamus, has been associated 
with mild parkinsonian signs165, 166 and parkinsonism.21 We can propose several mechanisms 
how CSVD can contribute to the development of parkinsonism. First, CSVD could disrupt 
the basal ganglia-thalamo-cortical circuits, as well as other important (frontal) motor 
pathways, which might be an explanation why patients exhibit predominant gait problems. 
Our results might support this possible mechanism by finding lower structural integrity in 
motor white matter tracts in VP, including the internal capsule, corona radiata and the genu 
of the corpus callosum. Furthermore, we found a lower volume of grey matter (cortical and 
subcortical) structures in patients with VP, which might be caused by direct ischemic damage 
or by secondary neuronal degeneration to WMH, lacunes and/or microbleeds, although we 
made adjustments for these traditional CSVD markers. We could not rule out the possibility 
that other age-related neurodegenerative pathology could have caused lower grey matter 
volumes in our patients with VP as well. Second, accumulation of pathology, including CSVD, 
age-related nigro-striatal loss, as well as amyloid, tau and possible Lewy-body pathology, 
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can lower the threshold for motor symptoms of parkinsonism to become apparent. This 
concept is strengthened by a previous study that showed that comorbid WMH in idiopathic 
Parkinson's disease were associated with more severe motor symptoms independent of the 
degree of nigrostriatal dopaminergic denervation.167 Another indication of this mechanism 
might be the fact that our patients with parkinsonism were significantly older in comparison 
to those without parkinsonism with as a result probably more age-related pathology, apart 
from CSVD, although all our analyses were age-adjusted. This might possibly also explain 
why parkinsonism is often a late feature in, relatively young, patients with cerebral autosomal 
dominant arteriopathy with subcortical infarcts (CADASIL).168 As our study did not include 
nuclear imaging, we were not able to unravel the contributions of these different pathologies 
to the development of  parkinsonism in our cohort. 
An interesting parallel of VP can be made with vascular dementia. There is a major overlap 
in symptoms, risk factors and neuroimaging characteristics between VP and vascular 
dementia.169 Gait difficulties are often reported in vascular dementia170 and vice versa.171 This 
might suggest that they are part of the same disease entity. However, why some patients 
present with predominant gait problems, whereas others exhibit mainly cognitive problems 
is not exactly understood. Possible factors or mechanisms can be the location of CSVD 
markers and loss of white matter integrity in specific brain areas, or reduced structural 
cerebral network connectivity, which might capture the cumulative effects of CSVD as well 
as concomitant neurodegenerative pathology172 (e.g. β-amyloid plaques, tau deposits and 
α-synuclein aggregates in the brain). Future research including these different factors may 
shed light on this issue. 
Determinants of mortality in cerebral small vessel disease
In the RUN DMC study, participants with the highest mortality risk were those with a high 
age, low gait speed, low grey matter volume and low structural integrity of the white matter 
(chapter 6). The most prominent finding in our study on 8-year mortality was that imaging 
markers, including structural integrity of the white matter and grey matter volume, could 
improve the precision in prediction of mortality, next to demographic and clinical parameters 
(age and gait speed) in our CSVD population. DTI has been proven to be a possible surrogate 
marker of adverse outcomes, including disability, cognitive disturbances and new onset 
strokes in CADASIL patients173 and functional outcome  and mortality  in community dwelling 
populations. 174-176 We showed that diffusion parameters had a higher predictive value for 
mortality than the traditional CSVD markers, probably because they better reflect the overall 
damage to the white matter in CSVD.91 Another remarkable finding was that the presence 
of CSVD was associated with an increased risk of all-cause mortality, and not only with an 
increased risk of vascular death. This might be the result of the previous found association 
between CSVD and pathologic changes in other organ systems.102 And this could also 
be a reason why gait speed seemed to be a better predictor of mortality than cognitive 
performance, as cognition is less affected by damage to other organ systems than the brain. 
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This is in line with a recent study in CADASIL patients (n=278), showing that the combination 
of demographic, clinical and MRI measures might be of help in the prediction of adverse 
outcomes after 3 years of follow-up, including incident stroke, severe disability, dementia 
or death.177 Gait difficulties, number of lacunes and total brain volume were found to be 
predictors of the combined endpoint, including all adverse outcomes mentioned above. DTI 
was not included in this study and the contribution of grey and white matter volume was not 
studied separately. Only age was found to be a predictor of 3-year mortality. However, this 
result should be interpreted with caution due to the small number of deaths (n=14). 
Clinical implications
Motor decline in CSVD has always been somewhat neglected in comparison to cognitive 
decline so far. Our results might be of help to physicians seeing a patient with CSVD who 
experience motor problems, including gait disturbances or parkinsonism. Our studies 
indicate that CSVD-related brain changes, especially brain atrophy and loss of white matter 
integrity should be considered as one of the possible causes in these motor problems. 
Furthermore, our results underpin the importance of examination of gait in patients with 
CSVD, with a special attention to stride length. Our results indicate that a decline in gait speed 
(by a decline in stride length) could be a reflection of progression of white matter pathology 
(chapter 4), might indicate early stage of parkinsonism (chapter 5), and might increase the 
risk of mortality (chapter 6). Therefore, it can be suggested that changes in gait speed need 
further evaluation in patients with CSVD. As it might reflect a lower vital health status, also the 
assessment of organ systems other than the brain should be incorporated in this evaluation, 
including cardiopulmonary and musculoskeletal systems. Possible cut-off points for this 
evaluation could be a gait speed decrease of ≥0.1m/s or the development of gait impairment 
(gait speed <1.0m/s), as these cut-off points have been consistently associated with adverse 
outcomes.25, 86 Gait speed, stride length and cadence can be easily obtained in the outpatient 
department by measuring the time and number of steps taken at a certain walking distance. 
Surrogate imaging markers in CSVD
Establishing MRI measures as a surrogate marker for clinical consequences of CSVD might 
be of great interest for several reasons. First, abnormalities on brain imaging often exist long 
before clinical symptoms occur and possibly might have a faster progression rate than clinical 
outcome measures. As a result, including surrogate imaging markers in trials can reduce 
sample size.178 Our results indicate that especially the microstructural integrity of the white 
matter and brain atrophy have the best potential to serve as a surrogate markers for motor 
decline, as well as for long-term mortality in populations with CSVD. A reason might be that 
brain atrophy and DTI measures better capture the overall damage of diverse pathologies 
in the brain. The structural integrity of the corpus callosum might be of special interest as a 
potential marker of deterioration of motor performance in CSVD, as we found lower baseline 
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structural integrity in this white matter tract in patients with incident parkinsonism (chapter 
5). In addition, we found that loss of structural integrity of the corpus callosum was also 
associated with gait decline (chapter 4).  
Second, surrogate imaging markers might provide a better understanding of the mechanisms 
of clinical manifestations of CSVD, including deterioration in motor performance. This 
especially applies for DTI measures, since a number of pathological processes could underlie 
changes in DTI measures, including axonal degeneration and ischemic demyelination. Radial 
diffusivity (RD) and axonal diffusivity (AD) have been proposed to give information on the 
type of neuronal damage; RD is proposed to give information on demyelination and AD is 
thought to represent axonal degeneration.116 In our CSVD population, an increase in MD and 
RD was associated with gait decline (chapter 4), which might advocate a role for ischemic 
demyelination in CSVD related gait decline. This result should however, be interpreted with 
caution since diffusion parameters are dependent on eigenvalue sorting, which is difficult to 
reliably obtain in complex brain tissue.118 DTI can also be used to study network connectivity 
by using tractography, which might increase our understanding how CSVD can affect gait 
and motor function from a network perspective. Studies using network analyses in motor 
decline are currently lacking. DTI is, however, not used in clinical practice yet and before 
these measures can be used as surrogate markers, future studies are needed to investigate 
the reproducibility of our results and study the standardization and validation of the DTI 
protocol and its measures. Lastly, if surrogate markers are proven to have clinical relevance, 
they might be possible targets for intervention. To date, there are no established therapeutic 
interventions for prevention or treatment of CSVD.179  Some studies have shown that lowering 
blood pressure might reduce the progression of WMH.180, 181 Furthermore, in cross-sectional 
studies it has been shown that physical activity may help to prevent or delay brain atrophy.182, 
183 Randomized trials are necessary to investigate whether prevention of deterioration of these 
surrogate imaging markers e.g. by cardiovascular risk management or by increasing physical 
activity and ambulatory function can improve motor function, life-expectancy and cognitive 
performance. The effect of cardiovascular risk management and exercise has already been 
studied in relation to cognitive decline and dementia, although the results are somewhat 
conflicting.184, 185 Until proven, it seems reasonable to promote a healthy lifestyle (e.g. quitting 
smoking, promoting a balanced diet) and stimulate patients to be physical active in order to 
reduce potential risk factors for the development of brain pathology. 
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Directions for future research
With the ageing of the society, CSVD and its clinical consequences more and more burdens 
the health care system. CSVD is responsible for about 20% of all strokes worldwide186 and 
triples the risk of future stroke14 and doubles the risk of dementia.187 Future research is 
therefore needed, as little effective treatments for CSVD and cognitive and motor decline are 
available yet. Several directions for future research can be suggested. 
First, the results of our studies should be replicated and extended to other longitudinal studies 
and the hypotheses generated in this thesis should be tested. Future studies on the long-
term prognosis of CSVD should ideally take functional dependence, besides mortality, into 
account, as hospitalization and being dependent on home care, have a significant impact on 
the perceived quality of life of older adults. A prediction model for functional dependence in 
CSVD increases the external validity towards clinical practice. Increasing knowledge on the 
determinants of a functional worse outcome in CSVD could possibly lead to the development 
of strategies for prevention or treatment options. 
In order to gain more insight into the pathogenesis of parkinsonism in CSVD cohorts and 
the contribution of diverse brain pathology (including CSVD, neurodegenerative pathology 
and normal ageing), prospective multimodal imaging, including MRI techniques and SPECT, 
should be incorporated in future studies.
Second, we need a better understanding of the aetiology and progression of CSVD over time. 
As already mentioned, DTI is a promising tool for unravelling the underlying pathophysiology 
of white matter damage. In addition, the use of higher field strength imaging at 7 Tesla may 
improve our understanding by visualizing the vascular pathology itself in the perforating 
arteries and brain parenchym.188, 189 Furthermore, serial imaging with short intervals in-
between, might provide a closer look at the progression of CSVD and changes of brain 
structure over time and give the opportunity to study the direct clinical consequences of 
these changes. A sub-study of the RUN DMC study is underway to further investigate this. 
It would also be interesting to investigate the development of CSVD and brain changes in 
younger healthy populations (e.g. aged 30 years) with and without vascular risk factors to 
study aetiology and brain changes and identify risk factors of these brain changes, including 
lifestyle and genetic factors.
Another interesting direction for future research is to gain more insight into the mechanisms 
of the clinical consequences of CSVD by using DTI followed by tractography and network 
analyses, to study the contribution of disruption of white matter networks to clinical 
symptoms. It would also be of interest to study the difference and the interaction between 
cognitive and motor decline in CSVD populations with these techniques. Studying the 
longitudinal associations between these imaging measures and clinical measures would 
provide further evidence for a causal relationship. 
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Cerebral small vessel disease (CSVD), a disease of the small perforating cerebral arteries, 
arterioles, venules and capillaries, is very common in the elderly population, with a prevalence 
of >90% in individuals aged 60 years and over. On a cerebral magnetic resonance imaging 
(MRI), this disease is visible as white matter hyperintensities (WMH), lacunes, microbleeds and 
brain atrophy. These imaging makers are considered as the traditional CSVD markers. Main 
risk factors are longstanding arterial hypertension, smoking and diabetes. CSVD is associated 
with a broad clinical spectrum, including cognitive disturbances, dementia, depression, 
stroke, as well as motor problems, including gait disturbances and mild parkinsonian signs. 
It is assumed that these clinical symptoms are the result of disruption of white matter tracts 
and loss of connectivity between brain areas by CSVD. However, the traditional CSVD makers 
do not explain the whole clinical spectrum. Therefore, other factors, such as the underlying 
white matter microstructural integrity, which can be assessed by diffusion tensor imaging 
(DTI), may play a role in the development of clinical symptoms in CSVD. 
In this thesis, I mainly focused on the brain changes in CSVD associated with the development 
of motor disturbances over time, including gait decline and the development of parkinsonism. 
In addition, I studied the determinants of 8-year mortality in CSVD. All studies described in 
this thesis are conducted as part of the RUN DMC study, a prospective cohort study among 
503 older adults, aged 50-85 years with CSVD on neuroimaging, which started in 2006. Follow-
up assessment took place in 2011-2012. This study is designed to investigate the risk factors 
and clinical consequences of brain changes assessed by conventional MRI and DTI. In this 
chapter I will summarize the main findings of each chapter. 
Part II: Cerebral small vessel disease and cognitive performance
In chapter 2 we reported on the association between the white matter integrity, assessed 
by DTI, and cognitive performance, including verbal memory performance.  Verbal memory 
failure may eventually result in cognitive decline and dementia in some. With a region of 
interest (ROI) approach and a Tract-Based Spatial Statistics (TBSS) analysis, we demonstrated 
that the microstructural integrity of the cingulum is specifically associated with verbal 
memory performance at the cross-sectional level, independent of the presence of traditional 
CSVD markers. The cingulum is a white matter bundle, which connects the medial temporal 
lobe structures (e.g. hippocampus) and the posterior cingulated cortex, and has a pivot role 
in memory function. In addition, we showed that microstructural integrity of the cingulum 
is associated with the structural integrity of the hippocampus. The cingular integrity 
was significantly lower in participants with a low structural integrity of the hippocampus 
compared to those with a high structural integrity of the hippocampus. These results might 
indicate that cingular microstructural integrity could serve as a surrogate marker for (the 
development of) impaired verbal memory and possibly also dementia in individuals with 
CSVD. 
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Part III: Cerebral small vessel disease and motor performance
This part of the thesis reports on the motor consequences of CSVD after 5 years of follow-up. 
Traditional CSVD markers (WMH volume, lacunes, microbleeds and white and grey matter 
volume), as well as DTI measures of the white matter were related to gait decline and the 
development of parkinsonism after 5 years. A TBSS analysis was used in each chapter, to 
study the microstructural integrity of important white matter tracts. 
In chapter 3 we investigated the associations between baseline CSVD and gait decline 
and the development of incident gait impairment, defined as a gait speed below 1.0m/s. 
We found no significant associations between baseline imaging markers and gait decline 
or incident gait impairment after 5 years in our population. In addition, the TBSS analysis 
revealed no significant differences in DTI measures between participants with and those 
without incident gait impairment after additional adjustments for the traditional CSVD 
markers. In chapter 4 we extended this study and investigated whether changes in these MRI 
and DTI markers are associated with gait decline after 5 years. We found that white matter 
atrophy and loss of white matter integrity were associated with gait decline. Gait decline 
was affected by a smaller stride length and not with a decline in cadence. Progression of the 
other markers of CSVD (WMH volume, lacunes and microbleeds) was not associated with 
gait decline. Changes in DTI measures, especially an increase in mean diffusivity and radial 
diffusivity, were associated with stride length decline. The strongest associations were found 
in the corpus callosum and posterior and anterior corona radiata and were independent of 
traditional CSVD markers. These findings suggest that progression of white matter pathology, 
especially white matter atrophy and loss of white matter structural integrity, should be 
considered as a possible cause of gait decline in older adults with CSVD. 
In chapter 5 we reported on the association between baseline CSVD and incident 
parkinsonism. Of our 503 baseline participants, parkinsonism developed in 20 participants 
after 5 years. The cumulative 5-year risk for parkinsonism was 3.5% (95% CI 1.9-5.2). We found 
that a high WMH volume and a high number of lacunes were associated with an increased 
5-year risk of parkinsonism. For vascular parkinsonism, this risk was also increased by the 
presence of microbleeds and a low grey matter volume. Moreover, participants with vascular 
parkinsonism had a lower structural integrity in bifrontal white matter tracts in comparison 
to those without, independent of the presence of traditional CSVD markers. These findings 
are building the case for a role of CSVD in the aetiology of parkinsonism. 
Part IV: Long-term mortality in cerebral small vessel disease
In chapter 6 we studied the 8-year mortality in CSVD and investigated potential clinical and 
imaging factors associated with mortality. 80 Participants of the 503 died during the follow-
up period (mean 7.8 years (SD 1.5)). All-cause mortality was highest in participants with the 
presence of lacunes and microbleeds, with the highest WMH volume and mean diffusivity of 
the white matter, and with the lowest white and grey matter volumes. In the prediction of 
mortality, older age, lower gait speed, lower grey matter volumes and greater mean diffusivity 
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of the white matter were factors that best predicted 8-year mortality in our population with 
older adults with CSVD aged 50-85 years. Cognitive performance and other traditional CSVD 
markers were not retained in the prediction model. The predictive factors are probably a 
reflection of the vital health status of our population. 
Conclusion
The studies described in this thesis showed that several brain changes are associated with 
the development of motor disturbances after 5 years, as well as functional outcome in older 
adults with CSVD. The presence of traditional CSVD makers at baseline imaging increased 
the 5-year risk of incident parkinsonism, as well as the 8-year mortality. In addition, impaired 
white matter microstructural integrity at baseline was associated with incident vascular 
parkinsonism, and was an important predictor of 8-year mortality, next to age, gait speed 
and grey matter volume in our population. The development of gait impairment or gait 
decline after 5 years was, however, not associated with baseline CSVD. Tough, gait decline 
was associated with white matter atrophy and loss of white matter microstructural integrity 
after 5 years in our population. 
Our findings suggest that DTI holds promise for unravelling the underlying mechanisms, as well 
as for serving as a surrogate marker in the development of motor disturbances and functional 
outcome (e.g. mortality) in CSVD. More studies are needed to investigate the reproducibility 
of our results and further elucidate the mechanisms of the development of clinical deficits in 
CSVD by using novel imaging techniques and network analysis. Furthermore, future research 
should also be directed at whether preventive strategies, e.g. on CSVD and gait decline, could 
improve motor and cognitive performance and functional outcome. 
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Met de Engelse term ‘cerebral small vessel disease’, afgekort CSVD, wordt schade aan de kleine 
bloedvaten in de hersenen aangeduid. Op een magnetic resonance imaging (MRI) scan van 
de hersenen is deze schade zichtbaar als witte stof afwijkingen, kleine herseninfarcten, ook 
wel lacunaire infarcten genoemd, en microbloedingen, alsook verminderd hersenvolume; 
deze afwijkingen worden ook wel de traditionele CSVD markers genoemd. CSVD komt veel 
voor de op de oudere leeftijd, meer dan 90% van de mensen boven de 60 jaar heeft het in 
meer of mindere mate. Belangrijke risicofactoren voor CSVD zijn langer bestaande hoge 
bloeddruk, roken en suikerziekte. CSVD is een belangrijke oorzaak voor problemen met het 
denken, dementie, depressie en een beroerte. Ook is CSVD geassocieerd met motorische 
problemen, zoals loopproblemen en milde parkinsonistische verschijnselen. Verondersteld 
wordt dat deze klachten ontstaan doordat deze aandoening leidt tot beschadigingen van 
witte stof banen en daardoor leidt tot een verstoorde communicatie tussen verschillende 
hersengebieden die door witte stof banen met elkaar worden verbonden. De specifieke MRI 
afwijkingen correleren echter niet volledig met het klinisch spectrum van CSVD; personen met 
eenzelfde hoeveelheid beschadigingen op de MRI hoeven niet in dezelfde mate problemen 
met bijvoorbeeld het geheugen of motoriek te ervaren. Met een speciale MRI techniek, de 
diffusion tensor imaging (DTI), kan de witte stof van de hersenen die verbindingsbanen 
bevat, in groter detail onderzocht worden. Kleine veranderingen in de witte stof, welke 
nog niet zichtbaar hoeven zijn op de gebruikelijke MRI, kunnen hiermee in kaart worden 
gebracht. Deze techniek kan daardoor behulpzaam zijn om beter inzicht te krijgen in de 
hersenveranderingen die mogelijk ten grondslag liggen aan het ontstaan van klinische 
verschijnselen van CSVD. 
In dit proefschrift heb ik me vooral gericht op de hersenveranderingen bij ouderen met 
CSVD die optreden bij achteruitgang in het motorisch functioneren, in het bijzonder bij 
het ontstaan van loopproblemen en parkinsonisme. Ook heb ik gekeken naar factoren die 
geassocieerd zijn met het 8-jaars sterfterisico in personen met CSVD, om een indruk te krijgen 
welke factoren een rol spelen bij een slechte uitkomst en mogelijk een afspiegeling zijn van 
de gezondheidstoestand van deze groep. 
De onderzoeken in dit proefschrift zijn uitgevoerd in het kader van de Radboud University 
Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort (RUN DMC) studie, 
een prospectieve studie waarin 503 mensen tussen de 50-85 jaar oud en met tekenen van 
CSVD op de MRI-scan van de hersenen zijn ge-includeerd. Dit onderzoek is opgezet om de 
risicofactoren en de klinische gevolgen van hersenveranderingen in personen met CSVD te 
onderzoeken. Het onderzoek is gestart in 2006 en een eerste follow-up heeft plaatsgevonden 
in 2011-2012. Tijdens deze 2 bezoeken ondergingen deelnemers een MRI-scan van de 
hersenen, kregen zij uitgebreide neuropsychologische testen om het geheugen in kaart 
te brengen en werd het lopen onderzocht met behulp van een elektronische loopmat, de 
GAITRite. De aanwezigheid van parkinsonisme werd onderzocht met behulp van de Unified 
Parkinson’s Disease Rating Scale. 
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Deel II: Cerebrale small vessel disease en cognitief functioneren
In hoofdstuk 2 beschrijven we de associatie tussen de microstructurele integriteit van 
de witte stof, gemeten met DTI, en het verbale geheugen, onderdeel van het episodisch 
geheugen. Stoornissen in het verbale geheugen kunnen een voorstadium zijn van dementie. 
We hebben hiervoor 2 speciale DTI analyse methoden gebruikt, de zogenoemde region-of-
interest (ROI) methode, waarbij op anatomische gronden een regio wordt gekozen om het 
gewenste baansysteem te selecteren, en een Tract-Based Spatial Statistics (TBSS) methode, 
waarmee gekeken kan worden naar de kern van de belangrijke witte stof banen. Met beide 
methoden vonden we dat de structurele integriteit van het cingulum, een witte stof baan 
die de mediale temporale structuren (zoals hippocampus) verbindt met de cingulaire 
cortex, cross-sectioneel geassocieerd is met het verbale geheugen. Deze associatie was 
onafhankelijk van de traditionele CSVD markers (witte stof afwijkingen, lacunes, microbleeds 
en hersenvolume). De structurele integriteit van het cingulum was ook geassocieerd met de 
integriteit van de hippocampus. De structurele integriteit van het cingulum bleek significant 
lager in deelnemers met een lagere hippocampale integriteit in vergelijking met deelnemers 
met een hogere hippocampale integriteit. Deze resultaten zouden er op kunnen wijzen dat de 
integriteit van het cingulum mogelijk gebruikt kan worden als marker voor (de ontwikkeling 
van) stoornissen in het verbale geheugen en daarmee een vroege marker van dementie kan 
zijn.   
Deel III: Cerebrale small vessel disease en motorisch functioneren
In deel 3 van dit proefschrift onderzochten we de gevolgen van CSVD op het motorisch 
functioneren na 5 jaar follow-up. We hebben ons hierbij gericht op het ontstaan van 
loopproblemen en de ontwikkeling van parkinsonisme. We hebben gekeken welke MRI 
markers geassocieerd zijn met deze achteruitgang in motorisch functioneren. Om de 
structurele integriteit van de witte stof banen te bestuderen maakten wij gebruik van de 
eerder genoemde TBSS methode.  
De associatie tussen CSVD op de baseline scan en de relatie tussen achteruitgang in het 
lopen en de ontwikkeling van een loopstoornis (gedefinieerd als een loopsnelheid <1.0m/s) 
5 jaar later hebben we onderzocht in hoofdstuk 3. We stelden vast dat er geen relatie is 
tussen de hoeveelheid CSVD op de baseline scan en de achteruitgang in lopen in onze studie 
populatie. Ook liet de TBSS analyse geen verschillen zien in de microstructurele integriteit 
van de witte stof banen tussen personen met en zonder loopstoornissen, onafhankelijk van 
de traditionele CSVD markers. De baseline scan kan de ontwikkeling van loopproblemen dus 
niet goed voorspellen in onze populatie. Hoofdstuk 4 borduurt voort op het voorgaande 
hoofdstuk en hierin bestuderen we of hersenveranderingen op de MRI die optreden tussen 
baseline en follow-up onderzoek gerelateerd zijn aan de achteruitgang in het lopen. We 
laten zien dat zowel verlies van witte stof volume (witte stof atrofie) als een afname van 
de microstructurele integriteit van de witte stof geassocieerd zijn met achteruitgang in het 
lopen. Opmerkelijk was dat een toename van de hoeveelheid witte stof afwijkingen, lacunes 
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en microbleeds niet geassocieerd was met achteruitgang in het lopen. Een kleinere paslengte 
bleek de oorzaak voor de achteruitgang in het lopen en daarmee een lagere loopsnelheid, 
terwijl de cadans, het aantal stappen per minuut, gelijk bleef in onze populatie 5 jaar later. 
Bij het bestuderen van de verschillende DTI parameters, laten we zien dat een toename van 
de gemiddelde diffusiviteit en de radiale diffusiviteit van witte stof banen, die wijzen op een 
slechtere microstructurele integriteit van de witte stof, de sterkste associaties tonen met een 
afname van de paslengte. De TBSS analyse laat zien dat vooral een verlies van structurele 
integriteit in het corpus callosum (de hersenbalk) en het voorste deel van de corona radiata 
een belangrijke rol spelen in het ontstaan van loopproblemen in onze populatie. Onze 
resultaten suggereren dat veranderingen in de witte stof, zelfs voordat ze zichtbaar zijn op de 
gebruikelijke MRI, een rol spelen in het ontstaan van loopproblemen. 
In hoofdstuk 5 beschrijven we de relatie tussen CSVD op de baseline scan en het 
ontstaan van parkinsonisme. Van de 503 deelnemers aan het baseline onderzoek, kregen 
20 deelnemers de diagnose parkinsonisme 5 jaar later. Het 5-jaars cumulatieve risico op 
parkinsonisme was hiermee 3.5% (95% CI 1.9-5.2). In dit hoofdstuk laten we zien dat een 
groter volume van witte stof afwijkingen en een hoger aantal lacunes geassocieerd zijn 
met een verhoogd 5-jaarsrisico op het ontwikkelen van parkinsonisme. Bij het alleen in 
ogenschouw nemen van de patiënten met vasculair parkinsonisme, wordt dit risico ook 
verhoogd door de aanwezigheid van microbleeds en een kleiner grijze stof volume. Verder 
zagen we dat patiënten met vasculair parkinsonisme een lagere structurele integriteit van de 
bifrontale witte stof banen hebben in vergelijkingen met deelnemers zonder parkinsonisme, 
onafhankelijk van de traditionele CSVD markers. Deze bevindingen pleiten voor een rol van 
CSVD in het ontstaan van parkinsonisme. 
Deel IV: Lange termijn sterfterisico in cerebrale small vessel disease
In hoofdstuk 6 onderzochten we het 8-jaars sterfterisico bij mensen met CSVD en tevens 
onderzochten we potentiële klinische en beeldvormende factoren die geassocieerd zijn met 
het 8-jaars sterfterisico. In totaal overleden 80 deelnemers van de 503 na een gemiddelde 
follow-up duur van 7.8 jaar (SD 1.5). Het 8-jaars sterfterisico is verhoogd voor deelnemers 
met de aanwezigheid van lacunes en microbleeds op de baseline MRI-scan, een verhoogde 
gemiddelde diffusiviteit van de witte stof, alsook een groot volume van witte stof afwijkingen 
en een klein volume witte en grijze stof. De belangrijkste voorspellers voor het 8-jaars 
sterfterisico bleken een hogere leeftijd, lagere loopsnelheid, kleiner grijze stof volume 
en een verhoogde gemiddelde diffusiviteit van de witte stof. Deze factoren samen geven 
waarschijnlijk een afspiegeling van de algemene gezondheidstoestand van onze populatie. 
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Conclusie:
De studies die beschreven zijn in dit proefschrift laten zien dat diverse hersenveranderingen 
geassocieerd zijn met het ontwikkelen van problemen op motorisch gebied en functionele 
uitkomst op lange termijn bij personen met CSVD. De aanwezigheid van traditionele CSVD 
makers op een MRI-scan verhoogt het 5-jaars risico op parkinsonisme, als ook het 8-jaars 
sterfterisico. Een lagere structurele integriteit van de witte stof is daarnaast geassocieerd 
met het ontstaan van vasculair parkinsonisme en is tevens een belangrijker voorspeller 
van mortaliteit in onze populatie, naast leeftijd, loopsnelheid en grijze stof volume. Het 
ontwikkelen van loopproblemen is niet gerelateerd aan de aanwezigheid van CSVD op de 
baseline MRI-scan, maar juist geassocieerd met het ontstaan van witte stof atrofie en verlies 
van microstructurele integriteit van de witte stof op de MRI-scan 5 jaar later.  
Uit onze resultaten blijkt dat DTI een belangrijke bijdrage kan leveren aan het inzichtelijk 
maken van de mechanismen die ten grondslag liggen aan het ontstaan van problemen in het 
motorisch functioneren en de functionele uitkomst (zoals mortaliteit) in personen met CSVD. 
Tevens doen onze resultaten vermoeden dat DTI parameters gebruikt kunnen worden als 
(vroege) marker voor ontstaan van problemen op deze gebieden. Toekomstige prospectieve 
studies zijn echter nodig om verder inzicht te verkrijgen in de onderliggende mechanismen 
van de klinische gevolgen van CSVD, onder andere ook door gebruik te maken van nieuwe 
beeldvormende technieken en netwerk analyse. Ook dient onderzocht te worden of het 
(preventief) behandelen van CSVD en loopproblemen, kan leiden tot vermindering van 
motorische en cognitieve problemen en verbetering van de functionele uitkomst. 
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AD  axial diffusivity
AIC  Akaike information criterion
ANCOVA  analysis of covariance
ARWMC  age-related white matter changes scale
CADASIL  cerebral autosomal dominant arteriopathy with subcortical infarcts and 
  leukoencephalopathy
CARASIL  cerebral autosomal recessive arteriopathy with subcortical infarcts and 
  leukoencephalopathy
CES-D  centre of epidemiologic studies on depression scale
CI  confidence interval
CSF  cerebrospinal fluid
CSVD  cerebral small vessel disease
CT  compute tomography
DTI  diffusion tensor imaging
FA  fractional anisotropy
FDR  false discovery rate
FLAIR  fluid-attenuated inversion recovery
FSL  FMRIB’s software library
GM  grey matter
HR  hazard ratio
ICD-10  international statistical classification of disease and related health 
  problems, 10th revision
ICV   intracranial volume
IPD  idiopathic Parkinson’s disease
IQR  interquartile range
MCI  mild cognitive impairment
MD  mean diffusivity
MMSE  Mini Mental State Examination
MNI  Montreal neurological institute
MPRAGE  magnetization-prepared rapid gradient-echo
MRI  magnetic resonance imaging
NAWM  normal-appearing white matter
NI  not included
NR  not retained
NS  not significant
OPD  outpatient department
OR  odds ratio
PSP  progressive supranuclear palsy
RAVLT  Rey auditory verbal learning test
RCFT  Rey complex figure test
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RD  radial diffusivity
ROI  region of interest
RUN DMC Radboud university Nijmegen diffusion tensor and magnetic resonance 
  imaging cohort
SAT  speed accuracy tradeoff
SD  standard deviation
SPM  statistical parametric mapping
STRIVE  standards for reporting vascular changes on neuroimaging
TBSS  Tract-Based Spatial Statistics
TBV  total brain volume
TE  echo time
TI  inversion time
TIA  transient ischemic attack
TR  time repetition
UPDRS  unified Parkinson’s disease rating scale
UPDRS-m unified Parkinson’s disease rating scale motor section 
VIF  variance inflation factor
VP  vascular parkinsonism
WM  white matter
WMH  white matter hyperintensities
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Marvin), ook al hebben we al een tijdje niet meer geskied samen, de ‘après-ski’ afspraakjes 
zijn altijd erg gezellig. Dank voor jullie vriendschap en betrokkenheid. Hopelijk gaan we in de 
toekomst weer skiën samen. 
Lieve Anneke, Erica, Jacolien, Katrien, Marit, Sally en Suzan, wat ben ik bevoorrecht met 
vriendinnen zoals jullie. De passie voor muziek bracht ons samen in onze studententijd. 
Inmiddels delen we lief en leed. Dank voor jullie interesse en niet aflatende steun bij het 
afronden van dit proefschrift. Er zit nog altijd veel muziek in onze vriendschap, jullie zijn 
geweldig. Op naar onze volgende Qladies date!
Lieve Daphne en Maaike, mijn studievriendinnen van het eerste uur, wat bof ik met zulke lieve, 
trouwe en hartelijke vriendinnen. Met jullie was mijn studententijd zoveel leuker! Dank voor 
al jullie steun, belangstelling en gezelligheid en dat jullie er altijd voor me zijn. Lieve Daphne, 
wat een geluk dat we allebei in Nijmegen konden blijven voor onze specialisatie en ook nog 
in dezelfde periode konden starten met een promotieonderzoek. Het was ontzettend fijn om 
samen te praten over de ups en downs van onderzoek doen en om onze successen samen te 
vieren. Dank dat ik bij jou altijd welkom ben. Ik voel me vereerd dat jij mijn paranimf wil zijn. 
Lieve Marieke, Janneke, Inge en Geert, wat ben ik blij met jullie als zussen en broer. In onze 
jeugd waren we al een hecht team en deden we graag veel samen. Ondanks dat we elkaar nu 
minder zien, voel ik dit nog steeds zo. Ik koester onze gezellige theedrinkmomenten, etentjes, 
uitjes en familieweekenden. Dank dat ik bij jullie altijd thuis ben. Ik ben trots op jullie! 
Lieve Marieke en Janneke, het zijn van drielingzussen en het alle drie doorlopen van een 
medische studie schept een zeer bijzondere band. Jullie begrijpen mij als geen ander. En 
zoals met alles, hebben jullie me ook bij mijn promotieonderzoek van uitgebreid advies en 
steun voorzien. Veel dank. 
Lieve Janneke, ik vind het een eer dat jij mijn paranimf wil zijn en vind het erg fijn dat jij op 
deze bijzondere dag ook letterlijk naast me staat. 
Lieve Inge, dank voor je hulp bij het onderzoek. Mede door jouw inzet hadden we de gegevens 
van ons onderzoek veel sneller compleet. Extra leuk dat ik met jou ook inhoudelijk kon 
discussiëren over het onderzoek en je me van de nodige epidemiologische en statistische 
kennis voorzag. Ik heb het ook erg gewaardeerd dat je vaak zorgde voor de nodige muzikale 
afleiding. Hopelijk spelen we nog heel lang muziek samen. 
Lieve Geert, mijn stoere broer(tje ;-)), door je drukke werk op onregelmatige tijden zien wij 
elkaar helaas weinig. Dank voor je humor en je vaak grappige berichtjes over de app. 
Lieve Tom, Olivier en Bas, ik kan me geen betere zwagers wensen. Dank dat jullie deur altijd 
voor me open staat en jullie bereidheid me altijd te helpen. 
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Lieve Mees, Nina en Fien, wat een geweldig neefje en lieve nichtjes zijn jullie. Met jullie 
betoverende lachjes en enthousiaste verhaaltjes doen jullie mij alles om me heen even 
helemaal vergeten. 
Lieve papa en mama, ik kan niet in woorden uit drukken hoe dankbaar ik ben en hoe belangrijk 
jullie voor me zijn, daarom is dit boekje voor jullie. Dank voor jullie onvoorwaardelijke liefde 
en steun en dank voor alle kansen die jullie me hebben geboden. Mama, veel dank voor je 
luisterend oor en onze gezellige uitjes en (mini)vakanties op de momenten dat ik het juist zo 
nodig had. Papa, veel dank voor je bijdrage aan dit boekje. Ik vind het ontzettend bijzonder 
dat jij de voorkant van dit boekje hebt gefotografeerd. Ik ben trots op het resultaat; het had 
niet mooier gekund. 
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at the Radboud University Nijmegen. 
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at the department of Neurology, Radboud University Medical Centre, Nijmegen. In June 
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(2010-2015), as well as a board member of the association of neurology residents of the 
Radboud University Medical Centre (2015-2016). In 2011, she started her PhD project, 
under the supervision of Prof. dr. FE de Leeuw, which resulted in this thesis. In 2013, she 
won the ‘young investigators award’ of the European Stroke Conference, London, United 
Kingdom. She finished her specialization in January 2017 and as of February 2017, she is 
working as a neurologist at the Jeroen Bosch Hospital in ‘s-Hertogenbosch. 
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Vascular disorders of movement – The Radboud Stroke centre
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 University Nijmegen, 12 March 2010
• Karlijn F. de Laat. Motor performance in individuals with cerebral small vessel 
 disease: an MRI study. Radboud University Nijmegen, 29 November 2011
• Anouk G.W. van Norden. Cognitive function in elderly individuals with cerebral small 
 vessel disease. An MRI study. Radboud University Nijmegen, 30 November 2
• Rob Gons. Vascular risk factors in cerebral small vessel disease. A diffusion tensor 
 imaging study. Radboud University Nijmegen, 10 December 2012
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 University Nijmegen, 14 April 2014 
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 after stroke in young adults. Radboud University Nijmegen, 12 June 2015
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 Radboud University Nijmegen, 29 November 2010
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Non-Parkinsonian disorders of movement
• Sacha Vermeer. Clinical and genetic characterization of autosomal recessive 
 cerebellar ataxias. Radboud University Nijmegen, 5 April 2012
• Susanne T. de Bot. Hereditary spastic paraplegias in the Netherlands. Radboud 
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Neuromuscular disorders of movement
• Mireille van Beekvelt. Quantitative near infrared spectroscopy (NIRS) in human 
 skeletal muscle. Radboud University Nijmegen, 24 April 2002
• Johan Hiel. Ataxia telangiectasia and Nijmegen Breakage syndrome, neurological, 
 immunological and genetic aspects. Radboud University Nijmegen, 23 April 2004
• Gerald JD Hengstman. Myositis specific autoantibodies, specificity and clinical 
 applications. Radboud University Nijmegen, 21 September 2005
• M. Schillings. Fatigue in neuromuscular disorders and chronic fatigue syndrome, a 
 neurophysiological approach. Radboud University Nijmegen, 23 November 2005
• Bert de Swart. Speech therapy in patients with neuromuscular disorders and 
 Parkinson’s disease. Diagnosis and treatment of dysarthria and dysphagia. Radboud 
 University Nijmegen, 24 march 2006
• J. Kalkman. From prevalence to predictors of fatigue in neuromuscular disorders. 
 The building of a model. Radboud University Nijmegen, 31 October 2006
• Nens van Alfen. Neuralgic amyotrophy. Radboud University Nijmegen, 1 November 
 2006
• Gea Drost. High-density surface EMG, pathophysiological insights and clinical 
 applications. Radboud University Nijmegen, 9 March 2007
• Maria Helena van der Linden. Pertubations of gait and balance: a new experimental 
 setup applied to patients with CMT type 1a. Radboud University Nijmegen, 6 October 
 2009
• Jeroen Trip. Redefining the non-dystrophic myotonic syndromes. Radboud 
 University Nijmegen, 22 January 2010
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A7 Donders Graduate School for Cognitive Neuroscience Series
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For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established 
the Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially 
recognised as a national graduate school in 2009. The Graduate School covers training at 
both Master’s and PhD level and provides an excellent educational context fully aligned 
with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centres guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.. Positions outside 
academia spread among the following sectors: specialists in a medical environment, 
mainly in genetics, geriatrics, psychiatry and neurology. Specialists in a psychological 
environment, e.g. as specialist in neuropsychology, psychological diagnostics or therapy. 
Positions in higher education as coordinators or lecturers. A smaller percentage enters 
business as research consultants, analysts or head of research and development. Fewer 
graduates  stay in a research environment as lab coordinators, technical support or policy 
advisors. Upcoming possibilities are positions in the IT sector and management position 
in pharmaceutical industry. In general, the PhDs graduates almost invariably continue with 
high-quality positions that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/donders-graduate/
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